

CITATION REPORT

List of articles citing

**Antithrombotic therapy for VTE disease:
Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest
Physicians Evidence-Based Clinical Practice Guidelines**

**DOI: 10.1378/chest.11-2301
Chest, 2012, 141, e419S-e496S.**

Source: <https://exaly.com/paper-pdf/53899243/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2315	Paradoxical Embolisms and Strokes. 565-574		0
2314	The Misunderstood Coagulopathy of Liver Disease: A Review for the Acute Setting. 2018 , 19, 863-871		45
2313	Recurrent venous thromboembolism: what is the risk and how to prevent it. 2012 , 2012, 391734		23
2312	Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. 2012 , 366, 1287-97		1692
2311	Influence of hereditary or acquired thrombophilias on the treatment of venous thromboembolism. 2012 , 19, 363-70		22
2310	Prescribing anticoagulation medication for the elderly. 2012 , 8, 205-216		1
2309	[New endovascular treatment options of deep vein thrombosis]. 2012 , 137, 1524-9		3
2308	[Upper extremity deep venous thrombosis]. 2012 , 137, 2537-9		0
2307	[The tumor patient with an indication for intensive anticoagulation]. 2012 , 137, 2160-3		
2306	D-dimer assays in diagnosis and management of thrombotic and bleeding disorders. 2012 , 38, 673-82		84
2305	Asymptomatic deep vein thrombosis and superficial vein thrombosis in ambulatory cancer patients: impact on short-term survival. 2012 , 107, 1244-8		28
2304	Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. 2012 , 69, 1473-84		87
2303	Outcome of incidentally diagnosed pulmonary embolism in patients with malignancy. 2012 , 18, 399-405		16
2302	Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. 2012 , 345, e7498		106
2301	New prospective for the management of low-risk pulmonary embolism: prognostic assessment, early discharge, and single-drug therapy with new oral anticoagulants. 2012 , 2012, 502378		
2300	Thrombosis in hematologic malignancies: risks and consequences. 2012 , 1, 87-95		
2299	Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e351S-e418S	5.3	449

2298 Gerinnungsstörungen und Thrombosen bei onkologischen Patienten. **2012**, 15, 46-50

2297 Clarification of once-daily low-molecular-weight heparin dosing in pulmonary embolism. *Chest*, **2012**, 142, 1074-1075 53 1

2296 Clarification of Once-Daily Low-Molecular-Weight Heparin Dosing in Pulmonary Embolism: Response. *Chest*, **2012**, 142, 1075-1076 53 1

2295 What NPs need to know about anticoagulation therapy. **2012**, 37, 28-34 1

2294 Steps toward simplifying the treatment of pulmonary embolism. **2012**, 9, 659-667

2293 Pulmonary embolism: risk assessment and management. **2012**, 33, 3014-22 96

2292 [Epidemiology and management of isolated distal deep venous thrombosis]. **2012**, 33, 678-85 17

2291 Symptomatic subsegmental pulmonary embolism: what is the next step?. **2012**, 10, 1486-90 62

2290 Prevention of post-thrombotic syndrome: a case for new oral anticoagulant drugs or for heparins?. **2012**, 10, 1702-3 22

2289 Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study. **2012**, 10, 2205-6 7

2288 Risk of post-thrombotic syndrome after subtherapeutic warfarin anticoagulation for a first unprovoked deep vein thrombosis: results from the REVERSE study. **2012**, 10, 2039-44 94

2287 Anticoagulant treatment of pulmonary embolism: impact and implications of the EINSTEIN PE study. **2012**, 89, 281-7 8

2286 Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: a meta-analysis of 5 randomized trials in non-cancer and cancer patients. **2012**, 130, 853-8 16

2285 Management of deep vein thrombosis of the upper extremity. **2012**, 126, 768-73 60

2284 Extra-abdominal venous thromboses at unusual sites. **2012**, 25, 265-74 8

2283 Epidemiology, diagnosis, treatment and management of superficial-vein thrombosis of the legs. **2012**, 25, 275-84 32

2282 Venous thromboembolism associated with pregnancy and hormonal therapy. **2012**, 25, 319-32 29

2281 Perioperative management of patients on chronic antithrombotic therapy. **2012**, 120, 4699-705 58

2280	Clinical causes and treatment of the thrombotic storm. 2012 , 5, 653-9		21
2279	An adolescent patient with post-thrombotic syndrome achieves excellence in sport. 2012 , 48, E190-3		2
2278	Nouveaux anticoagulants : ont-ils dj une place en oncologie ?. 2012 , 14, 659-662		
2277	Recommandations et rffentiels : tous pareils ?. 2012 , 14, 650-658		
2276	Avances en el tratamiento antitrombico. Nuevos anticoagulantes orales para reemplazar a acenocumarol (Sintrom). 2012 , 11, 1421-1427		
2275	Antipsychotic drugs and venous thromboembolism. 2012 , 130 Suppl 1, S29-31		8
2274	Clinical scores to predict recurrence risk of venous thromboembolism. 2012 , 108, 1061-4		29
2273	Aspirin and the prevention of venous thromboembolism. 2012 , 366, 2028-30		14
2272	Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. 2012 , 108, 493-8		41
2271	Common complications in the critically ill patient. 2012 , 92, 1519-57		25
2270	Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. 2012 , 159, 528-40		138
2269	VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e691S-e736S	5-3	977
2268	Anticoagulants in cancer. 2012 , 10, 2230-41		11
2267	Management of bleeding in patients receiving conventional or new anticoagulants: a practical and case-based approach. 2012 , 72, 1965-75		10
2266	Diagnosis and treatment of cerebral venous thrombosis. 2012 , 10, 1545-53		25
2265	New oral anticoagulants in the ED setting: a review. 2012 , 30, 2046-54		17
2264	Usefulness of aspiration of pulmonary emboli and prolonged local thrombolysis to treat pulmonary embolism. 2012 , 110, 1841-5		12
2263	Use of warfarin therapy among residents who developed venous thromboembolism in the nursing home. 2012 , 10, 361-72		8

2262	Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review. 2012 , 60, 651-662.e4	57
2261	New anticoagulants for treatment of venous thromboembolism. 2012 , 23, 692-5	28
2260	Significant changes to antithrombotic therapy and prevention of thrombosis guidelines. 2012 , 33, 297-301	
2259	Protocolo de diagnóstico y tratamiento de la enfermedad tromboembólica venosa. 2012 , 11, 1366-1370	
2258	Incidence and characteristics of asymptomatic distal deep vein thrombosis unexpectedly found at admission in an Internal Medicine setting. 2012 , 130, 591-5	12
2257	Managing venous thromboembolism in Asia: winds of change in the era of new oral anticoagulants. 2012 , 130, 291-301	14
2256	Statins are better than fibrates in patients with a previous venous thromboembolism. 2012 , 130, 831-2	
2255	Chronic thromboembolic pulmonary hypertension: a review of current practice. 2012 , 55, 134-43	27
2254	Clinical approach to splanchnic vein thrombosis: risk factors and treatment. 2012 , 130 Suppl 1, S1-3	46
2253	Low-dose aspirin for preventing recurrent venous thromboembolism. 2012 , 367, 1979-87	358
2252	Post-thrombotic syndrome: current prevention and management strategies. 2012 , 10, 1555-66	7
2251	Prediction of recurrent venous thromboembolism by clot lysis time: a prospective cohort study. 2012 , 7, e51447	22
2250	Diagnosis and management of upper extremity deep-vein thrombosis in adults. 2012 , 108, 1097-108	91
2249	The role of anticoagulation clinics in the era of new oral anticoagulants. 2012 , 2012, 835356	19
2248	Thrombosis in pregnancy: updates in diagnosis and management. 2012 , 2012, 203-207	43
2247	[Apixaban]. 2012 , 32, 203-11	1
2246	Perioperative management of patients on chronic antithrombotic therapy. 2012 , 2012, 529-535	18
2245	22 Erworbene Thrombophilie. 2012 ,	

2244	Prophylaxis of venous thromboembolism in medical patients: too much or too little?. 2012 , 4, 315-8		
2243	Monitoring new oral anticoagulants, managing thrombosis, or both?. 2012 , 107, 803-5		30
2242	Will the new target-specific oral anticoagulants improve the treatment of venous thromboembolism?. 2012 , 107, 1009-11		6
2241	Should the commonly accepted definition of "unprovoked venous thrombembolism" be revisited?. 2012 , 107, 806-7		4
2240	Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e495S-e530S	5:3	687
2239	Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, 7S-47S	5:3	1225
2238	Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> , 2012 , 141, e152S-e184S	5:3	920
2237	The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients. 2012 , 14, 295-306		24
2236	[Thrombosis prophylaxis in geriatric patients]. 2012 , 45, 231-40; quiz 241		1
2235	Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders. 2012 , 34, 766-87		15
2234	Prevalence and predictors for post-thrombotic syndrome 3 to 16 years after pregnancy-related venous thrombosis: a population-based, cross-sectional, case-control study. 2012 , 10, 840-7		59
2233	Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism. 2012 , 10, 751-9		51
2232	Superficial vein thrombosis and recurrent venous thromboembolism: a pooled analysis of two observational studies. 2012 , 10, 1004-11		23
2231	Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term. 2012 , 158, 433-41		20
2230	Derivation of the non-inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism. 2013 , 11, 13		22
2229	Preventing thrombophilia-related complications of pregnancy: an update. 2013 , 6, 287-300		8
2228	CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. 2013 , 13, 284		45
2227	Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. 2013 , 14, 75		31

2226	Initial and long-term treatment of deep venous thrombosis: recent clinical trials and their impact on patient management. 2013 , 14, 385-96	7
2225	Venous thromboembolic disease. 2013 , 93, 983-95, x	6
2224	The post-thrombotic syndrome: a 2012 therapeutic update. 2013 , 15, 153-63	16
2223	Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. 2013 , 15, 224-39	9
2222	New oral anticoagulants for the treatment of venous thromboembolism. 2013 , 26, 151-61	16
2221	New anticoagulants in the treatment of patients with cancer-associated venous thromboembolism. 2013 , 26, 163-9	8
2220	Review of the American College of Chest Physicians 2012 Guidelines for Anticoagulation Therapy and Prevention of Thrombosis. 2013 , 50, 251-8	10
2219	Aktuelle Therapie und Sekundärprävention der Lungenembolie. 2013 , 7, 217-230	
2218	Rivaroxaban and other non-vitamin K antagonist oral anticoagulants in the emergency treatment of thromboembolism. 2013 , 6, 25	4
2217	Rivaroxaban for the treatment of pulmonary embolism. 2013 , 30, 589-606	9
2216	Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. 2013 , 369, 1406-15	1298
2215	Vena cava filters for management of venous thromboembolism: a clinical review. 2013 , 27, 225-41	40
2214	Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. 2013 , 35, 352-8	59
2213	Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. 2013 , 1, 83-97	95
2212	Association between sympathetic response, neurogenic cardiomyopathy, and venous thromboembolization in patients with primary subarachnoid hemorrhage. 2013 , 155, 1501-10	6
2211	Antikoagulation nach tiefer Venenthrombose. 2013 , 18, 41-43	
2210	Aspirin in the secondary prevention of unprovoked thromboembolism: the WARFASA and ASPIRE studies. 2013 , 8, 757-60	5
2209	Risk of asymptomatic pulmonary embolism in patients with deep venous thrombosis. 2013 , 1, 370-5	7

2208	Risk of recurrent venous thromboembolism among young women after a first event while exposed to combined oral contraception versus not exposed to: a cohort study. 2013 , 132, 51-5	24
2207	[Recurrence risk in venous thromboembolic disease after anticoagulation discontinuation]. 2013 , 140, 310-3	2
2206	Patología venosa y linfática. 2013 , 11, 2691-2699	
2205	Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. 2013 , 108, 1486-95	19
2204	Seeking optimal treatment for phlegmasia cerulea dolens. 2013 , 131, 372-3	7
2203	Clinical impact of a value-based decision: a surgical case study. 2013 , 216, 800-11; discussion 811-3	6
2202	[Are temporary vena cava filters becoming permanent?]. 2013 , 38, 333-4	1
2201	Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. 2013 , 163, 160-7	30
2200	Diagnostic de l'embolie pulmonaire au service des urgences. 2013 , 22, 593-599	
2199	Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. 2013 , 132, 175-9	33
2198	The new oral anticoagulants in atrial fibrillation: once daily or twice daily?. 2013 , 59, 53-62	20
2197	Supplemental patient education for patients taking oral anticoagulants: systematic review and meta-analysis. 2013 , 11, 491-502	14
2196	[Pulmonary embolism and pregnancy]. 2013 , 32, 257-66	5
2195	Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies. 2013 , 11, 25	21
2194	[New oral anticoagulants in the treatment of venous thromboembolism]. 2013 , 42, 1232-8	0
2193	National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism. 2013 , 49, 534-547	1
2192	The skin and hypercoagulable states. 2013 , 69, 450-62	45
2191	GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. 2013 , 66, 726-35	667

2190	Pulmonary embolism in a stroke patient after systemic thrombolysis: clinical decisions and literature review. 2013 , 22, e667-70	1
2189	Massive pulmonary embolism. 2013 , 31, 503-18, vii	18
2188	Renaissance of Aspirin for the Primary and Secondary Prevention of Venous Thromboembolism. 2013 , 1, 217-225	
2187	Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. 2013 , 11, 21	378
2186	Diagnosis and treatment of pulmonary embolism: a multidisciplinary approach. 2013 , 8, 75	21
2185	Konservative Therapie der tiefen Bein-Becken-Venenthrombose. 2013 , 18, 683-688	
2184	Foramen ovale permèable et ischémie aiguë de membre. [propos d'un cas. 2013 , 3, 390-392	
2183	[Prevention of recurrent thromboembolisms: WARFASA (aspirin for the prevention of recurrent venous thromboembolism - the Warfarin and Aspirin Study)]. 2013 , 54, 1393-6	3
2182	Are MPNs vascular diseases?. 2013 , 8, 307-16	14
2181	Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG). 2013 , 30, 1019-28	12
2180	Aktuelle Therapie und Sekundärprävention der Lungenembolie. 2013 , 10, 443-456	
2179	Bemiparin: a guide to its use in thromboprophylaxis and the treatment of deep vein thrombosis. 2013 , 29, 27-33	
2178	Optimal treatment duration of venous thrombosis. 2013 , 11 Suppl 1, 151-60	10
2177	Anticoagulation with rivaroxaban: covering a broad spectrum of thromboembolic disease. 2013 , 11, 817-28	
2176	Venous thromboembolism prevention guidelines for medical inpatients: mind the (implementation) gap. 2013 , 8, 582-8	8
2175	Catheter-related thrombosis in cancer patients. 2013 , 162, 748-57	26
2174	Meta-analysis of rivaroxaban and bleeding risk. 2013 , 112, 454-60	37
2173	Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. 2013 , 88, 1-18	40

2172	Thrombolysis for the management of massive pulmonary embolism in pregnancy. 2013 , 22, 149-52	15
2171	Management of venous thromboembolism. 2013 , 40, 73-90	5
2170	Stress ulcer prophylaxis, thromboprophylaxis and coagulation management in patients with hip fractures. 2013 , 163, 442-7	3
2169	The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. 2013 , 11, 1053-8	32
2168	Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment. 2013 , 11, 1968-76	19
2167	Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH. 2013 , 11, 1760-5	121
2166	Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. 2013 , 70, 1914-29	47
2165	Certoparin for the treatment and prevention of thrombosis: pharmacological profile and results from clinical studies. 2013 , 9, 901-9	3
2164	Pharmacologic prevention of venous thromboembolism in obese patients. 2013 , 36, 247-57	13
2163	Presenting D-dimer and early symptom severity are independent predictors for post-thrombotic syndrome following a first deep vein thrombosis. 2013 , 160, 817-24	24
2162	Portal vein thrombosis: should anticoagulation be used?. 2013 , 15, 306	21
2161	Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease. 2013 , 175-237	
2160	The evolution of oral anticoagulant therapy. 2013 , 40, 109-34	6
2159	A current approach to superficial vein thrombosis. 2013 , 90, 85-8	9
2158	Management of unsuspected pulmonary embolism in cancer patients. 2013 , 6, 83-8; quiz 89	4
2157	Nonbacterial thrombotic endocarditis with ST-elevation myocardial infarction treated with percutaneous coronary aspiration thrombectomy. 2013 , 22, 386-9	5
2156	New Oral Anticoagulants. 2013 , 2, e456-e471	
2155	Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. 2013 , 165, 523-530.e3	140

2154	Haemostatic challenges in the cancer patient: focus on the perioperative period. 2013 , 27, 493-511	5
2153	Therapeutic options for the treatment of venous thromboembolism in case of warfarin intolerance: Effects of novel oral anticoagulants. 2013 , 8, 116-117	
2152	Tratamiento de la trombosis venosa profunda iliofemoral y del síndrome postrombótico. 2013 , 65, 218-227	1
2151	Timing of recurrent venous thromboembolism early after the index event: a meta-analysis of randomized controlled trials. 2013 , 132, 420-6	32
2150	Clinical, demographic, and medicolegal factors associated with geographic variation in inferior vena cava filter utilization: an interstate analysis. 2013 , 153, 683-8	36
2149	Treatment for deep vein thrombosis and pulmonary thromboembolism is almost the same--it does not seem quite logical. 2013 , 45, e49-51	2
2148	Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis. 2013 , 24, 17-24; quiz 26	63
2147	National Consensus on the Diagnosis, Risk Stratification and Treatment of Patients with Pulmonary Embolism. Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Society Española Internal Medicine (SEMI). Spanish Society of Thrombosis and Haemostasis (SETH). Spanish Society of Cardiology (ESC). Spanish Society of Medicine Accident and Emergency (SEMES). Spanish Society of	48
2146	Sixteen-year-old athlete with chest pain and shortness of breath due to pulmonary emboli. 2013 , 44, 939-42	7
2145	Prevalence of thrombophilia according to age at the first manifestation of venous thromboembolism: results from the MAISTHRO registry. 2013 , 163, 655-65	42
2144	[Feasibility of patient-injected anticoagulation therapy: the GRANTED experience]. 2013 , 38, 345-51	1
2143	Presentation and treatment outcomes of patients with symptomatic inferior vena cava filters. 2013 , 27, 84-8	14
2142	Analysis of venous thromboembolic events after saphenous ablation. 2013 , 1, 26-32	16
2141	Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism. 2013 , 126, 819-24	18
2140	[New oral anticoagulants in the treatment of venous thromboembolic disease]. 2013 , 39, 146-9	0
2139	Isolated calf muscular vein thrombosis is associated with pulmonary embolism and a high incidence of additional ipsilateral and contralateral deep venous thrombosis. 2013 , 1, 33-8	6
2138	A turning point for clinical research in China?. 2013 , 382, 835-6	15
2137	The incidence, risk factors, and prognosis of recurrent venous thromboembolism (VTE) in patients with advanced solid cancers receiving anticoagulation therapy after the diagnosis of index VTE. 2013 , 131, e133-40	5

2136	Hospital costs of acute pulmonary embolism. 2013 , 126, 127-32		84
2135	Clasificaci3n y tratamiento de la embolia pulmonar aguda. 2013 , 65, 146-154		1
2134	Optimal initial anticoagulant therapy in pulmonary thromboembolism: randomized trial suggested. 2013 , 31, 407-9		
2133	Rivaroxaban: an oral factor Xa inhibitor. 2013 , 35, 4-27		19
2132	Long-term clinical course of acute pulmonary embolism. 2013 , 27, 185-92		21
2131	Intraosseous administration of thrombolytics for pulmonary embolism. 2013 , 45, e197-200		3
2130	The history and historical treatments of deep vein thrombosis. 2013 , 11, 402-11		50
2129	Medical emergencies: pulmonary embolism and acute severe asthma. 2013 , 68 Suppl 1, 102-16		7
2128	Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. 2013 , 126, 425-434.e1		36
2127	Management of pulmonary embolism: state of the art treatment and emerging research. 2013 , 15, 137-52		5
2126	Point: should systemic lytic therapy be used for submassive pulmonary embolism? Yes. <i>Chest</i> , 2013 , 143, 296-299	5-3	11
2125	Apixaban for extended treatment of venous thromboembolism. 2013 , 368, 699-708		882
2124	Low-molecular-weight heparin use with thrombolysis: is it effective and safe? Ten years' clinical experience. 2013 , 86, 318-23		6
2123	Hospitalization for vitamin-K-antagonist-related bleeding: treatment patterns and outcome. 2013 , 11, 651-9		29
2122	Top practice-changing articles over the last two years. 2013 , 35, 325-32		
2121	Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. 2013 , 36, 187-94		41
2120	Assessing bleeding risk in patients taking anticoagulants. 2013 , 35, 312-9		115
2119	Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. <i>Chest</i> , 2013 , 143, 1106-1116	5-3	23

2118	Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. 2013 , 69, 1617-33	71
2117	Prosthetic valve thrombosis: when and how should we lyse?. 2013 , 6, 217-9	4
2116	Prophylaxis of thromboembolic events in patients with nephrotic syndrome. 2013 , 47, 725-34	27
2115	Management of venous thromboembolism--controversies and the future. 2013 , 161, 755-63	7
2114	The new oral anticoagulants in clinical practice. 2013 , 88, 495-511	79
2113	Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. 2013 , 161, 764-77	17
2112	Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. 2013 , 45, 423-9	43
2111	Management of antithrombotic therapy in patients undergoing invasive procedures. 2013 , 368, 2113-24	314
2110	Conventional and new oral anticoagulants in the treatment of chest disease and its complications. 2013 , 188, 413-21	4
2109	Guidelines for use of anticoagulation in pregnancy. 2013 , 33, 343-56	7
2108	Use of new oral anticoagulants in antiphospholipid syndrome. 2013 , 15, 331	44
2107	Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). 2013 , 111, 273-7	350
2106	Inferior vena cava filters. 2013 , 6, 539-47	43
2105	Pulmonary Vascular Disease. 2013 , 603-625	1
2104	Oral apixaban for the treatment of acute venous thromboembolism. 2013 , 369, 799-808	1495
2103	Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition. 2013 , 11, 1154-62	7
2102	When a test is too good: how CT pulmonary angiograms find pulmonary emboli that do not need to be found. 2013 , 347, f3368	156
2101	Transitions of care in anticoagulated patients. 2013 , 6, 215-28	12

2100 Venous Thromboembolic Disease. **2013**, 109-120

- 2099 Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. **2013**, 131, 24-30 122
- 2098 Inferior vena cava thrombosis: a review of current practice. **2013**, 18, 32-43 85
- 2097 Statin treatment and the risk of recurrent pulmonary embolism. **2013**, 34, 1800-6 63
- 2096 Recommendations for prophylaxis of pregnancy-related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines: a rebuttal. **2013**, 11, 1782-4 6
- 2095 Venous thromboembolism management: where do novel anticoagulants fit?. **2013**, 29, 783-90 6
- 2094 [Adherence to guidelines for the treatment of venous thromboembolism in cancer patients: a retrospective analysis of 145 cases]. **2013**, 38, 185-92 11
- 2093 [Regarding: Benefit/risk ratio analysis from a possible anticoagulation of asymptomatic deep venous thrombosis in major orthopedic surgery]. **2013**, 38, 280-1
- 2092 [Temporary vena caval filters: report on cohort of 72 patients in Grenoble, France]. **2013**, 38, 335-40 1
- 2091 Chez quels patients ayant fait une thrombose veineuse y a-t-il une indication ^ prescrire de l'aspirine en relais du traitement anticoagulant ?. **2013**, 38, 74-75
- 2090 Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. **2013**, 132, 515-9 100
- 2089 Management of New Anticoagulants in the ICU. **2013**, 4, 326-331
- 2088 Pharmacoeconomic implications of thromboprophylaxis with new oral anticoagulants after total hip or knee replacement in the USA. **2013**, 14, 525-34 2
- 2087 Tissue plasminogen activator prevents mortality from sulfur mustard analog-induced airway obstruction. **2013**, 48, 439-47 35
- 2086 Should the presence of an antiphospholipid antibody affect the duration of anticoagulant treatment in patients with venous thromboembolism?. **2013**, 2013, 681-3 2
- 2085 Lemierre syndrome-should we anticoagulate? A case report and review of the literature. **2013**, 22, 137-42 56
- 2084 [Management of catheter-related upper extremity deep vein thrombosis]. **2013**, 138 Suppl 2, e86-94 2
- 2083 [Lower extremity deep vein thrombosis - diagnostic algorithm]. **2013**, 138, 369-74 2

2082 [Monitoring of coagulation during treatment with direct oral anticoagulants]. **2013**, 138, 1997-2000

2081 Comprehensive update on the prevention and treatment of venous thromboembolism in cancer patients. **2013**, 39, 127-40 7

2080 Symptom burden and job absenteeism after treatment with additional catheter-directed thrombolysis for deep vein thrombosis. **2013**, 4, 55-9 7

2079 Apixaban. **2013**, 48, 494-509 8

2078 Treatment of venous thromboembolism: the single-drug approach. **2013**, 10, 607-613 0

2077 Barriers to the diagnosis and treatment of venous thromboembolism in advanced cancer patients: a qualitative study. **2013**, 27, 339-48 18

2076 Residual thrombosis after a first episode of proximal deep venous thrombosis. **2013**, 24, 335-60 3

2075 Assessing recurrence risk following acute venous thromboembolism: use of algorithms. **2013**, 19, 407-12 19

2074 Treating large pulmonary emboli: do the guidelines guide us?. **2013**, 19, 413-21 9

2073 Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac/noniliac venous thrombosis: a subanalysis from the home-LITE study. **2013**, 19, 476-81 13

2072 Thrombophilia in Pregnancy. **2013**, 627-647 2

2071 Long-term treatment of deep-vein thrombosis with low-molecular-weight heparin: an update of the evidence. **2013**, 110, 14-22 16

2070 Venous thromboembolism and cancer. **2013**, 128, 2614-8 25

2069 Venous Thromboses at Unusual Sites. **2013**, 262-290 1

2068 Inferior vena cava filters: truth or dare?. **2013**, 6, 498-500 3

2067 Acute pulmonary emboli in a patient on long-term dabigatran therapy. **2013**, 47, e20 5

2066 Acute pulmonary embolectomy. **2013**, 43, 1087-95 25

2065 Venous thromboembolism in hospitalized patients with active cancer. **2013**, 19, 469-75 10

2064	Current advances in understanding and managing secondary brain metastasis. 2013 , 2, 75-85	3
2063	Acute pulmonary embolism being the first presentation of undetected HIV infection: report of two cases. 2013 , 24, 497-9	
2062	Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism. 2013 , 109, 47-52	56
2061	An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. 2013 , 2, e000136	23
2060	Postthrombotic Syndrome. 2013 , 291-297	
2059	Leg pain and gynecologic malignancy. 2013 , 30, 594-600	
2058	Should low molecular weight heparin dosing be based on anti-Xa assays in antiphospholipid syndrome?. 2013 , 24, 82-4	
2057	Prophylaxis and treatment of venous thromboembolism in the critically ill. 2013 , 3, 143-51	10
2056	Decision aids: when 'nudging' patients to make a particular choice is more ethical than balanced, nondirective content. 2013 , 32, 303-10	42
2055	Thrombogenic catheter-associated superior vena cava syndrome. 2013 , 2013, 793054	10
2054	Thrombosis in women: what are the knowledge gaps in 2013?. 2013 , 11 Suppl 1, 180-91	34
2053	Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. 2013 , 11, 778-82	8
2052	A review on state-of-the-art data regarding safe early discharge following admission for pulmonary embolism: what do we know?. 2013 , 36, 507-15	16
2051	Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. 2013 , 76, 776-86	208
2050	Diagnosis and anticoagulant treatment. 2013 , 19, 187-98	7
2049	The ASH Choosing Wisely [®] campaign: five hematologic tests and treatments to question. 2013 , 2013, 9-14	23
2048	Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism. 2013 , 2013, 471-7	18
2047	The diagnosis and treatment of venous thromboembolism. 2013 , 2013, 457-63	43

2046	Computed tomography-assessed right ventricular dysfunction and risk stratification of patients with acute non-massive pulmonary embolism: systematic review and meta-analysis. 2013 , 11, 1823-32	67
2045	Cost-effectiveness of additional catheter-directed thrombolysis for deep vein thrombosis. 2013 , 11, 1032-42	35
2044	Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis. 2013 , 11, 998-1000	37
2043	Catheter-directed thrombolysis for deep venous thrombosis might be cost-effective, but for whom?. 2013 , 11, 1029-31	4
2042	Aspirin and recurrent venous thromboembolism. 2013 , 28 Suppl 1, 99-104	7
2041	Postintervention duration of anticoagulation in venous surgery. 2013 , 28 Suppl 1, 105-11	3
2040	Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. 2013 , 11, 1287-94	61
2039	Presence of varicose veins in cancer patients increases the risk for occurrence of venous thromboembolism. 2013 , 11, 1993-2000	16
2038	Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. 2013 , 347, f5133	125
2037	Venous thrombosis: understanding the paradoxes of recurrence. 2013 , 11 Suppl 1, 161-9	18
2036	Health-related quality of life after catheter-directed thrombolysis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. 2013 , 3, e002984	56
2035	Successful alteplase bolus administration for a presumed massive pulmonary embolism during cardiopulmonary resuscitation. 2013 , 47, 1730-5	6
2034	The use of thrombolytic therapy in pregnancy. 2013 , 6, 105-111	34
2033	Spontaneous plantar vein thrombosis: state of the art. 2013 , 28, 432-7	10
2032	Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. 2013 , 122, 817-24	86
2031	The ASH Choosing Wisely [®] campaign: five hematologic tests and treatments to question. 2013 , 122, 3879-83	126
2030	Successful treatment of acute portal vein thrombosis with rivaroxaban. 2013 , 110, 626-7	42
2029	Accuracy of emergency physician-performed ultrasonography in the diagnosis of deep-vein thrombosis: a systematic review and meta-analysis. 2013 , 109, 137-45	111

2028	ACP Journal Club: apixaban reduced recurrence and did not increase major bleeding in previously treated VTE. 2013 , 158, JC2		
2027	Response. <i>Chest</i> , 2013 , 143, 874-875	5:3	
2026	Correlation between early direct communication of positive CT pulmonary angiography findings and improved clinical outcomes. <i>Chest</i> , 2013 , 144, 1546-1554	5:3	16
2025	Teaching patients INR self-management. 2013 , 43, 67-9		3
2024	Probiotics in critically ill patients: more data are needed. <i>Chest</i> , 2013 , 143, 873-874	5:3	
2023	Are asymptomatic DVTs relevant?: one measure for all. <i>Chest</i> , 2013 , 143, 874	5:3	1
2022	Counterpoint: should systemic lytic therapy be used for submassive pulmonary embolism? No. <i>Chest</i> , 2013 , 143, 299-302	5:3	4
2021	Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis. 2013 , 19, 2182-9		11
2020	Acute pulmonary embolism. 2013 , 43, 25-6		1
2019	The utility of screening for asymptomatic lower extremity deep venous thrombosis during inflammatory bowel disease flares: a pilot study. 2013 , 19, 1053-8		13
2018	Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis. 2013 , 110, 732-41		73
2017	Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. 2013 , 110, 697-705		68
2016	A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism. 2013 , 110, 959-65		16
2015	Are new oral anticoagulants ready for use in patients with cancer?. 2013 , 11, 1446-9		5
2014	Venous thromboembolic disease. 2013 , 11, 1402-29		73
2013	[Controversies in massive pulmonary embolism]. 2013 , 141, 486-94		
2012	Vena cava filters in hospitalised patients with chronic obstructive pulmonary disease and pulmonary embolism. 2013 , 109, 897-900		14
2011	Respiratory review of 2013: pulmonary thromboembolism. 2013 , 75, 89-94		5

2010	Fondaparinux reversal with activated prothrombin complex concentrate in anaesthetised bleeding rats. 2013 , 109, 560-3	6
2009	The influence of thrombophilia on the long-term survival of patients with a history of venous thromboembolism. 2013 , 109, 79-84	12
2008	Venous insufficiency and thromboembolic disease in bariatric surgery patients. 2013 , 50, 191-5	4
2007	Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. 2013 , 110, 834-43	74
2006	Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. 2013 , 9, 207-28	18
2005	An update of consensus guidelines for warfarin reversal. 2013 , 198, 198-9	105
2004	A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis. 2013 , 2013, 247913	10
2003	Deep Vein Thrombosis and Pulmonary Embolism. 2013 , 247-261	1
2002	Thrombolysis in submassive pulmonary embolism, prudent or puerile?. 2013 , 2013,	3
2001	A rare nidus for pulmonary thromboembolism after vertebroplasty. 2013 , 2013,	3
2000	Acute Thromboembolic Pulmonary Hypertension. 2013 ,	
1999	Relationship between Specific Distributions of Isolated Soleal Vein Thrombosis and Risk Factors. 2014 , 7, 246-55	5
1998	Characteristics and clinical management of acute pulmonary embolism in real world: findings from TUSCAN-PE Study. 2014 ,	
1997	The recent clinical trials on use of the novel direct oral anticoagulants in patients with venous thromboembolism: a review. 2014 , 3,	
1996	Massive pulmonary embolism in a young boy with T-cell leukaemia. Successful thrombolytic therapy by recombinant tissue plasminogen activator (rtPA). 2014 , 34, 233-6	1
1995	Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. 2014 , 8, 453-61	54
1994	Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients. 2014 , 10, 841-50	6
1993	Effect of rivaroxaban on fibrinolytic therapy in massive pulmonary embolism: two cases. 2014 , 76, 127-30	

1992	Evidence and clinical judgment: vena cava filters. 2014 , 111, 618-24	9
1991	Bleeding risk and mortality of edoxaban: a pooled meta-analysis of randomized controlled trials. 2014 , 9, e95354	6
1990	The adherence to initial processes of care in elderly patients with acute venous thromboembolism. 2014 , 9, e100164	0
1989	Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. 2014 , 9, e114445	46
1988	Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice. 2014 , 111, 607-14	15
1987	IVC Filters: Challenges and Future Directions. 2014 , 2014, 1-6	
1986	Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. 2014 , 8, 2181-91	3
1985	New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. 2014 , 10, 423-36	25
1984	Tempofilter II implantation in patients with lower extremity fractures and proximal deep vein thrombosis. 2014 , 20, 245-50	1
1983	Thrombolytic therapy complemented by ECMO: successful treatment for a case of massive pulmonary thromboembolism with hemodynamic collapse. 2014 , 29, 735-8	6
1982	Catheter-directed clot fragmentation using the Cleaner [®] device in a patient presenting with massive pulmonary embolism. 2014 , 8, 30-6	6
1981	Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal. 2014 , 27, 615-24	7
1980	OPTIMAL PREVENTION OF HOSPITAL VENOUS THROMBOEMBOLISM WITH THE HELP OF MEDICAL INFORMATION SYSTEM. 2014 , 10, 425-431	
1979	. 2014 ,	2
1978	Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective. 2014 , 20, 174-86	33
1977	Baseline Analysis on the Outcome of Patients with Deep Vein Thrombosis (DVT) Before the Global Impact of New Oral Anticoagulants in Italy: Data from RIETE Registry. 2014 , 04,	
1976	Impact of anatomical location of lower limb venous thrombus on the risk of subsequent cancer. 2014 , 112, 1129-36	16
1975	Epidemiology and prevention of deep vein thrombosis. 2014 , 6-22	

1974	Inferior Vena Cava Filters in Trauma Patients: A National Practice Patterns Survey of U.S. Trauma Centers. 2014 , 80, 1237-1244	5
1973	Pre-diagnostic management of patients suspicious of deep vein thrombosis. 2014 , 3, 34	1
1972	Inflammatory bowel disease and thromboembolism. 2014 , 20, 13863-78	91
1971	Popliteal vein aneurysm: Is it necessary to apply anticoagulants after a surgery?. 2014 , 43, 89-92	
1970	Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. 2014 , 17, 691-5	38
1969	Inferior vena cava filters in patients with advanced-stage cancer. 2014 , 7, 136-41	14
1968	The Role of Leg Compression in the Treatment of Deep Vein Thrombosis. 2014 , 29, 66-70	10
1967	Outpatient versus inpatient treatment for acute pulmonary embolism. 2014 , CD010019	16
1966	Incidental Findings in Stress Echocardiography: Embolization of an Iliofemoral Stent. 2014 , 30, 99-102	
1965	Efficacy of a short course of complex lymphedema therapy or graduated compression stocking therapy in the treatment of post-thrombotic syndrome. 2014 , 19, 42-8	19
1964	Selection of contraceptive therapy for patients with thrombophilia: a review of the evidence. 2014 , 23, 318-26	3
1963	Duration of anticoagulation for venous thromboembolic events. 2014 , 130, 2343-8	2
1962	Decreased incidence of venous thromboembolism after spine surgery with early multimodal prophylaxis: Clinical article. 2014 , 21, 677-84	72
1961	Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. 2014 , 4, 619-639	1
1960	No consensus exists for use of anticoagulation for calf vein thrombosis. 2014 , 22, 93-7	7
1959	From pre-operative comorbidities to post-operative cognitive dysfunction: The challenging face of geriatric anaesthesia. 2014 , 58, 248-50	5
1958	Direct oral anticoagulants as alternative treatment options for the effective long-term treatment of patients with pulmonary embolism in primary care: a review. 2014 , 46, 341-52	1
1957	Computational investigation of potential dosing schedules for a switch of medication from warfarin to rivaroxaban-an oral, direct Factor Xa inhibitor. 2014 , 5, 417	11

1956	Experience with vena cava filters at a large community hospital and level-I trauma center: indications, complications, and compliance barriers. 2014 , 20, 546-52	4
1955	Recurrent venous thromboembolism in a patient with heterozygous factor v leiden mutation. 2014 , 49, 748-51	2
1954	New insights into treatment of venous thromboembolism. 2014 , 2014, 297-305	5
1953	Prevention and treatment of venous thromboembolism in patients with cancer. 2014 , 2014, 312-7	5
1952	Management of non-vitamin K antagonist oral anticoagulants in the perioperative setting. 2014 , 2014, 385014	19
1951	Glycosaminoglycans: anticoagulant and nonanticoagulant actions: a short history of symposia held at villa vigoni. 2014 , 40, 831-6	3
1950	Life-saving systemic thrombolysis in a patient with massive pulmonary embolism and a recent hemorrhagic cerebrovascular accident. 2014 , 41, 174-6	10
1949	How long to treat acute venous thrombosis in cancer: can treatment be personalized?. 2014 , 32, 3586-7	2
1948	Thrombolysis for acute submassive pulmonary embolism: CON viewpoint. 2014 , 69, 105-7	3
1947	Antithrombotic treatment of splanchnic vein thrombosis: results of an international registry. 2014 , 40, 99-105	36
1946	Direct oral anticoagulants: integration into clinical practice. 2014 , 90, 529-39	13
1945	How long to anticoagulate?. 2014 , 107, 495-7	1
1944	Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. 2014 , 4, e005379	1
1943	Thrombosis prophylaxis and mortality risk among critically ill adults. <i>Chest</i> , 2014 , 146, 51-57	5.3 30
1942	How should we treat May-Thurner syndrome and other causes of iliac vein obstruction? Examining the evidence. 2014 , 6, 95-101	4
1941	Treatment of deep vein thrombosis. 2014 , 136-160	1
1940	Venous Thromboembolism in Cancer Patients. 2014 , 42, 24-33	7
1939	Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants. 2014 , 30, 1513-20	16

1938	The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism. 2014 , 30, 2179-90	3
1937	Central venous catheter-related thrombosis. 2014 , 2014, 306-11	76
1936	Management of incidental splanchnic vein thrombosis in cancer patients. 2014 , 2014, 318-20	5
1935	Five hematologic tests and treatments to question. 2014 , 2014, 599-603	7
1934	Venous access catheter-related thrombosis in patients with cancer. 2014 , 55, 501-8	11
1933	[Cancer-associated venous thromboembolic recurrence: disregard of treatment recommendations]. 2014 , 101, 295-301	10
1932	Aktuelle Aspekte der Kompressionstherapie in der Phlebologie. 2014 , 40, 510-513	
1931	[Aggressive treatment of deep vein thrombosis - contra]. 2014 , 139, 539-45	1
1930	How can we improve the diagnosis of deep vein thrombosis and pulmonary embolism at the primary level?. 2014 , 11, 131-134	
1929	PK evaluation of fondaparinux sodium for the treatment of thrombosis. 2014 , 10, 269-77	2
1928	Interventionelle Therapie der venösen Thrombembolie. 2014 , 3, 50-54	
1927	Relationships of DVT with PE, PTS, superficial vein thrombosis and cellulitis. 2014 , 108-116	
1926	Duodenal perforation by an inferior vena cava filter in a polyarteritis nodosa sufferer. 2014 , 5, 1164-6	6
1925	The AABB recommendations for the Choosing Wisely campaign of the American Board of Internal Medicine. 2014 , 54, 2344-52	105
1924	Prior myocardial infarction and presence of upper gastrointestinal conditions among patients with venous thromboembolism: prevalence, associated comorbidities and burden. 2014 , 39, 253-8	
1923	Direct oral anticoagulants: new drugs and new concepts. 2014 , 7, 1333-51	67
1922	Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. 2014 , 23, 1468-76	68
1921	Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community-based study. 2014 , 12, 831-8	52

1920	Randomised trial of no hydration vs. sodium bicarbonate hydration in patients with chronic kidney disease undergoing acute computed tomography-pulmonary angiography. 2014 , 12, 1658-66	34
1919	The use of oral anticoagulants for the treatment of venous thromboembolic events in an ED. 2014 , 32, 1526-33	4
1918	The risk of recurrence in women with venous thromboembolism while using estrogens: a prospective cohort study. 2014 , 12, 635-40	38
1917	Deep Vein Thrombosis. 2014 , 1-31	
1916	Risk of falls and bleeding in elderly patients with acute venous thromboembolism. 2014 , 276, 378-86	12
1915	Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. 2014 , 17, 763-70	17
1914	Upper extremity deep vein thrombosis in hospitalized patients: a descriptive study. 2014 , 9, 48-53	8
1913	The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus: comment. 2014 , 12, 1372-3	1
1912	Thrombolysis for hemodynamically stable pulmonary embolism: time to close the book?. 2014 , 134, 1169-70	1
1911	Inferior vena cava filter usage, complications, and retrieval rate in cancer patients. 2014 , 127, 1111-1117	30
1910	Prophylactic use of heparin for deep vein thrombosis in restrained psychiatric patients: a chart review. 2014 , 36, 690-3	7
1909	Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. 2014 , 12, 436-43	76
1908	Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. 2014 ,	2
1907	Evolving use of new oral anticoagulants for treatment of venous thromboembolism. 2014 , 124, 1020-8	95
1906	Chronic Thromboembolic Pulmonary Hypertension: Experience Improves Outcomes. 2014 , 50, 507-508	
1905	Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: comment. 2014 , 12, 2136-8	9
1904	Value of complete full-length lower extremity sonography in patients undergoing computed tomographic pulmonary angiography. 2014 , 33, 2137-43	2
1903	Antiphospholipid syndrome in renal transplantation. 2014 , 19, 177-85	19

1902 Protocolo diagnóstico y terapéutico de la tromboembolia de pulmón. **2014**, 11, 4093-4096

1901 Nonsurgical Therapeutic Options in Portal Vein Thrombosis. **2014**, 30, 388-92

6

1900 The contribution of immobility risk factors to the incidence of venous thrombosis in an older population. **2014**, 12, 290-6

48

1899 Massive and submassive pulmonary embolism: diagnostic challenges and thrombolytic therapy. **2014**, 21, 208-10

1898 Portal vein thrombosis: a clinician-oriented and practical review. **2014**, 20, 498-506

21

1897 The risk of venous thromboembolism in renal cell carcinoma patients with residual tumor thrombus. **2014**, 12, 855-9

9

1896 Unexpectedly high recanalization rate in patients with pulmonary embolism treated with anticoagulants alone. **2014**, 189, 1277-9

18

1895 The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study: comment. **2014**, 12, 421-3

2

1894 Medical literature, vena cava filters and evidence of efficacy. A descriptive review. **2014**, 111, 761-9

26

1893 The Use of Echocardiography in Diagnosis, Risk Stratification and Management of Pulmonary Embolism: A Retrospective Single-Centre Analysis. **2014**, 15, 199-204

1

1892 Inherited Thrombophilia. **2014**, 27, 227-33

12

1891 Superficial Thrombophlebitis. **2014**, 1-6

1890 Venöse Thromboembolie. **2014**, 9, 1-13

1889 [Deep vein thrombosis - advances in diagnosis and treatment]. **2014**, 156 Spec no 2, 59-63; quiz 64

2

1888 The Massachusetts General Hospital Pulmonary Embolism Response Team (MGH PERT): creation of a multidisciplinary program to improve care of patients with massive and submassive pulmonary embolism. **2014**, 42, 31-7

87

1887 Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. **2014**, 12, 22

20

1886 Treatment options for venous thromboembolism: lessons learnt from clinical trials. **2014**, 12, 27

17

1885 An empirical comparison of key statistical attributes among potential ICU quality indicators. **2014**, 42, 1821-31

22

1884	Postthrombotic syndrome: a 2014 update. 2014 , 29, 514-9	17
1883	Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin. 2014 , 25, 838-44	2
1882	Incidence of venous thromboembolism in the setting of hematopoietic cell transplantation. 2014 , 21, 15-9	5
1881	Treatment and complications in orthopaedic trauma patients with symptomatic pulmonary embolism. 2014 , 28 Suppl 1, S6-9	4
1880	Calf muscle venous thrombosis: a review of the clinical implications and therapy. 2014 , 48, 396-401	18
1879	Outcomes of patients requiring insertion of an inferior vena cava filter: a retrospective observational study. 2014 , 25, 266-71	8
1878	Below-knee deep vein thrombosis: an opportunity to prevent pulmonary embolism?. 2014 , 77, 459-63	22
1877	Long-term outcomes after pulmonary embolism: current knowledge and future research. 2014 , 25, 407-15	43
1876	Pulmonary embolism. 2014 , 9, 14-20	0
1875	Lower limb joint replacement in patients with a history of venous thromboembolism. 2014 , 96-B, 1515-9	7
1874	Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. 2014 , 10, 627-39	16
1873	Highlights of the American Society of Hematology Meeting 2013: hemostaseology. 2014 , 7, 126-129	0
1872	Fibrinogen and catheter-directed thrombolysis. 2014 , 27, 182-95	4
1871	'Popcorn thrombus': a case of massive intracardiac thromboembolism. 2014 , 100, 520-1	1
1870	Systematic review and meta-analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism. 2014 , 8, 275-82	15
1869	Catheter-directed thrombolysis for acute limb ischaemia: An audit. 2014 , 7, 471-5	5
1868	What is the Best Treatment for a Cancer Patient with Thrombosis?. 2014 , 8, 49-55	8
1867	Cancer-associated thrombosis: an overview. 2014 , 8, 129-37	103

1866	Comparison of initial loading doses of 5 mg and 10 mg for warfarin therapy. 2014 , 13, 12-17	1
1865	Novel oral anticoagulants in cardiovascular disease. 2014 , 19, 34-44	20
1864	Incidence and Treatment Options for Massive Pulmonary Embolism in Sweden. 2014 , 15, 15-16	
1863	Duration of treatment. 2014 , 162-177	
1862	Venous thromboembolism in older adults: A community-based study. 2014 , 127, 530-7.e3	32
1861	Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism. 2014 , 133, 743-9	16
1860	Distal deep vein thrombosis--a benign disease?. 2014 , 134, 5-6	3
1859	Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. 2014 , 59, 1362-7.e1	32
1858	The incidence of contralateral iliac venous thrombosis after stenting across the ilio caval confluence in patients with acute or chronic venous outflow obstruction. 2014 , 2, 253-9	20
1857	The newer anticoagulants in thrombosis control in cancer patients. 2014 , 41, 339-45	4
1856	Factors affecting Cook Gunther Tulip and Cook Celect inferior vena cava filter retrieval success. 2014 , 2, 21-5	8
1855	[Portal vein thrombosis associated with an acute cytomegalovirus infection]. 2014 , 39, 224-30	5
1854	Residual rates of reflux and obstruction and their correlation to post-thrombotic syndrome in a randomized study on catheter-directed thrombolysis for deep vein thrombosis. 2014 , 2, 123-30	22
1853	Venous gangrene and intravascular coagulation and fibrinolysis in a patient treated with rivaroxaban. 2014 , 127, e7-8	4
1852	Time-dependent hardening of blood clots quantitatively measured in vivo with shear-wave ultrasound imaging in a rabbit model of venous thrombosis. 2014 , 133, 265-71	31
1851	Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations. 2014 , 134, 227-33	15
1850	Risk factors for recurrent venous thromboembolism in young and middle-aged women. 2014 , 133, 762-7	9
1849	Evaluation of initial heparin infusion rates for a high-dose protocol. 2014 , 37, 419-26	

1848	Pulmonary thromboembolism after operation for bilateral open distal radius fractures: a case report. 2014 , 7, 36	4
1847	A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. 2014 , 38, 137-49	23
1846	Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. 2014 , 146, 835-848.e6	205
1845	An unusual presentation of a swollen arm: a case report. 2014 , 8, 22	2
1844	Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism. 2014 , 74, 243-62	25
1843	Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. 2014 , 35, 1836-43	15
1842	[What are the indications for vena cava filters in 2014?]. 2014 , 35, 349-52	0
1841	Aspirin for prevention and treatment of venous thromboembolism. 2014 , 28, 103-8	35
1840	Leg discomfort: beyond the joints. 2014 , 98, 429-44	3
1839	Subcutaneous enoxaparin for therapeutic anticoagulation in hemodialysis patients. 2014 , 133, 1023-8	14
1838	Venous stenting after deep venous thrombosis and antithrombotic therapy: A systematic review. 2014 , 2, 88-97	27
1837	Study of clinical profile and management of patients with pulmonary embolism - single center study. 2014 , 66, 197-202	5
1836	Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism. 2014 , 12, 1116-20	108
1835	Clinical problem-solving. Out of the blue. 2014 , 370, 1742-8	10
1834	Edoxaban: a focused review of its clinical pharmacology. 2014 , 35, 1844-55	90
1833	Diagnosis and management of pulmonary embolism in the elderly. 2014 , 25, 343-9	19
1832	Treating infrainguinal deep venous thrombosis. 2014 , 17, 103-8	6
1831	Postprocedural management of patients undergoing endovascular therapy for acute and chronic lower-extremity deep venous disease. 2014 , 17, 127-31	3

1830	[The initial management in intensive care of pelvic ring injury patients]. 2014 , 33, 344-52	1
1829	Venous thromboembolism following arthroscopic knee surgery: a current concepts review of incidence, prophylaxis, and preoperative risk assessment. 2014 , 44, 331-43	20
1828	Antithrombotics in heart failure with reduced ejection fraction and normal sinus rhythm: an evidence appraisal. 2014 , 48, 226-37	5
1827	Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. 2014 , 17, 52-64	56
1826	Update on pharmacologic therapy for pulmonary embolism. 2014 , 19, 159-69	3
1825	Current state of anticoagulants to treat deep venous thrombosis. 2014 , 16, 463	8
1824	Managing iliofemoral deep venous thrombosis of pregnancy with a strategy of thrombus removal is safe and avoids post-thrombotic morbidity. 2014 , 59, 456-64	34
1823	Combined surgical and interventional therapy of acute portal vein thrombosis without cirrhosis: a new effective hybrid approach for recanalization of the portal venous system. 2014 , 218, e79-86	11
1822	Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants. 2014 , 28, 1-8	25
1821	International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. 2014 , 32, 587-600	255
1820	Accelerated thrombolysis for pulmonary embolism: will clinical benefit be ULTIMATEly realized?. 2014 , 129, 420-1	17
1819	Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. 2014 , 129, 479-86	538
1818	Managing pulmonary embolism from presentation to extended treatment. 2014 , 133, 139-48	30
1817	Cirugía de la trombosis venosa profunda iliofemoral: postura en contra. 2014 , 66, 322-325	
1816	Use of rivaroxaban in a patient with history of nephrotic syndrome and hypercoagulability. 2014 , 48, 1655-8	12
1815	New oral anticoagulants and the cancer patient. 2014 , 19, 82-93	149
1814	Interventional Treatment of Deep Vein Thrombosis. 2014 , 1-7	
1813	Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism. 2014 , 12, 1353-63	22

1812	Maths in medicine: a life saving formula?. 2014 , 31, 167-168	
1811	Clinical outcome in patients with venous thromboembolism receiving concomitant anticoagulant and antiplatelet therapy. 2014 , 25, 821-5	10
1810	Chronic thromboembolic pulmonary hypertension: experience improves outcomes. 2014 , 50, 507-8	
1809	Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. 2014 , 74, 1587-603	27
1808	Peri-operative massive pulmonary embolism management: is veno-arterial ECMO a therapeutic option?. 2014 , 58, 1280-6	20
1807	Edoxaban: Review of pharmacology and key phase I to III clinical trials. 2014 , 19, 409-16	17
1806	Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism. 2014 ,	1
1805	Prognostic significance of tricuspid annular displacement in normotensive patients with acute symptomatic pulmonary embolism. 2014 , 12, 1020-7	45
1804	Prophylaxis against venous thromboembolism in ambulatory patients with cancer. 2014 , 370, 2515-9	40
1803	Extensive pulmonary embolism after severe postpartum haemorrhage: management with an inferior vena cava filter. 2014 , 23, 390-3	6
1802	Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach. 2014 , 36, 1454-64.e3	11
1801	New approaches on diagnosis and treatment of venous thromboembolism. 2014 , 4, 147-151	0
1800	New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. 2014 , 74, 2015-32	19
1799	[Should we treat an incidentally discovered pulmonary embolism?]. 2014 , 35, 775-8	0
1798	Management of venous thrombo-embolism: an update. 2014 , 35, 2855-63	296
1797	Pulmonary Embolism. 2014 , 3, 479-493	
1796	Endovascular Treatment of Deep Vein Thrombosis. 2014 , 3, 607-617	
1795	Economic implications of inadequate treatment of venous thromboembolism and potential solutions. 2014 , 27, 178-86	5

1794	Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. 2014 , 30, 829-37	79
1793	Prevention and treatment of thrombosis associated with central venous catheters in cancer patients. 2014 , 7, 599-616	12
1792	Stratégies diagnostiques devant une suspicion d'embolie pulmonaire aiguë place actuelle et perspectives de la scintigraphie pulmonaire de ventilation-perfusion. 2014 , 38, 275-282	1
1791	Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. 2014 , 25, 1317-25	98
1790	Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients. 2014 , 134, 617-21	11
1789	Shock. 2014 , 32, 747-58	11
1788	Management dilemmas in acute pulmonary embolism. 2014 , 69, 174-80	47
1787	Risk factors associated with bleeding after alteplase administration for pulmonary embolism: a case-control study. 2014 , 34, 818-25	17
1786	Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis. 2014 , 12, 595-605	27
1785	Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database. 2014 , 25, 1181-5	125
1784	Clinical use of the activated partial thromboplastin time and prothrombin time for screening: a review of the literature and current guidelines for testing. 2014 , 34, 453-77	62
1783	Acute pulmonary embolus: the next frontier in venous thromboembolic interventions. 2014 , 16, 336	
1782	Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. 2014 , 134, 774-82	88
1781	Treatment and long-term management of venous thromboembolism. 2014 , 34, 519-36	2
1780	Edoxaban: an update on the new oral direct factor Xa inhibitor. 2014 , 74, 1209-31	75
1779	Thrombosis of the inferior vena cava and malignant disease. 2014 , 134, 668-73	20
1778	Dabigatran etexilate: a review of its use in the treatment of acute venous thromboembolism and prevention of venous thromboembolism recurrence. 2014 , 74, 1785-800	19
1777	Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. 2014 , 32, 3607-12	67

1776	Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. 2014 , 134, 1214-9	129
1775	What are the pharmacotherapy options for treating venous thromboembolism in cancer patients?. 2014 , 15, 799-807	1
1774	XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. 2014 , 12, 16	26
1773	Case records of the Massachusetts General Hospital. Case 29-2014. A 60-year-old woman with syncope. 2014 , 371, 1143-50	10
1772	Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis. 2014 , 12, 344-8	20
1771	Safety of ventilation/perfusion single photon emission computed tomography for pulmonary embolism diagnosis. 2014 , 41, 1957-64	29
1770	Aktuelle Therapie und Sekundärprävention der Lungenembolie. 2014 , 19, 77-90	
1769	Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function: results of an observational study. 2014 , 22, 89-99	3
1768	Pulmonary embolism: current and new treatment options. 2014 , 30, 1975-89	9
1767	Effective diagnosis and treatment of pulmonary embolism: Improving patient outcomes. 2014 , 107, 406-14	20
1766	Unusual venous thrombosis in a 35-year-old man. 2014 , 186, 51-5	2
1765	Shorter or longer anticoagulation to prevent recurrent venous thromboembolism: systematic review and meta-analysis. 2014 , 4, e005674	2
1764	Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data. 2014 , 9, 375-84	14
1763	Comparison of four scores to predict major bleeding in patients receiving anticoagulation for venous thromboembolism: findings from the RIETE registry. 2014 , 9, 847-52	26
1762	The value of inhibitors of factor Xa for the treatment of pulmonary embolism. 2014 , 9, 617-22	1
1761	Catheter-based therapies for deep vein thrombosis. 2014 , 16, 497	
1760	Medical and interventional options to treat pulmonary embolism. 2014 , 16, 503	2
1759	The role of novel anticoagulants in the management of venous thromboembolic disease. 2014 , 16, 326	2

1758	Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. 2014 , 31, 473-93	27
1757	Use of Fibrinolysis in Acute Pulmonary Embolism. 2014 , 2, 91-96	
1756	New oral anticoagulants in practice: pharmacological and practical considerations. 2014 , 14, 175-89	52
1755	Right ventricular dysfunction as an echocardiographic prognostic factor in hemodynamically stable patients with acute pulmonary embolism: a meta-analysis. 2014 , 14, 64	59
1754	A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study. 2014 , 15, 122	10
1753	Consenso intersociedades espa�el sobre el diagn�stico, estratificaci�n de riesgo y tratamiento de pacientes con tromboembolia pulmonar. 2014 , 66, 70-84	
1752	Submassive pulmonary embolism. 2014 , 30, 447-73	12
1751	Management of right heart failure in the critically ill. 2014 , 30, 475-98	19
1750	Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. 2014 , 742, 15-21	12
1749	An update on current management strategies for antiphospholipid syndrome-related thrombosis. 2014 , 9, 91-100	1
1748	The new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy. 2014 , 76, 76-83	7
1747	Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice. 2014 , 134, 807-13	12
1746	The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. 2014 , 130, 1636-61	331
1745	Treatment patterns of venous thromboembolism in a real-world population: the Q-VTE study cohort. 2014 , 134, 795-802	12
1744	2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. 2014 , 35, 3033-69, 3069a-3069k	1974
1743	Managing venous thromboembolism with novel oral anticoagulants in the elderly and other high-risk patient groups. 2014 , 25, 600-6	17
1742	Educar al paciente para el autocontrol del INR. 2014 , 31, 61-63	
1741	Natural history of venous thromboembolism in patients from the Mediterranean region. A systematic review. 2014 , 214, 184-91	2

1740 Embolismo pulmonar agudo. **2014**, 31, 43-44

- 1739 Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. **2014**, 30, 1233-40 11
- 1738 National trends in utilization of inferior vena cava filters in the United States, 2000-2009. **2014**, 2, 15-20 20
- 1737 Therapy for cancer-related thromboembolism. **2014**, 41, 319-38 19
- 1736 Anatomic and functional outcomes of pharmacomechanical and catheter-directed thrombolysis of iliofemoral deep venous thrombosis. **2014**, 2, 246-52 12
- 1735 Low-molecular-weight heparin modulates vein wall fibrotic response in a plasminogen activator inhibitor 1-dependent manner. **2014**, 2, 441-450.e1 12
- 1734 Clinical course and predictive factors for complication of inferior vena cava filters. **2014**, 133, 538-43 25
- 1733 Succinct review of the new VTE prevention and management guidelines. **2014**, 89, 394-408 18
- 1732 Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. **2014**, 63, 1675-83 126
- 1731 Oral anticoagulant therapy does not modify the bleeding pattern associated with the levonorgestrel-releasing intrauterine system in women with thrombophilia and/or a history of thrombosis. **2014**, 89, 48-53 7
- 1730 Natural history of venous thromboembolism in patients from the Mediterranean region. A systematic review. **2014**, 214, 184-191
- 1729 Effect of delayed inferior vena cava filter retrieval after early initiation of anticoagulation. **2014**, 113, 389-94 22
- 1728 Large embolus in transit - an unresolved therapeutic dilemma (case report and review of literature). **2014**, 43, 152-4 12
- 1727 Management of venous leg ulcers: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. **2014**, 60, 3S-59S 348
- 1726 The role of novel anticoagulants in the management of venous thromboembolism. **2014**, 19, 205-214 8
- 1725 Fibrinolysis for patients with intermediate-risk pulmonary embolism. **2014**, 370, 1402-11 852
- 1724 Advances in the diagnosis and management of acute pulmonary embolism. **2014**, 133 Suppl 2, S10-6 13
- 1723 Ultrasound-assisted thrombolysis for acute pulmonary embolism: a systematic review. **2014**, 35, 758-64 85

1722	Efficacy and safety of flow-directed pulmonary artery catheter thrombolysis for treatment of submassive pulmonary embolism. 2014 , 202, 1355-60	22
1721	Cancer-associated unsuspected pulmonary embolism. 2014 , 133 Suppl 2, S172-8	55
1720	Derivation and validation of multimarker prognostication for normotensive patients with acute symptomatic pulmonary embolism. 2014 , 189, 718-26	127
1719	Current Approaches to Deep Vein Thrombosis. 2014 ,	
1718	Fibrinolysis of pulmonary emboli--steer closer to Scylla. 2014 , 370, 1457-8	14
1717	Thrombophilia Screening. 2014 , 27, 253-9	0
1716	Predictors of attempted inferior vena cava filters retrieval in a tertiary care centre. 2014 , 134, 300-4	15
1715	Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. 2014 , 192, 1026-34	85
1714	Massive pulmonary embolism and cardiac arrest; thrombolytic therapy in a patient with recent intracranial surgery and glioblastoma multiforme. 2014 , 32, 1441.e1-3	5
1713	The American Venous Forum: Leveraging our strengths. 2014 , 2, 342-8	0
1712	Pharmacodynamics assessment of Bemiparin after multiple prophylactic and single therapeutic doses in adult and elderly healthy volunteers and in subjects with varying degrees of renal impairment. 2014 , 133, 1029-38	4
1711	Catheter-directed thrombolytic intervention is effective for patients with massive and submassive pulmonary embolism. 2014 , 28, 1589-94	16
1710	Bedside inferior vena cava filter placement by intravascular ultrasound in critically ill patients is safe and effective for an extended time. 2014 , 2, 377-82	9
1709	Meta-analysis to assess the quality of international normalized ratio control and associated outcomes in venous thromboembolism patients. 2014 , 134, 310-9	33
1708	Heparins and cancer survival: where do we stand?. 2014 , 133 Suppl 2, S133-8	27
1707	Approach to the management of incidental venous thromboembolic events in patients with cancer. 2014 , 12, 1557-60	9
1706	Oxygen delivery, cardiac function and monitoring. 1-12	
1705	Pharmacogenetics role in the safety of acenocoumarol therapy. 2014 , 112, 522-36	20

1704	Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. 2014 , 111, 172-9	70
1703	Intermediate doses of low-molecular-weight heparin for the long-term treatment of pregnancy thromboembolism. A systematic review. 2014 , 111, 559-61	11
1702	Fixed low-dose ultrasound-assisted catheter-directed thrombolysis followed by routine stenting of residual stenosis for acute ilio-femoral deep-vein thrombosis. 2014 , 111, 1153-60	44
1701	Upper extremity deep vein thrombosis. 2014 , 118-134	
1700	The association of statin use with reduced incidence of venous thromboembolism: a population-based cohort study. 2014 , 4, e005862	12
1699	Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patients. 2014 , 12, 365-73	28
1698	Prevention and treatment of venous thromboembolism: the nurse's role in management. 2014 , 9, 534-540	2
1697	Deep vein thrombosis and cancer. 2014 , 52-67	
1696	Diagnosis of deep vein thrombosis. 2014 , 24-38	
1695	Cancer and Thrombosis. 2014 , 284-295	
1694	Vena Cava Filters. 2014 , 467-473	
1693	Current venous thromboembolism management and outcomes in Japan. 2014 , 78, 708-17	81
1692	Use of a stent after catheter-directed thrombolysis is very seldom necessary. 2014 , 78, 1069-70	
1691	How I treat isolated distal deep vein thrombosis (IDDVT). 2014 , 123, 1802-9	78
1690	Magnetic resonance direct thrombus imaging differentiates acute recurrent ipsilateral deep vein thrombosis from residual thrombosis. 2014 , 124, 623-7	67
1689	Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. 2014 , 123, 1794-801	164
1688	D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. 2014 , 124, 196-203	127
1687	Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. 2014 , 123, 3972-8	125

1686	Postthrombotic syndrome following upper extremity deep vein thrombosis in children. 2014 , 124, 1166-73	38
1685	Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. 2014 , 124, 1968-75	491
1684	How I treat splanchnic vein thrombosis. 2014 , 124, 3685-91	53
1683	Five hematologic tests and treatments to question. 2014 , 124, 3524-8	44
1682	Current approaches to deep vein thrombosis. 2014 , 2-4	
1681	Post-thrombotic Syndrome. 2014 , 186-196	
1680	Peripherally inserted central catheter (PICC)-related thrombosis in critically ill patients. 2014 , 15, 329-37	50
1679	Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer. 2014 , 112, 255-63	120
1678	Central venous access. 28-37	
1677	Massive hemorrhage following thrombolysis for postpartum pulmonary embolism with cardiac arrest. 2014 , 36, 498-501	5
1676	Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. 2014 , 71, 158-67	11
1675	Venous thromboembolism and antithrombotic therapy in pregnancy. 2014 , 36, 527-53	160
1674	Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. 2014 ,	4
1673	Welcome from the chairman. 2014 , 133, 4	
1672	Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. 2014 , 93, 309-317	37
1671	VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. <i>Chest</i> , 2015 , 148, 1224-1230	148
1670	Role of coexisting contralateral primary venous disease in development of post-thrombotic syndrome following catheter-based treatment of iliofemoral deep venous thrombosis. 2015 , 3, 354-357	3
1669	Management of alveolar-pleural fistula: a complex medical and surgical problem. <i>Chest</i> , 2015 , 147, 590-593	4

1668	Using direct oral anticoagulants (DOACs) in cancer and other high-risk populations. 2015 , 2015, 125-31	12
1667	The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry. 2015 , 13, 41	35
1666	Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method. 2015 , 37, 375-80	7
1665	Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous Thromboembolism. 2015 , 94, e1235	31
1664	Incidentally found pulmonary embolism: what's the clinician to do?. 2015 , 2015, 197-201	6
1663	Guideline on aspects of cancer-related venous thrombosis. 2015 , 170, 640-8	116
1662	Rivaroxaban for the treatment and prevention of thromboembolic disease. 2015 , 67, 1119-32	10
1661	Index clinical manifestation of venous thromboembolism predicts early recurrence type and frequency: a meta-analysis of randomized controlled trials. 2015 , 13, 1043-52	14
1660	Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. 2015 , 13, 1019-27	19
1659	Spontaneous acute superficial vein thrombosis of the legs: do we really need to treat?. 2015 , 13 Suppl 1, S230-7	21
1658	Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. 2015 , 13, 1606-14	39
1657	Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism. 2015 , 100, 188-93	14
1656	Pentasaccharides for the treatment of deep vein thrombosis. 2015 ,	1
1655	Platelets: Small in Size But Essential in the Regulation of Vascular Homeostasis - Translation From Basic Science to Clinical Medicine. 2015 , 79, 1871-81	19
1654	How I treat incidental pulmonary embolism. 2015 , 125, 1877-82; quiz 2009	21
1653	Superficial venous thrombosis: deeper than meets the eye?. 2015 , 125, 208-9	2
1652	Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model. 2015 , 126, 1949-51	31
1651	Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis?. 2015 , 97-B, 458-62	51

1650	Validation of the multivariable In-hospital Mortality for Pulmonary embolism using Claims data (IMPACT) prediction rule within an all-payer inpatient administrative claims database. 2015 , 5, e009251		14
1649	Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests. 2015 , 113, 1210-5		15
1648	Antithrombotic therapy in patients with acute coronary syndrome in the intermountain heart collaborative study. 2015 , 2015, 270508		3
1647	Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. 2015 , 100, 1486-92		67
1646	Prognostic accuracy of clinical prediction rules for early post-pulmonary embolism all-cause mortality: a bivariate meta-analysis. <i>Chest</i> , 2015 , 147, 1043-1062	5:3	62
1645	Retrievable inferior vena cava filters can always be removed using "fall-back" techniques. 2015 , 3, 364-369		5
1644	Seasonal variation in the superficial vein thrombosis frequency. 2015 , 136, 1116-9		5
1643	Highlights of the American Society of Hematology Meeting 2014: Hemostaseology. 2015 , 8, 180-183		0
1642	Management of Bleeding Complications in Patients Taking Direct Oral Anticoagulants at a Large Tertiary Academic Medical Center. 2015 , 3, 162-167		
1641	[Graded compression stockings and deep vein thrombosis]. 2015 , 157, 49-51		
1640	Kein Vorteil durch Vena-cava-Filter in Ergänzung zur Antikoagulation. 2015 , 7, 32-33		
1639	Retrievable inferior vena cava filters can be placed and removed with a high degree of success: Initial experience. 2015 , 86, 719-25		8
1638	Risk of deep vein thrombosis and pulmonary embolism after heart transplantation: clinical outcomes comparing upper extremity deep vein thrombosis and lower extremity deep vein thrombosis. 2015 , 29, 629-35		16
1637	A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity. 2015 , 13, 1274-8		6
1636	Diagnostic performance of magnetic resonance imaging for acute pulmonary embolism: a systematic review and meta-analysis. 2015 , 13, 1623-34		15
1635	Surgical hardware-related iatrogenic venous compression syndrome. 2015 , 20, 162-7		3
1634	Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited?. 2015 , 13, 33		6
1633	Readiness of hospital-based internists to embrace and discuss high-value care with patients and family members: a single-centre cross-sectional survey study. 2015 , 3, E382-6		4

1632	Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. 2015 , CD010957	16
1631	The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: results of the THE-VTE study. 2015 , 13, 1642-52	52
1630	High risk use of OTC NSAIDs and ASA in family medicine: A retrospective chart review. 2015 , 27, 191-9	5
1629	Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. 2015 , 113, 231-46	29
1628	Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. 2015 , 114, 645-50	40
1627	Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. 2015 , 114, 1268-76	71
1626	Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. 2015 , 114, 150-7	112
1625	Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism. 2015 , 114, 26-34	59
1624	The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism. 2015 , 26, 709-11	4
1623	Progress in the management of acute pulmonary embolism. 2015 , 21, 417-24	7
1622	Additional value of combining low-dose computed tomography to V/Q SPECT on a hybrid SPECT-CT camera for pulmonary embolism diagnosis. 2015 , 36, 922-30	23
1621	A Multicenter Cohort Study of Inferior Vena Cava Filter Use in Children. 2015 , 62, 2089-93	13
1620	Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline. 2015 , 187, 1288-1296	27
1619	Venous thromboembolism and problems related to its continuous medical surveillance. 2015 , 69, 268-9	
1618	Postoperative Critical Care of the Adult Cardiac Surgical Patient: Part II: Procedure-Specific Considerations, Management of Complications, and Quality Improvement. 2015 , 43, 1995-2014	36
1617	Findings From 12-lead Electrocardiography That Predict Circulatory Shock From Pulmonary Embolism: Systematic Review and Meta-analysis. 2015 , 22, 1127-37	53
1616	Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. 2015 , CD010956	33
1615	Management and outcomes of axial isolated distal deep vein thrombosis at North Shore Hospital, New Zealand: a retrospective audit. 2015 , 45, 177-82	7

1614	Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital. 2015 , 40, 447-51	26
1613	Is it useful to also image the asymptomatic leg in patients with suspected deep vein thrombosis?: comment. 2015 , 13, 2127-30	1
1612	Comorbidity and the risk of venous thromboembolism in prostate cancer. 2015 , 121, 3574-6	1
1611	Alteplase for the Treatment of Pulmonary Embolism: A Review. 2015 , 37, 258-72; quiz E4	4
1610	Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients. 2015 , 35, 1007-15	17
1609	Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study. 2015 , 13, 1823-32	45
1608	Ultrasound screening for deep venous thrombosis detection: a prospective evaluation of 200 plastic surgery outpatients. 2015 , 3, e332	45
1607	Extensive thrombotic complications after inferior vena cava filter placement in 2 adolescents with spinal cord injury: a cautionary tale and review. 2015 , 37, e227-9	4
1606	Literaturverzeichnis. 2015 ,	
1605	Gastrointestinal and visceral thromboembolism. 47-59	
1604	Cancer and thrombosis. 72-87	
1603	Prophylaxis and Management of Deep Vein Thrombosis in Trauma Patients. 2015 , 28, 82	
1602	Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States. 2015 , 21, 965-72	7
1601	Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. 2015 , 9, 3557-69	
1600	Economic Evaluations of Medical Cost Differences: Use of Targeted-Specific Oral Anticoagulants vs. Warfarin among Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism in the U.S.. 2015 , 03,	
1599	Critical appraisal of dabigatran in the treatment of deep vein thrombosis and pulmonary embolism. 2015 , 6, 177-84	2
1598	Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants. 2015 , 15, 139-47	
1597	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. 2015 , 50, 7-18	3

1596	Acute phase treatment of venous thromboembolism: advanced therapy. Systemic fibrinolysis and pharmacomechanical therapy. 2015 , 113, 1202-9	4
1595	Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran. 2015 , 11, 271-82	6
1594	Patients' Experiences of Living with CANCER-associated thrombosis: the PELICAN study. 2015 , 9, 337-45	61
1593	Blood Accessibility to Fibrin in Venous Thrombosis is Thrombus Age-Dependent and Predicts Fibrinolytic Efficacy: An In Vivo Fibrin Molecular Imaging Study. 2015 , 5, 1317-27	16
1592	Assessing the risk of recurrent venous thromboembolism--a practical approach. 2015 , 11, 451-9	31
1591	10 Venous Thromboembolism (DVT and PE): Diagnosis and Treatment. 2015 ,	
1590	Outcomes of retrievable inferior vena cava filters in patients with deep vein thrombosis and transient contraindication for anticoagulation. 2015 , 89, 30-6	5
1589	Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study. 2015 , 2015, 620217	9
1588	Pulmonary embolism. 16-32	
1587	Feasibility and safety of rehabilitation after venous thromboembolism. 2015 , 11, 397-401	19
1586	Statins improve the resolution of established murine venous thrombosis: reductions in thrombus burden and vein wall scarring. 2015 , 10, e0116621	37
1585	Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. 2015 , 10, e0144856	103
1584	Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?. 2015 , 10, e0128741	26
1583	Bed rest versus early ambulation with standard anticoagulation in the management of deep vein thrombosis: a meta-analysis. 2015 , 10, e0121388	23
1582	The role of factor Xa inhibitors in venous thromboembolism treatment. 2015 , 11, 117-23	27
1581	Mobile Intracardiac Mass after Inguinal Hernia Repair: An Unresolved Treatment Dilemma. 2015 , 2015, 375089	
1580	Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. 2015 , 2015, 920361	8
1579	Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches. 2015 , 2015, 951424	37

1578 Thrombolysis. 180-199

1577 The Saudi Clinical Practice Guideline for the treatment of venous thromboembolism. Outpatient versus inpatient management. **2015**, 36, 1004-10 10

1576 Analysis of Risk Factors for Lower-limb Deep Venous Thrombosis in Old Patients after Knee Arthroplasty. **2015**, 128, 1358-62 21

1575 Electrocardiographic findings in pulmonary embolism. **2015**, 56, 533-7 3

1574 Timing of discharge follow-up for acute pulmonary embolism: retrospective cohort study. **2015**, 16, 55-61 15

1573 Edoxaban. **2015**, 50, 619-34 3

1572 Open removal of a retained retrohepatic inferior vena cava filter with a residual primary neuroectodermal renal tumoral thrombus. **2015**, 2015, 1

1571 Risk of bleeding during long-term anticoagulation with warfarin: a tertiary care center experience. **2015**, 26, 110-2 9

1570 Thrombolysis With Single Bolus Tenecteplase Compared With Streptokinase Infusion in the Treatment of Acute Pulmonary Embolism: A Pilot Study. **2015**, 21, 550-7 4

1569 Emergency Evaluation for Pulmonary Embolism, Part 2: Diagnostic Approach. **2015**, 49, 104-17 24

1568 The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. **2015**, 113, 671-3 17

1567 Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. **2015**, 125, 229-35 40

1566 Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist. **2015**, 13, 20 33

1565 Management of Crashing Patients with Pulmonary Hypertension. **2015**, 33, 623-43 2

1564 Contrast enhanced chest-MDCT in oncologic patients. Prospective evaluation of the prevalence of incidental pulmonary embolism and added value of thin reconstructions. **2015**, 25, 3200-6 12

1563 Pulmonary embolism response teams. **2015**, 17, 387 22

1562 Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study. **2015**, 15, 298 15

1561 Venous Thromboembolism in Cancer: Frequently Asked Questions When Guidelines are Inconclusive. **2015**, 33, 142-51 1

1560	Nephrotic syndrome complicated with deep venous thrombosis in the upper extremities. 2015 , 5, 1-5	4
1559	Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. 2015 , 13, 811-24	5
1558	Management of intermediate-risk pulmonary embolism: uncertainties and challenges. 2015 , 95, 489-97	10
1557	Incidence of hospital readmission in patients diagnosed with DVT and PE: clinical burden of recurrent events. 2015 , 69, 321-7	12
1556	Interventional therapy for venous thromboembolism. 2015 , 13 Suppl 1, S245-51	8
1555	Chemoprophylaxis for Venous Thromboembolism Prevention: Has the Horse Already Left the Barn?. 2015 , 136, 575e-577e	2
1554	Inferior vena cava filters. 2015 , 187, 1234	
1553	Thrombophilia testing patterns amongst patients with acute venous thromboembolism. 2015 , 136, 1160-4	12
1552	Fixed low-dose ultrasound-assisted catheter-directed thrombolysis for intermediate and high-risk pulmonary embolism. 2015 , 36, 597-604	59
1551	The triumph of medicine: how overdiagnosis is turning healthy people into patients. 2015 , 32, 127-8	10
1550	Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). 2015 , 132, 2403-11	97
1549	Rationale and design of three observational, prospective cohort studies including biobanking to evaluate and improve diagnostics, management strategies and risk stratification in venous thromboembolism: the VTEval Project. 2015 , 5, e008157	15
1548	Management of Bleeding Associated with New Oral Anticoagulants. 2015 , 41, 788-801	14
1547	Catheter-related thrombosis: Unresolved issues. 2015 , 136, 1055-6	1
1546	Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. <i>Chest</i> , 2015 , 147, 475-483	5-3 219
1545	[Diagnosis and management of acute pulmonary embolism. ESC guidelines 2014]. 2015 , 40, 1048-54	19
1544	Controversies in the Management of Life-Threatening Pulmonary Embolism. 2015 , 36, 835-41	13
1543	Venous clot lysis and stenting. 2015 , 2015, 210-4	4

1542	Bridging with half-therapeutic dose enoxaparin in outpatients with left ventricular assist devices and sub-therapeutic international normalized ratios. 2015 , 34, 860-2	13
1541	Practice variation in the management of distal deep vein thrombosis in primary vs. secondary cares: A clinical practice survey. 2015 , 136, 526-30	11
1540	Risk assessment and management of high and intermediate risk pulmonary embolism. 2015 , 44, e401-8	5
1539	Incidence and risk factors for venous thromboembolism after laparoscopic surgery for colorectal cancer. 2015 , 100, e35-8	20
1538	Duration of anticoagulation: the decision-making process. 2015 , 76, C156-60	
1537	Venous Thromboembolic Disease: DVT and PE. 2015 , 399-425	
1536	Pulmonary Thromboembolism. 2015 , 144-147	
1535	A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs. 2015 , 128, 90.e9-15	8
1534	Fatal pulmonary embolization after negative serial ultrasounds. 2015 , 48, 158-60	1
1533	Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States. 2015 , 37, 62-70	54
1532	Outcome of central venous catheter associated upper extremity deep vein thrombosis in cancer patients. 2015 , 135, 298-302	33
1531	Guidelines for the management of cancer and thrombosis - Special aspects in women. 2015 , 135 Suppl 1, S16-22	3
1530	Fondaparinux in the initial and long-term treatment of venous thromboembolism. 2015 , 135, 311-7	13
1529	Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy. 2015 , 135, 303-10	42
1528	Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials. 2015 , 47, 61-8	37
1527	Short-term clinical outcome of normotensive patients with acute PE and high plasma lactate. 2015 , 70, 333-8	39
1526	How D-dimer assay can be useful in deciding the duration of anticoagulation after venous thromboembolism: a review. 2015 , 8, 79-88	2
1525	Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. 2015 , 135, 281-8	66

1524	[Retrospective study about 73 consecutive patients treated by direct oral anticoagulant and admitted to an emergency room]. 2015 , 40, 1-9	4
1523	Long-term outcome after pregnancy-related venous thrombosis. 2015 , 135 Suppl 1, S1-4	10
1522	Role of thrombophilia testing: con. 2015 , 39, 379-91	1
1521	Bleeding risk with systemic thrombolytic therapy for pulmonary embolism: scope of the problem. 2015 , 6, 57-66	35
1520	Comparative outcomes of catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of inferior vena caval thrombosis. 2015 , 8, e001882	21
1519	Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin?. 2015 , 66, 241-53	18
1518	Benefit of anticoagulation for the treatment of lower extremity superficial venous thrombosis. 2015 , 3, 236-41	4
1517	Management of peri-operative anti-thrombotic therapy. 2015 , 70 Suppl 1, 58-67, e21-3	38
1516	The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders. 2015 , 135, 217-25	24
1515	Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. 2015 , 18, 399-409	23
1514	Superficial vein thrombosis: a current approach to management. 2015 , 168, 639-45	30
1513	Pharmacotherapy with oral Xa inhibitors for venous thromboembolism. 2015 , 16, 645-58	9
1512	Prevention and treatment of the post-thrombotic syndrome and of the chronic thromboembolic pulmonary hypertension. 2015 , 13, 193-207	7
1511	Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. 2015 , 13, 775-81	45
1510	Managing unusual presentations of venous thromboembolism. 2015 , 39, 304-10	2
1509	Periprocedural management of rivaroxaban-treated patients. 2015 , 16, 685-91	4
1508	Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach. 2015 , 45, 1142-9	13
1507	Pulmonary embolism in 2014--the mosaic seems completing. 2015 , 33, 302-4	

1506	Thrombophilia: clinical-practical aspects. 2015 , 39, 367-78	32
1505	Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results. 2015 , 40, 131-8	7
1504	Comparison of LMWH versus UFH for hemorrhage and hospital mortality in the treatment of acute massive pulmonary thromboembolism after thrombolytic treatment : randomized controlled parallel group study. 2015 , 193, 121-7	6
1503	Mortality at 30 and 90 days in elderly patients with pulmonary embolism: a retrospective cohort study. 2015 , 10, 431-6	18
1502	Effectiveness of inferior vena cava filters on mortality as an adjuvant to antithrombotic therapy. 2015 , 128, 312.e23-31	17
1501	Engaging with quality improvement in anticoagulation management. 2015 , 39, 403-9	13
1500	Warfarin: an expensive cause of delay in discharge of elective arthroplasty patients. 2015 , 6, 77-82	0
1499	Tranexamic Acid Tamponade to Control Postoperative Surgical Hemorrhage. 2015 , 41, e82-9	4
1498	Embolie pulmonaire de gravité intermédiaire : thrombolyse ou non ?. 2015 , 24, 98-103	
1497	Clinical significance and management of subsegmental pulmonary embolism. 2015 , 39, 311-4	31
1496	Safety and efficacy of target-specific anticoagulants in patients with venous thromboembolism. 2015 , 49, 448-57	1
1495	Portomesenteric venous thrombosis following major colon and rectal surgery: incidence and risk factors. 2015 , 29, 1071-9	14
1494	Anticoagulation therapy in 2015: where we are and where we are going. 2015 , 39, 264-72	10
1493	Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboembolism in the EINSTEIN DVT and EINSTEIN PE studies. 2015 , 22, 142-9	12
1492	Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 1: prophylaxis. 2015 , 22, 133-43	33
1491	Antiplatelet Therapy and Anticoagulation. 2015 , 109-130	
1490	Target-specific oral anticoagulants and the hospitalist. 2015 , 43, 1-12	0
1489	[Management of venous thromboembolism: A 2015 update]. 2015 , 36, 746-52	2

1488	A fractured inferior vena cava filter strut migrating to the left pulmonary artery. 2015 , 16, 3-6	7
1487	[Home care for acute pulmonary embolism: Feasibility and general practitioner acceptability]. 2015 , 40, 223-30	2
1486	Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France. 2015 , 56, 1212-7	26
1485	CLINICAL PRACTICE. Pregnancy Complicated by Venous Thrombosis. 2015 , 373, 540-7	98
1484	[Role of acetylsalicylic acid for preventing recurrent venous thromboembolism]. 2015 , 50, 159-60	
1483	Treating pulmonary embolism in Pacific Asia with direct oral anticoagulants. 2015 , 136, 196-207	4
1482	Coagulation activation after discontinuation of VTE treatment with different oral anticoagulants and impact on 12-month clinical outcomes. 2015 , 136, 261-6	3
1481	Pharmacomechanical catheter-directed thrombolysis for pregnancy-related iliofemoral deep vein thrombosis. 2015 , 26, 992-1000	22
1480	Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy. 2015 , 12, 1122-9	24
1479	Outpatient management eligibility criteria for patients who have acute symptomatic pulmonary embolism. 2015 , 12, 623-4	2
1478	Endovascular Interventions for Acute and Chronic Lower Extremity Deep Venous Disease: State of the Art. 2015 , 276, 31-53	24
1477	Treacherous Travelers: Emboli. 2015 , 128, 695-8	
1476	Edoxaban (Savaysa)--The Fourth New Oral Anticoagulant. 2015 , 314, 76-7	2
1475	Chronic Thromboembolic Pulmonary Hypertension: the End Result of Pulmonary Embolism. 2015 , 17, 63	10
1474	Rates of elastic compression stockings prescription following the diagnosis of deep venous thrombosis among Canadian emergency physicians and trainees. 2015 , 17, 248-52	2
1473	Non-Biological Complex Drugs. 2015 ,	6
1472	Incidence of arterial embolism in patients on treatment with old and new anticoagulants for venous thromboembolism. 2015 , 41, 154-9	2
1471	Acute surgical pulmonary embolectomy: a 9-year retrospective analysis. 2015 , 42, 25-9	14

1470	Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. 2015 , 175, 1474-80	131
1469	The Subtle Benefit of Anticoagulant Therapy for Splanchnic Vein Thrombosis. 2015 , 175, 1481-2	3
1468	Current management of isolated soleal and gastrocnemius vein thrombosis. 2015 , 3, 341-4	10
1467	Extrapolation of acenocoumarol pharmacogenetic algorithms. 2015 , 74, 151-157	5
1466	Systemic thrombolysis for acute pulmonary embolism. 2015 , 43, 22-7	3
1465	DIAGNÓSTICO Y TRATAMIENTO DEL TROMBOEMBOLISMO PULMONAR. 2015 , 26, 338-343	0
1464	Coagulopathy and Anticoagulation During Thoracic Surgery. 2015 , 25, 309-23	5
1463	Impact of relative contraindications to home management in emergency department patients with low-risk pulmonary embolism. 2015 , 12, 666-73	17
1462	Ultrasound-accelerated catheter-directed thrombolysis for acute submassive pulmonary embolism. 2015 , 26, 1001-6	48
1461	Surgical Embolectomy for Acute Massive and Submassive Pulmonary Embolism in a Series of 115 Patients. 2015 , 100, 1245-51; discussion 1251-2	84
1460	Disorders of Thrombosis and Hemostasis in Pregnancy. 2015 ,	
1459	Iliofemoral deep vein thrombosis: Percutaneous endovascular treatment options. 2015 , 33, 47-53	4
1458	A RIETE registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. 2015 , 3, 243-50.e1	16
1457	Aspirin in the primary prophylaxis of venous thromboembolism in surgical patients. 2015 , 13, 348-58	19
1456	The new or non-vitamin K antagonist oral anticoagulants: what have we learned since their debut. 2015 , 41, 188-94	11
1455	Tolerability and Acceptability of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Meta-Analysis. 2015 , 15, 259-65	8
1454	Low Molecular Weight Heparins, Biological Drugs close to Non-Biological Complex Drugs. 2015 , 291-331	
1453	Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment. 2015 , 22, 144-55	42

1452	Clinical challenges in patients with cancer-associated thrombosis: Canadian expert consensus recommendations. 2015 , 22, 49-59	31
1451	Systemic lupus erythematosus and thrombosis. 2015 , 13, 16	38
1450	Open surgical removal of retained and dislodged inferior vena cava filters. 2015 , 3, 201-6	13
1449	[Primary upper-extremity deep vein thrombosis]. 2015 , 41, e15-7	1
1448	Thrombophilia testing has limited usefulness in clinical decision-making and should be used selectively. 2015 , 3, 228-35	7
1447	An international, multicenter, prospective study of a prothrombin complex concentrate, Prothromplex Total [®] , in anticoagulant reversal. 2015 , 135, 485-91	9
1446	Managing central venous obstruction in cystic fibrosis recipients--lung transplant considerations. 2015 , 14, 255-61	5
1445	Duration of anticoagulation after venous thromboembolism in real world clinical practice. 2015 , 135, 666-72	42
1444	Clinical Pathway for Thyroidectomy. 2015 , 93, 283-299	
1443	Safety of therapeutic doses of tinzaparin during pregnancy. 2015 , 79, 256-62	3
1442	Update in venous thromboembolism pathophysiology, diagnosis, and treatment for surgical patients. 2015 , 52, 233-59	5
1441	Flegmasia cerulea dolens como presentaci3n de aneurisma ilíaco. 2015 , 67, 228-230	
1440	Emergency Evaluation for Pulmonary Embolism, Part 1: Clinical Factors that Increase Risk. 2015 , 48, 771-80	23
1439	Prevalence and significance of clinically unsuspected pulmonary embolism: detection using coronary computed tomography angiography. 2015 , 30, 301-6	1
1438	Vena cava filter use in cancer patients with acute venous thromboembolism in California. 2015 , 135, 809-15	10
1437	Outcomes in children with deep vein thrombosis managed with percutaneous endovascular thrombolysis. 2015 , 45, 719-26	12
1436	Transforming and simplifying the treatment of pulmonary embolism: "safe dose" thrombolysis plus new oral anticoagulants. 2015 , 193, 369-74	12
1435	Is diabetes a hypercoagulable state? A critical appraisal. 2015 , 52, 1007-16	35

1434	Inferior vena cava filters: current best practices. 2015 , 39, 315-27		12
1433	Aspirin in secondary prevention of recurrent venous thromboembolism. 2015 , 39, 392-4		5
1432	The Impact of Risk Stratification of Venous Thromboembolism on Complexity and Site of Management. 2015 , 3, 100-108		
1431	The Essentials of Bedside Ultrasound for Pulmonary Embolism. 2015 , 3, 113-119		
1430	Prevalence of Hereditary Thrombophilia in Patients Older Than 75 Years With Venous Thromboembolism Referred for Thrombophilia Screening. 2015 , 70, 977-81		4
1429	Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT): Initial Results From a Prospective Multicenter Registry. <i>Chest</i> , 2015 , 148, 667-673	5:3	284
1428	Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin. 2015 , 21, 632-8		9
1427	Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism - the J-EINSTEIN DVT and PE program. 2015 , 13, 2		72
1426	Low-Dose Systemic Alteplase (tPA) for the Treatment of Pulmonary Embolism. 2015 , 49, 818-24		21
1425	Edoxaban, a Novel Oral Factor Xa Inhibitor. 2015 , 49, 843-50		12
1424	Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants. 2015 , 113, 1193-202		20
1423	Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. 2015 , 20, 143-52		17
1422	Deep Venous Thrombosis and Pulmonary Embolism. 2015 , 73-81		
1421	In the Clinic. Deep venous thrombosis. 2015 , 162, ITC1		10
1420	Practical management of rivaroxaban for the treatment of venous thromboembolism. 2015 , 21, 309-18		3
1419	The critical care literature 2014. 2015 , 33, 828-833		
1418	Sub-segmental pulmonary embolism in three academic teaching hospitals: a review of management and outcomes. 2015 , 13, 214-8		28
1417	Spontaneous deep vein thrombosis in the upper extremity of a 45-year-old woman. 2015 , 187, 990-993		2

1416	High pitch, low voltage dual source CT pulmonary angiography: assessment of image quality and diagnostic acceptability with hybrid iterative reconstruction. 2015 , 22, 117-23		19
1415	Deep venous thrombosis and venous thromboembolism prophylaxis. 2015 , 95, 285-300		26
1414	May-Thurner syndrome and other obstructive iliac vein lesions: meaning, myth, and mystery. 2015 , 20, 74-83		81
1413	Clinical outcomes and adherence to guideline recommendations during the initial treatment of acute venous thromboembolism. 2015 , 49, 869-75		5
1412	Update in general internal medicine: evidence published in 2014. 2015 , 162, W80-5		
1411	Management of superficial vein thrombosis. 2015 , 13, 1175-83		42
1410	Deep Venous Thrombosis. 2015 , 135-149		
1409	Inferior Vena Cava Filters. 2015 , 183-198		1
1408	Venous thrombosis. 2015 , 1, 15006		127
1407	Pharmacokinetics of low molecular weight heparin in patients with malignant tumors. 2015 , 26, 106-11		12
1406	Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism. 2015 , 135, 659-65		14
1405	Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. 2015 , 20, 490-500		41
1404	Should they stay or should they go?: Identification of low-risk patients with acute pulmonary embolism who can be safely treated outside of the hospital. <i>Chest</i> , 2015 , 147, 589-590	5-3	1
1403	The prognostic value of undetectable highly sensitive cardiac troponin I in patients with acute pulmonary embolism. <i>Chest</i> , 2015 , 147, 685-694	5-3	19
1402	Long-term treatment with low-molecular-weight heparin prolonged the survival time for acute pulmonary embolism patients concurrent with malignancy: an observational analysis from a long-term follow-up study. 2015 , 135, 582-7		6
1401	Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer. 2015 , 10, 651-6		13
1400	Endovascular Management of Deep Vein Thrombosis with Rheolytic Thrombectomy: Final Report of the Prospective Multicenter PEARL (Peripheral Use of AngioJet Rheolytic Thrombectomy with a Variety of Catheter Lengths) Registry. 2015 , 26, 777-85; quiz 786		80
1399	Risk Factors, Diagnosis, Management, and Outcome of Splanchnic Vein Thrombosis: A Retrospective Analysis. 2015 , 41, 503-13		14

1398	Venous thromboembolism: identifying patients at risk and establishing prophylaxis. 2015 , 31, 2297-311	7
1397	Theme 4: Invasive management of (recurrent) VTE and PTS. 2015 , 136 Suppl 1, S19-25	6
1396	A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study. 2015 , 136, 938-42	6
1395	Management of chemotherapy-induced thromboembolism in breast cancer. 2015 , 4, 187-198	
1394	Postoperative Portal, Mesenteric, and Splenic Vein Thrombosis. 2015 , 261-269	
1393	A retrospective analysis of catheter-based thrombolytic therapy for acute submassive and massive pulmonary embolism. 2015 , 20, 122-30	15
1392	Venous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis. 2015 , 19, 287	128
1391	Medical management of tumor lysis syndrome, postprocedural pain, and venous thromboembolism following interventional radiology procedures. 2015 , 32, 209-16	3
1390	An IVC filter and anticoagulation for 3 months is unlikely to show a benefit over anticoagulation alone for high-risk patients with acute pulmonary embolism. 2015 , 20, 174	0
1389	Perioperative Management of Antithrombotic Therapy in Common Otolaryngologic Surgical Procedures: State of the Art Review. 2015 , 153, 493-503	18
1388	Surgical Pulmonary Embolectomy. 2015 , 132, 1146-51	10
1387	Should anticoagulation therapy be withheld in patients with active cancer after 6 months of low-molecular weight heparin?. 2015 , 33, 1713	1
1386	A study on the role of rivaroxaban in management of venous thromboembolism. 2015 , 64, 893-896	
1385	Cancer cells BXP3 and MCF7 differentially reverse the inhibition of thrombin generation by apixaban, fondaparinux and enoxaparin. 2015 , 136, 1273-9	13
1384	Rate and duration of hospitalization for deep vein thrombosis and pulmonary embolism in real-world clinical practice. 2015 , 47, 546-54	25
1383	Fibrinolysis for Acute Care of Pulmonary Embolism in the Intermediate Risk Patient. 2015 , 17, 68	6
1382	Pulmonary embolism: An update. 2015 , 44, e373-6	1
1381	Derivation and validation of the In-hospital Mortality for Pulmonary embolism using Claims data (IMPACT) prediction rule. 2015 , 31, 1461-8	13

1380	Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study. 2015 , 136, 298-307	28
1379	Anticoagulation Considerations for Travel to High Altitude. 2015 , 16, 181-5	2
1378	Venous thromboembolism in cancer patients: an underestimated major health problem. 2015 , 13, 204	70
1377	Venous thromboembolism in patients with chronic lymphocytic leukemia. 2015 , 136, 1082-6	15
1376	D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. 2015 , 162, 27-34	96
1375	Inferior Vena Cava Filters: Indications, Outcomes, and Evidence. 2015 , 17, 401	8
1374	Post-Bariatric Body Contouring. 2015 , 35, 672-87	25
1373	Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH. 2015 , 13, 880-3	75
1372	Venous thromboembolism prevention and treatment: expanding the rivaroxaban knowledge base with real-life data. 2015 , 17, D32-D41	7
1371	Pulmonary embolism: whom to discharge and whom to thrombolize?. 2015 , 13 Suppl 1, S252-8	12
1370	Inhalational use of antithrombotics in humans: Review of the literature. 2015 , 136, 1059-66	10
1369	Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study. 2015 , 136, 1145-8	9
1368	The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism. 2015 , 18, 323-32	4
1367	Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. 2015 , 132, 1891-7	86
1366	Secondary Prevention of Venous Thromboembolism: One Regimen May Not Fit All. 2015 , 132, 1856-9	5
1365	Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism. 2015 , 6, e97	29
1364	Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study. 2015 , 22, 299-307	26
1363	Immediate Discharge and Home Treatment With Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis. 2015 , 22, 788-95	54

1362	A 26-year-old woman with respiratory decompensation in the immediate postpartum period at Mount Sinai Medical Center in New York City. 2015 , 70, 1095-7	0
1361	Home treatment of deep venous thrombosis in the era of new oral anticoagulants. 2015 , 21, 729-32	9
1360	Management of acute pulmonary embolism. 2015 , 76, C150-5	2
1359	Research progress in the application of inferior vena cava filter on acute venous thrombosis. 2015 , 4, 97-100	
1358	Intensive care unit capacity strain and adherence to prophylaxis guidelines. 2015 , 30, 1303-9	29
1357	Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. 2015 , 314, 677-686	395
1356	Crohn's Disease. 2015 ,	1
1355	Thrombotic and Hemostatic Aspects of Assisted Conception. 2015 , 411-423	
1354	The impact of initiating rivaroxaban versus low-molecular weight heparin plus warfarin in patients admitted to the hospital for venous thromboembolism. 2015 , 198, 87-8	2
1353	[Optimal duration of anticoagulant treatment after venous thromboembolic disease]. 2015 , 44, 779-90	1
1352	Postoperative prophylaxis of venous thromboembolism (VTE) in patients undergoing high ligation and stripping of the great saphenous vein (GSV). 2015 , 20, 117-21	11
1351	Thrombolysis in Pulmonary Embolism. 2015 ,	3
1350	Handbook for Venous Thromboembolism. 2015 ,	7
1349	Systematic review of anticoagulant treatment of catheter-related thrombosis. 2015 , 136, 1103-9	17
1348	Developments in the management and treatment of pulmonary embolism. 2015 , 24, 484-97	17
1347	Dosing of rivaroxaban by indication: getting the right dose for the patient. 2015 , 11, 1665-77	2
1346	A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism: The SEATTLE II Study. 2015 , 8, 1382-1392 ⁴²⁷	
1345	Risk Factors Associated with Symptomatic Pulmonary Embolism of Catheter Directed Thrombolysis for Lower Extremity Deep Venous Thrombosis. 2015 , 50, 658-63	10

1344	Thrombolysis for acute intermediate-risk pulmonary embolism: A meta-analysis. 2015 , 136, 932-7	17
1343	Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. 2015 , 43, 249-57	16
1342	Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. 2015 , 4,	21
1341	Bilan de thrombophilie dans la maladie thromboembolique veineuse. 2015 , 2015, 20-22	
1340	Rivaroxaban for cancer-associated cardiac thrombosis. 2015 , 128, e43-4	6
1339	Trimodal venous thromboembolism prophylaxis in total knee replacement: A quality improvement project for best care practices. 2015 , 33, 119-26	2
1338	Pulmonary embolism: Epidemiology and registries. 2015 , 44, e377-83	14
1337	Protein N-linked homocysteine is associated with recurrence of venous thromboembolism. 2015 , 136, 911-6	3
1336	Morbidity and Mortality Associated with Geriatric Ankle Fractures: A Medicare Part A Claims Database Analysis. 2015 , 97, 1748-55	20
1335	Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism. 2015 , 75, 2025-34	4
1334	Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous Model. 2015 , 35, 2003-10	15
1333	Dabigatran for the treatment of venous thromboembolism. 2015 , 8, 413-25	3
1332	Is there a rationale for treatment of chronic liver disease with antithrombotic therapy?. 2015 , 29, 127-36	29
1331	External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. 2015 , 135, 796-801	34
1330	Outcomes and predictors of failure of thrombolysis for iliofemoral deep venous thrombosis. 2015 , 3, 35-41	21
1329	Catheter-directed interventions for acute pulmonary embolism. 2015 , 61, 559-65	47
1328	Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach. 2015 , 21, 297-308	4
1327	Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding. 2015 , 169, 1-3	3

1326	Outpatient or inpatient treatment for acute pulmonary embolism: a retrospective cohort study of 439 consecutive patients. 2015 , 40, 26-36	10
1325	Contemporary treatment of venous thromboembolic disease. 2015 , 33, 49-57	3
1324	Paradoxical embolism causing acute embolic events in a patient with hereditary thrombophilia. 2015 , 40, 314-7	5
1323	Nuevos anticoagulantes orales en el tratamiento del tromboembolismo venoso: análisis crítico de los resultados clínicos. 2015 , 67, 409-414	1
1322	The lung cancer patient, the pneumologist and palliative care: a developing alliance. 2015 , 45, 211-26	10
1321	Duplex imaging of residual venous obstruction to guide duration of therapy for lower extremity deep venous thrombosis. 2015 , 3, 326-32	10
1320	Successful catheter-directed thrombolysis of a massive pulmonary embolism in a patient after recent pneumonectomy. 2015 , 39, 140-3	2
1319	Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. 2015 , 36, 605-14	258
1318	Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review. 2015 , 45, 201-10	52
1317	The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants. 2015 , 31, 197-210	8
1316	Aging techniques for deep vein thrombosis: a systematic review. 2015 , 30, 77-84	20
1315	Time course and the recanalization rate of superficial vein thrombosis treated with low-molecular-weight heparin. 2015 , 66, 381-6	13
1314	Home treatment of patients with small to medium sized acute pulmonary embolism. 2015 , 39, 166-72	20
1313	Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. 2015 , 39, 155-65	57
1312	Pulmonary embolism risk stratification by European Society of Cardiology is associated with recurrent venous thromboembolism: Findings from a long-term follow-up study. 2016 , 202, 275-81	10
1311	The strong but nonspecific relationship between 18F-FDG uptake in the lower-extremity veins and venous thromboembolism. 2016 , 37, 322-8	6
1310	Pharmacologic Considerations in Oncology Critical Care. 2016 ,	1
1309	Physicians' attitudes toward, use of, and perceived barriers to clinical guidelines: a survey among Swiss physicians. 2016 , 7, 673-680	18

1308	Splanchnic Vein Thrombosis - an Uncommon Complication after Laparoscopic Sleeve Gastrectomy. 2016 , 9, 138-43	7
1307	Risk impact of edoxaban in the management of stroke and venous thromboembolism. 2016 , 12, 329-35	2
1306	THE ADVANCED TACTICS OF THE MANAGEMENT OF PATIENTS WITH VENOUS THROMBOEMBOLISM: THE ROLE OF RIVAROXABAN AT VARIOUS STAGES OF TREATMENT. 2016 , 12, 337-343	
1305	Edoxaban in venous thromboembolism and stroke prevention: an appraisal. 2016 , 12, 45-51	4
1304	Radiolabeled tirofiban - a potential radiopharmaceutical for detection of deep venous thrombosis. 2016 , 10, 2989-2996	1
1303	Case of intersurgical acute massive pulmonary embolism with successful thrombolysis therapy. 2016 , 2016, omw060	2
1302	Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants. 2016 , 9, 107-15	3
1301	Effectiveness of self-managed oral anticoagulant therapy in patients with recurrent venous thromboembolism. A propensity-matched cohort study. 2016 , 116, 524-9	6
1300	Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies. 2016 , 10, 1657-65	7
1299	Catheter-Directed Thrombolysis via Small Saphenous Veins for Treating Acute Deep Venous Thrombosis. 2016 , 22, 2972-80	4
1298	Incidence and interventions for post-thrombotic syndrome. 2016 , 6, 623-631	25
1297	Utility of thrombophilia testing in patients with venous thrombo-embolism. 2016 , 8, 3697-3703	6
1296	Effectiveness of Inferior Vena Cava Filters without Anticoagulation Therapy for Prophylaxis of Recurrent Pulmonary Embolism. 2016 , 7,	4
1295	Compression and deep vein thrombosis. 2016 , 5,	
1294	Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. 2016 , 2016, 1781684	17
1293	Retrievable Inferior Vena Cava Filters in Patients with Cancer: Complications and Retrieval Success Rate. 2016 , 2016, 6413541	1
1292	Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. 2016 , 115, 809-16	13
1291	Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism. 2016 , 12, 667-74	

1290	Outpatient treatment of low-risk venous thromboembolism with monotherapy oral anticoagulation: patient quality of life outcomes and clinician acceptance. 2016 , 10, 561-9	35
1289	Venoarterial Extracorporeal Membrane Oxygenation in Refractory Cardiogenic Shock and Cardiac Arrest. 2016 ,	2
1288	Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era. 2016 , 12, 23-34	5
1287	Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date. 2016 , 8, 25-38	
1286	Probability of developing proximal deep-vein thrombosis and/or pulmonary embolism after distal deep-vein thrombosis. 2016 , 115, 608-14	18
1285	Thromboembolic Disease in Cancer. 2016 , 213-225	
1284	The Use of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Pharmacist's Perspective. 2016 , 51, 26-34	
1283	Clinical practice guidelines for prophylaxis of venous thromboembolism in cancer patients. 2016 , 116, 618-25	16
1282	Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. 2016 , 11, e0160064	37
1281	Spotlight on real-world evidence for the treatment of DVT: XALIA. 2016 , 116, S41-S49	4
1280	evaluation of a new vena cava filter. 2016 , 15, 99-105	
1279	Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients. 2016 , 10, 2041-6	9
1278	Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients. 2016 , 10, 2677-9	
1277	Extended anticoagulation with apixaban reduces hospitalisations in patients with venous thromboembolism. An analysis of the AMPLIFY-EXT trial. 2016 , 115, 161-8	10
1276	Trends in incidence versus case fatality rates of pulmonary embolism: Good news or bad news?. 2016 , 115, 233-5	19
1275	Short-Term Anticoagulant Therapy and Thrombus Location Are Independent Risk Factors for Delayed Recanalization of Deep Vein Thrombosis. 2016 , 22, 219-25	8
1274	Very early initiation of chemical venous thromboembolism prophylaxis after blunt solid organ injury is safe. 2016 , 59, 118-22	22
1273	Characteristics of Venous Thromboembolism in Pancreatic Adenocarcinoma in East Asian Ethnic: A Large Population-Based Observational Study. 2016 , 95, e3472	18

1272	Reply: Venous Thromboembolism in Body Contouring: An Analysis of 17,774 Patients from the National Surgical Quality Improvement Databases. 2016 , 137, 479e-480e	
1271	Treatment Options in Massive and Submassive Pulmonary Embolism. 2016 , 24, 19-25	7
1270	Safety of anticoagulation in the treatment of venous thromboembolism in patients with haematological malignancies and thrombocytopenia: Report of 5 cases and literature review. 2016 , 105, 92-9	13
1269	Transfusion management of factor V deficiency: three case reports and review of the literature. 2016 , 56, 1745-9	18
1268	Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. 2016 , 56, 637-45	108
1267	Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study. 2016 , 97, 128-36	2
1266	Perioperative Management of Anticoagulation-Review of Latest Evidence. 2016 , 23, e474-84	7
1265	Prevalence of deep vein thrombosis and pulmonary embolism in patients with superficial vein thrombosis: a systematic review and meta-analysis. 2016 , 14, 964-72	43
1264	Current management strategies and long-term clinical outcomes of upper extremity venous thrombosis. 2016 , 14, 973-81	27
1263	Platelet reactivity in patients with venous thrombosis who use rosuvastatin: a randomized controlled clinical trial. 2016 , 14, 1404-9	4
1262	Low-molecular-weight heparins for cancer-associated thrombosis: Adherence to clinical practice guidelines and patient perception in TROPIQUE, a 409-patient prospective observational study. 2016 , 144, 85-92	25
1261	Extracorporeal membrane oxygenation for failed tPA therapy of pulmonary embolism. 2016 , 2, 205555201663396	
1260	Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. 2016 , 12, 419-33	4
1259	Initial management and outcomes after superficial thrombophlebitis: The Cardiovascular Research Network Venous Thromboembolism study. 2016 , 11, 432-4	3
1258	Superficial Vein Thrombophlebitis in a Football Athlete. 2016 , 26, e8-9	1
1257	Thrombolysis for Right Atrial Thrombus-in-Transit in a Patient With Massive Pulmonary Embolism. 2016 , 23, e930-2	0
1256	Treatment of Pulmonary Embolism. 2016 , 491-498	
1255	Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. 2016 , 3, e556-e562	97

1254	Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism. 2016 , 48, 1360-1368	15
1253	Anticoagulation: Heparins and Vitamin K Antagonists. 2016 , 240-252	
1252	Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE. 2016 , 6, e011190	52
1251	Prescribers' behavior following below- versus above-range international normalized ratio values in warfarin-treated deep vein thrombosis patients. 2016 , 32, 1213-5	
1250	Health-related quality of life after deep vein thrombosis. 2016 , 5, 1278	23
1249	Anti-Xa monitoring of low-molecular-weight heparin in adult patients with cancer. 2016 , 2016, 206-207	4
1248	The post-thrombotic syndrome. 2016 , 2016, 413-418	80
1247	Is it safe to withhold long-term anticoagulation therapy in patients with small pulmonary emboli diagnosed by SPECT scintigraphy?. 2016 , 14, 12	3
1246	Pulmonary issues in the elderly. 2016 , 298-310	
1245	Rebuttal From Drs Funaki and Haskal. <i>Chest</i> , 2016 , 150, 1184-1185	53
1244	Recurrence of venous thromboembolism. 2016 , 216, 485-487	3
1243	Efficacy and Safety of Outpatient Treatment Based on the Hestia Clinical Decision Rule with or without N-Terminal Pro-Brain Natriuretic Peptide Testing in Patients with Acute Pulmonary Embolism. A Randomized Clinical Trial. 2016 , 194, 998-1006	84
1242	Massive pulmonary embolism leading to cardiac arrest: one pathology, two different ECMO modes to assist patients. 2016 , 30, 933-937	10
1241	Improving the retrieval rate of inferior vena cava filters with a multidisciplinary team approach. 2016 , 4, 276-82	26
1240	Pharmacologic Therapies in Anticoagulation. 2016 , 100, 695-718	7
1239	A multicenter prospective study of risk factors and treatment of unusual site thrombosis. 2016 , 144, 100-5	9
1238	Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. 2016 , 55, 641-55	117
1237	Unnecessary Hospitalizations for Pulmonary Embolism: Impact on US Health Care Costs. 2016 , 129, 899-900	9

1236	A Clinician's Guide to Avoiding and Managing Common Complications During and After Robot-assisted Laparoscopic Radical Prostatectomy. 2016 , 2, 30-48	8
1235	Effect of compression stockings on post thrombotic syndrome in patients with deep vein thrombosis: a meta-analysis of randomised controlled trials. 2016 , 3, e293-300	30
1234	Normal ventricular diameter ratio on CT provides adequate assessment for critical right ventricular strain among patients with acute pulmonary embolism. 2016 , 32, 1153-61	10
1233	Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature. 2016 , 42, 671-81	5
1232	Treatment of Isolated Below the Knee Deep Vein Thrombosis. 2016 , 18, 37	7
1231	Hemodialysis catheter-associated superior vena cava syndrome and pulmonary embolism: a case report and review of the literature. 2016 , 9, 233	8
1230	Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort. 2016 , 143, 152-8	25
1229	High-dose corticosteroid associated with catheter-related thrombosis after allogeneic hematopoietic stem cell transplantation. 2016 , 144, 6-11	3
1228	[General medicine management of superficial venous thrombosis of the lower limbs: A survey in Saône-et-Loire]. 2016 , 41, 12-7	2
1227	D-Dimer Levels and Vitamin K Antagonist Therapy in Deep Vein Thrombosis of the Legs. 2016 , 34, 119-34	
1226	Inter-observer reliability of the HERDOO2 clinical decision rule. 2016 , 141, 136-8	1
1225	Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. 2016 , 3, e267-75	36
1224	Compression Stockings for Preventing the Postthrombotic Syndrome in Patients with Deep Vein Thrombosis. 2016 , 129, 447.e1-447.e20	15
1223	Anticoagulants et cancer en 2016. 2016 , 41, 116-117	
1222	Nutcracker syndrome and deep venous thrombosis in a patient with duplicated inferior vena cava. 2016 , 4, 231-5	3
1221	Inferior Vena Cava Filters, May-Thurner Syndrome, and Vein Stents. 2016 , 133, e383-7	16
1220	Tratamiento urgente de la embolia pulmonar aguda mediante el sistema de aspiraci3n por cat3ter Penumbra® . 2016 , 16, 59-65	
1219	Cancer-associated thrombosis. 2016 , 62, 121-58	37

1218	Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?. 2016 , 18, 26	10
1217	Retrospective review on isolated distal deep vein thrombosis (IDDVT) - A benign entity or not?. 2016 , 142, 11-6	12
1216	Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes. 2016 , 140 Suppl 1, S132-41	17
1215	Management of recurrent venous thromboembolism in cancer patients. 2016 , 140 Suppl 1, S128-31	8
1214	Comparison between systemic and catheter thrombolysis in patients with pulmonary embolism. 2016 , 34, 985-8	19
1213	Treatment of Venous Thromboembolism With New Anticoagulant Agents. 2016 , 67, 1941-55	48
1212	Clinical practice guidelines on cancer-associated thrombosis: a review on scope and methodology. 2016 , 140 Suppl 1, S119-27	5
1211	Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis. 2016 , 12, 575-80	1
1210	Home Treatment of Pulmonary Embolism in the Era of Novel Oral Anticoagulants. 2016 , 129, 974-7	39
1209	Clinical Outcome of Anticoagulant Treatment in Head or Neck Infection-Associated Cerebral Venous Thrombosis. 2016 , 47, 1271-7	23
1208	Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism. 2016 , 42, 296-311	18
1207	The treatment of cancer associated thrombosis: does one size fit all? Who should get LMWH/warfarin/DOACs?. 2016 , 140 Suppl 1, S154-9	17
1206	Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review. 2016 , 140 Suppl 1, S81-8	21
1205	High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. 2016 , 30, 2032-2038	55
1204	Handbook of Thromboprophylaxis. 2016 ,	
1203	The Role of Inferior Vena Cava Filters in Cancer Patients. 2016 , 33, 71-4	13
1202	Update on Anticoagulation: What the Interventional Radiologist Needs to Know. 2016 , 33, 122-31	4
1201	Creation of an iOS and Android Mobile Application for Inferior Vena Cava (IVC) Filters: A Powerful Tool to Optimize Care of Patients with IVC Filters. 2016 , 33, 137-43	1

1200	The Limitations of Using a National Database to Investigate Risk Factors for Venous Thromboembolism. 2016 , 137, 478e-479e	1
1199	Role of Vitamin K Antagonists in the Prevention of Thrombotic Bypass Occlusion After Infrainguinal Venous Bypass. 2016 , 52, 124-31	1
1198	Primary prophylaxis of VTE in cancer outpatients. 2016 , 140 Suppl 1, S103-8	6
1197	The discovery of dabigatran etexilate for the treatment of venous thrombosis. 2016 , 11, 717-31	6
1196	Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use. 2016 , 127, 1417-25	122
1195	How I treat recurrent deep-vein thrombosis. 2016 , 127, 696-702	12
1194	End of the road for heparin thromboprophylaxis. 2016 , 127, 1945-6	2
1193	Direct oral anticoagulants and venous thromboembolism. 2016 , 25, 295-302	18
1192	Clot Extraction With the FlowTrier Device in Acute Massive Pulmonary Embolism. 2016 , 31, 676-679	18
1191	Is forgoing chemical venous thromboembolism prophylaxis for women undergoing breast-conserving surgery for breast cancer safe?. 2016 , 212, 1162-1166	4
1190	The impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism. 2016 , 144, 21-6	16
1189	Risk stratifying emergency department patients with acute pulmonary embolism: Does the simplified Pulmonary Embolism Severity Index perform as well as the original?. 2016 , 148, 1-8	32
1188	Centralizing care of cancer-associated thromboembolism: The Cleveland Clinic experience. 2016 , 147, 102-103	7
1187	Safety and Efficacy of Extended Duration of Thromboembolic Prophylaxis Following Radical Cystectomy: An Initial Institutional Experience. 2016 , 3, 462-467	5
1186	Decision-making in a patient with cardiac arrest due to venous thromboembolism within 24 h after glioblastoma resection. 2016 , 158, 2259-2263	2
1185	Administration of Coagulation-Altering Therapy in the Patient Presenting for Oral Health and Maxillofacial Surgery. 2016 , 28, 443-460	2
1184	Evaluation of heparin dosing based on adjusted body weight in obese patients. 2016 , 73, 1512-22	12
1183	An overview of hematopoietic stem cell transplantation related thrombotic complications. 2016 , 107, 149-155	17

1182	Perioperative Management of the Direct Oral Anticoagulants: A Case-Based Review. 2016 , 30, 1073-84	12
1181	An update on the pharmaceutical management of thrombosis. 2016 , 17, 2149-2164	6
1180	Thrombolytic therapy for deep venous thrombosis. 2016 , 567-571	
1179	Mechanical and ultrasonic enhancement of catheter-directed thrombolytic therapy for deep venous thrombosis. 2016 , 572-573	
1178	Vena cava filters. 2016 , 597-614	
1177	Home treatment of deep venous thrombosis. 2016 , 617-621	
1176	Home treatment of acute pulmonary embolism. 2016 , 622-625	
1175	Prevention and treatment of deep venous thrombosis and acute pulmonary embolism: American College of Chest Physicians Guidelines. 2016 , 639-645	
1174	Pulmonary thromboembolism in Asians/Pacific Islanders. 2016 , 108-115	
1173	Venous thromboembolism in patients with heart failure. 2016 , 128-132	
1172	Pulmonary embolism and deep venous thrombosis in hospitalized adults with chronic obstructive pulmonary disease. 2016 , 149-155	
1171	Upper extremity deep venous thrombosis. 2016 , 61-65	
1170	Subsegmental pulmonary embolism. 2016 , 435-439	
1169	Novel perspectives on diagnosis and clinical significance of the post-thrombotic syndrome in children. 2016 , 9, 965-75	7
1168	Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism. 2016 , 148, 145-151	13
1167	Significance of Echocardiographically Detected Central Venous Catheter Tip-Associated Thrombi. 2016 , 27, 1872-1877	10
1166	Radial Artery Occlusion After Cardiac Catheterization: Significance, Risk Factors, and Management. 2016 , 41, 214-227	9
1165	Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. 2016 , 17, 2033-47	4

1164	Catheter-directed treatment for acute pulmonary embolism: Systematic review and single-arm meta-analyses. 2016 , 225, 128-139	30
1163	Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism. 2016 , 30, 1035-51	5
1162	Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy. 2016 , 34, 586-99	15
1161	Thrombolysis for acute upper extremity deep vein thrombosis. 2016 ,	1
1160	Impact of inferior vena cava thrombus extension on thrombolysis for acute iliofemoral thrombosis. 2016 , 4, 385-91	6
1159	Recent developments in the diagnosis and treatment of pulmonary embolism. 2016 , 279, 16-29	13
1158	Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. 2016 , 14, 1480-3	234
1157	Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment. 2016 , 48, 1369-1376	95
1156	Evaluation and Management of Chest Pain in the Elderly. 2016 , 34, 523-42	11
1155	Risk of recurrent venous thromboembolism and major hemorrhage in cancer-associated incidental pulmonary embolism among treated and untreated patients: a pooled analysis of 926 patients. 2016 , 14, 105-13	74
1154	Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients. 2016 , 50, 824-31	4
1153	Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis. 2016 , 14, 2107-2113	43
1152	Analysis of the Final DENALI Trial Data: A Prospective, Multicenter Study of the Denali Inferior Vena Cava Filter. 2016 , 27, 1531-1538.e1	18
1151	The safety of fondaparinux sodium for the treatment of venous thromboembolism. 2016 , 15, 1259-65	3
1150	Safety of fondaparinux for prevention of postoperative venous thromboembolism in urological malignancy: A prospective randomized clinical trial. 2016 , 23, 923-928	16
1149	Pathogenesis, Diagnosis, and Treatment of Venous Thromboembolism in Older Adults. 2016 , 64, 1869-78	14
1148	Management of bleeding in patients treated with direct oral anticoagulants. 2016 , 20, 249	17
1147	When deep vein thrombosis occurs in the upper limb. 2016 , 77, 448-53	1

1146	Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC-4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers. 2016 , 5, 532-543	8
1145	Vein thrombosis after ECMO decannulation, a frequent and sometimes missed complication. 2016 , 223, 538-539	4
1144	Handbook of Consult and Inpatient Gynecology. 2016 ,	
1143	Thrombolytic therapy delay is independent predictor of mortality in acute pulmonary embolism at emergency service. 2016 , 32, 572-578	10
1142	The use of novel oral anticoagulants in cancer patients with venous thromboembolism. 2016 , 43, 655-665	2
1141	The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism. 2017 , 906, 89-100	
1140	The Role of New Oral Anticoagulants (NOACs) in Cancer Patients. 2017 , 906, 137-148	5
1139	To close or not to close: contemporary indications for patent foramen ovale closure. 2016 , 14, 1235-1244	8
1138	The Treatment of Venous Thromboembolism in Patients with Cancer. 2017 , 906, 123-135	5
1137	Post Thrombotic Syndrome. 2017 , 906, 363-375	6
1136	Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment. 2016 , 52, 658-664	8
1135	Thrombolytic Therapy by Tissue Plasminogen Activator for Pulmonary Embolism. 2017 , 906, 67-74	2
1134	CT pulmonary angiography of adult pulmonary vascular diseases: Technical considerations and interpretive pitfalls. 2016 , 85, 2049-2063	5
1133	Role of Catheter-directed Thrombolysis in Management of Iliofemoral Deep Venous Thrombosis. 2016 , 36, 1565-75	11
1132	Therapeutic Anticoagulation for Isolated Calf Deep Vein Thrombosis. 2016 , 151, e161770	24
1131	Diagnosis, prognosis and therapeutic management of acute pulmonary embolism. 2016 , 44, 164-72	3
1130	Significance of Isolated Calf Vein Thrombosis-Further Evidence. 2016 , 151, e161799	1
1129	The management of patients with venous thromboembolism in Italy: insights from the PREFER in VTE registry. 2016 , 11, 1095-1102	5

1128	Direct oral anticoagulants and cancer: no swansong yet for the low-molecular-weight heparins. 2016 , 3, e357-8	2
1127	Management of idiopathic venous thromboembolism. 2016 , 14, 1371-1384	4
1126	Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report. 2016 , 10, 276	2
1125	Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients. 2016 , 34, 408-14	1
1124	Venous Thromboembolism. 2016 , 195-209	
1123	Can Inferior Vena Cava Filters Change Their Struts?. 2016 , 9, 2449-2451	
1122	Venous thromboembolism prophylaxis during neoadjuvant therapy for resectable and borderline resectable pancreatic cancer-Is it indicated?. 2016 , 114, 581-586	17
1121	Surgical Treatment of Thromboembolic Disease. 2016 , 549-560	
1120	Postpartum ovarian vein thrombosis. 2016 , 18, 291-299	14
1119	Outcomes of Stent Placement for Chronic Occlusion of a Filter-bearing Inferior Vena Cava in Patients with Severe Post-thrombotic Syndrome. 2016 , 52, 839-846	19
1118	The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal. 2016 , 11, 1031-1035	11
1117	Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin. 2016 , 38, 2496-2503	10
1116	COUNTERPOINT: Do the Benefits Outweigh the Risks for Most Patients Under Consideration for Inferior Vena Cava Filters? No. <i>Chest</i> , 2016 , 150, 1182-1184	5-3 2
1115	Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved. 2016 , 68, 2099-2106	15
1114	Diagnosis and management of factor V Leiden. 2016 , 9, 1139-1149	28
1113	Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions. 2016 , 5,	17
1112	Impact of a dedicated cancer-associated thrombosis service on clinical outcomes: a mixed-methods evaluation of a clinical improvement exercise. 2016 , 6, e013321	10
1111	Patient with Hematologic Disorders. 2016 , 41-43	

1110	Quantitation of Venous Clot Lysis With D-Dimer Assay During Catheter-Directed Thrombolysis for Lower Extremity Deep Venous Thrombosis. 2016 , 101, 487-491	1
1109	Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. 2016 , 115, 424-32	26
1108	Rivaroxaban for the treatment of venous thromboembolism. The SWISS Venous ThromboEmbolic Registry (SWIVTER). 2016 , 116, 472-9	32
1107	Role of Novel Oral Anticoagulants in the Treatment of Antiphospholipid Syndrome. 2016 , 51, 759-767	6
1106	Platelet-Monocyte Aggregates and C-Reactive Protein are Associated with VTE in Older Surgical Patients. 2016 , 6, 27478	16
1105	Low-molecular-weight heparin for the treatment of acute venous thromboembolism in patients with active cancer. 2016 , 21, 66	1
1104	Management considerations for patients with uterine fibroids and concurrent venous thromboembolism. 2016 , 28, 329-35	4
1103	Deep Vein Thrombosis [Current Management Strategies]. 2016 , 8, CMT.S18890	2
1102	Anticoagulated patient's perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy - study protocol for The Switching Study: a prospective cohort study. 2016 , 16, 22	5
1101	Management of venous thromboembolism: an update. 2016 , 14, 23	25
1100	Caprini Scores, Risk Stratification, and Rivaroxaban in Plastic Surgery: Time to Reconsider Our Strategy. 2016 , 4, e733	20
1099	Thromboembolic disease and breathlessness. 2016 , 10, 249-55	3
1098	A Review on the Reversal of the Old and New Anticoagulants. 2016 , 38, 279-294	0
1097	Trousseau's Syndrome in Cholangiocarcinoma: The Risk of Making the Diagnosis. 2016 , 14, 53-9	11
1096	Risk factors associated with portomesenteric venous thrombosis in patients undergoing restorative proctocolectomy for medically refractory ulcerative colitis. 2016 , 18, 393-9	14
1095	Pharmacomechanical Thrombectomy in Paget-Schroetter Syndrome. 2016 , 39, 1272-9	15
1094	Venous Thromboembolism in the Elderly. 2016 , 5, 132-139	2
1093	Clinical Outcomes of Venous Thromboembolism in Patients with and without Cancer: The SWISS Venous ThromboEmbolic Registry (SWIVTER). 2016 , 42, 642-9	7

1092	Incidence of actionable findings on contrast enhanced magnetic resonance angiography ordered for pulmonary embolism evaluation. 2016 , 85, 1383-9	11
1091	Hematological Issues in Liver Disease. 2016 , 32, 385-96	15
1090	Prevention of the Post-Thrombotic Syndrome. 2016 , 18, 51	3
1089	AngioVac Removal of a Saddle Pulmonary Embolus Using TEE Guidance and Venoarterial ECMO Support. 2016 , 30, 749-52	15
1088	Endovascular therapy for advanced post-thrombotic syndrome: Proceedings from a multidisciplinary consensus panel. 2016 , 21, 400-7	35
1087	[Venous thrombo-embolic disease in cancer. Low molecular weight heparin indications]. 2016 , 41, 197-204	2
1086	Percutaneous Retrieval of Permanent Inferior Vena Cava Filters. 2016 , 39, 538-46	11
1085	Drug Treatment of Venous Thromboembolism in the Elderly. 2016 , 33, 475-90	6
1084	Contemporary developments in the discovery of selective factor Xa inhibitors: A review. 2016 , 121, 671-698	28
1083	Research Priorities in Submassive Pulmonary Embolism: Proceedings from a Multidisciplinary Research Consensus Panel. 2016 , 27, 787-94	19
1082	Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment?. 2016 , 11, 1037-1040	1
1081	Impact of Physician Education and a Dedicated Inferior Vena Cava Filter Tracking System on Inferior Vena Cava Filter Use and Retrieval Rates Across a Large US Health Care Region. 2016 , 27, 740-8	20
1080	Upper-Extremity Deep-Vein Thrombosis: A Retrospective Cohort Evaluation of Thrombotic Risk Factors at a University Teaching Hospital Antithrombosis Clinic. 2016 , 50, 637-44	6
1079	Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database. 2016 , 14, 4	15
1078	Mechanical Prophylaxis for Post-Traumatic VTE: Stockings and Pumps. 2016 , 2, 35-41	2
1077	Clinical management and outcome of major bleeding in patients on treatment with vitamin K antagonists. 2016 , 33, 47-54	2
1076	Outcomes related to variation in hospital pulmonary embolus observation stay utilization. 2016 , 44, 133-7	1
1075	SIRT1 prevents pulmonary thrombus formation induced by arachidonic acid via downregulation of PAF receptor expression in platelets. 2016 , 27, 735-742	11

1074	Comparing effects of different routes of heparin administration on the serum biomarkers of thrombosis. 2016 , 5, 249-57	
1073	Home parenteral nutrition-associated thromboembolic and bleeding events: results of a cohort study of 236 individuals. 2016 , 14, 1364-73	11
1072	Assessing prescribing of NSAIDs, antiplatelets, and anticoagulants in Canadian family medicine using chart review. 2016 , 38, 1094-102	6
1071	Prognostic value of D-dimer in elderly patients with Pulmonary Embolism. 2016 , 42, 386-92	8
1070	Acute pulmonary embolism: risk assessment, risk stratification and treatment options. 2016 , 10, 545-54	6
1069	Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism. 2016 , 29, 392-405	2
1068	Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States. 2016 , 22, 5-11	17
1067	Does prescription of medical compression prevent development of post-thrombotic syndrome after proximal deep venous thrombosis?. 2016 , 31, 160-9	8
1066	Rediscussing Anticoagulation in Distal Deep Venous Thrombosis. 2016 , 22, 772-778	9
1065	A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES). 2016 , 29, 59-64	29
1064	Prophylaxie primaire de la maladie thromboembolique veineuse chez les patients cancéreux ambulatoires traités par les anti-thrombotiques. 2016 , 18, 23-31	
1063	Guidance for the management of venous thrombosis in unusual sites. 2016 , 41, 129-43	60
1062	Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. 2016 , 41, 92-128	214
1061	Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. 2016 , 41, 206-32	210
1060	Pharmacology of anticoagulants used in the treatment of venous thromboembolism. 2016 , 41, 15-31	66
1059	Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. 2016 , 41, 165-86	98
1058	Guidance for the treatment of deep vein thrombosis and pulmonary embolism. 2016 , 41, 32-67	167
1057	Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. 2016 , 41, 68-80	59

1056 Venous Thromboembolism. **2016**, 671-682

1055 Transitions in the Prophylaxis, Treatment and Care of Patients with Venous Thromboembolism. **2016**, 33, 29-45 2

1054 Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. **2016**, 19, 557-67 9

1053 Risk stratification of patients with acute symptomatic pulmonary embolism. **2016**, 11, 11-8 32

1052 Chronic Pulmonary Complications of Sickle Cell Disease. *Chest*, **2016**, 149, 1313-24 5:3 29

1051 Major Bleeding and Hemorrhagic Stroke With Direct Oral Anticoagulants in Patients With Renal Failure: Systematic Review and Meta-Analysis of Randomized Trials. *Chest*, **2016**, 149, 1516-24 5:3 35

1050 Analysis of 1,338 Patients with Acute Lower Limb Deep Venous Thrombosis (DVT) Supports the Inadequacy of the Term "Proximal DVT". **2016**, 51, 415-20 21

1049 Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases. **2016**, 137, 30-35 9

1048 Efficacy and Safety of Rivaroxaban in Patients with Venous Thromboembolism and Active Malignancy: A Single-Center Registry. **2016**, 129, 615-9 56

1047 Critical Review and Update on the Treatment of Acute and Chronic Pulmonary Embolism. **2016**, 29, 35-45 4

1046 Subsegmental pulmonary embolism: A narrative review. **2016**, 138, 55-60 22

1045 Current Status of Clot Removal for Acute Pulmonary Embolism. **2016**, 31, 211-20 6

1044 Oncologic Emergencies. **2016**, 1 1

1043 Pharmacology of Heparin and Related Drugs. **2016**, 68, 76-141 176

1042 Direct Oral Anticoagulants for the Management of Thromboembolic Disorders: The Importance of Adherence and Persistence in Achieving Beneficial Outcomes. **2016**, 22, 605-16 16

1041 Management of isolated calf vein thrombosis in cancer patients. **2016**, 24, 64-9 2

1040 Target-specific Oral Anticoagulants in the Emergency Department. **2016**, 50, 246-57 3

1039 Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. **2016**, 3, e12-21 173

1038	Assessment of algorithms to identify patients with thrombophilia following venous thromboembolism. 2016 , 137, 97-102	4
1037	Extended anticoagulation and mortality in venous thromboembolism. A meta-analysis of six randomized trials. 2016 , 139, 22-8	9
1036	Superficial vein thrombosis treated for 45 days with rivaroxaban versus fondaparinux: rationale and design of the SURPRISE trial. 2016 , 42, 197-204	13
1035	Antiviral therapy of primary cytomegalovirus infection with vascular thrombosis in immunocompetent adults. 2016 , 46, 87-92	8
1034	Prior thromboprophylaxis and outcome in patients experiencing acute venous thromboembolism after an acute medical illness. 2016 , 30, 72-76	5
1033	Practice patterns and complication rates of thrombolysis for pulmonary embolism. 2016 , 42, 313-21	2
1032	Predictors of the post-thrombotic syndrome and their effect on the therapeutic management of deep vein thrombosis. 2016 , 4, 531-4	21
1031	[Thrombosis of the subclavian vein after conservative treatment of a clavicular fracture: A rare complication]. 2016 , 119, 255-8	0
1030	External validation of the In-hospital Mortality for Pulmonary embolism using Claims data (IMPACT) multivariable prediction rule. 2016 , 70, 82-8	5
1029	Emergent reversal of vitamin K antagonists: addressing all the factors. 2016 , 211, 919-25	13
1028	Review of venous thromboembolism and race: the generalizability of treatment guidelines for high-risk populations. 2016 , 42, 167-71	3
1027	Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. 2016 , 3, e228-36	41
1026	Effect of vital sign measurement timing on Pulmonary Embolism Severity Index (PESI) and simplified PESI 30-day mortality risk determination. 2016 , 141, 8-10	4
1025	Validation of the International Medical Prevention Registry on Venous Thromboembolism Bleeding Risk Score. <i>Chest</i> , 2016 , 149, 372-9	53 35
1024	Venous Thromboembolism Prevention and Perioperative Management of Anticoagulants. 2016 , 5, 242-267	
1023	Improved early right ventricular function recovery but increased complications with catheter-directed interventions compared with anticoagulation alone for submassive pulmonary embolism. 2016 , 4, 268-75	24
1022	Management of Pulmonary Embolism: An Update. 2016 , 67, 976-990	182
1021	Acute Pulmonary Embolism: With an Emphasis on an Interventional Approach. 2016 , 67, 991-1002	57

1020	[Splanchnic venous thrombosis: A monocentric study of 31 cases]. 2016 , 41, 26-35		2
1019	Clinical presentations, risk factors, treatment and outcomes in patients with splanchnic vein thrombosis: a single-center experience. 2016 , 42, 267-71		4
1018	Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer. <i>Chest</i> , 2016 , 149, 1245-51	5:3	25
1017	Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place. 2016 , 50, 402-9		26
1016	Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. 2016 , 41, 154-64		158
1015	Delayed anticoagulation is associated with poor outcomes in high-risk acute pulmonary embolism. 2016 , 32, 21-5		8
1014	Non-vitamin K antagonist oral anticoagulants and antiphospholipid syndrome. 2016 , 55, 1726-35		28
1013	Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. 2016 , 41, 187-205		70
1012	Pharmacomechanical thrombectomy: 2015 update. 2016 , 14, 463-75		15
1011	Guidance for the prevention and treatment of the post-thrombotic syndrome. 2016 , 41, 144-53		89
1010	HSP90 and TLR4 Interplay in Keloids. 2016 , 137, 480e-481e		1
1009	La importancia de la trombosis venosa superficial. A propósito de un caso. 2016 , 68, 519-520		
1008	Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study. 2016 , 30, 77-81		5
1007	Insuficiencia venosa crónica. 2016 , 23, 5-38		
1006	Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation. 2016 , 10, 231-41		0
1005	Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. 2016 , 3, e64-71		216
1004	Cardiovascular Complications of Novel Multiple Myeloma Treatments. 2016 , 133, 908-12		26
1003	Clinical significance and management of right heart thrombi: more questions than answers. 2016 , 47, 702-3		3

1002	Systemic Full Dose, Half Dose, and Catheter Directed Thrombolysis for Pulmonary Embolism. When to Use and How to Choose?. 2016 , 18, 31	3
1001	Vena Caval Filter Utilization and Outcomes in Pulmonary Embolism: Medicare Hospitalizations From 1999 to 2010. 2016 , 67, 1027-1035	47
1000	[Venous thrombosis and pulmonary embolism : Updated S2 guidelines on diagnostics and therapy]. 2016 , 65, 212-20	0
999	A Prospective Study of Adequacy of Anticoagulation with Fixed Dose Weight Adjusted Unfractionated Heparin in Patients with Deep Vein Thrombosis. 2016 , 32, 83-6	
998	Inferior Vena Cava Thrombosis. 2016 , 9, 629-43	75
997	Treatment of upper-extremity outflow thrombosis. 2016 , 31, 28-33	17
996	Home Treatment of Deep Venous Thrombosis According to Comorbid Conditions. 2016 , 129, 392-7	14
995	Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. 2016 , 138, 1-6	11
994	Trends in the Management and Outcomes of Acute Pulmonary Embolism: Analysis From the RIETE Registry. 2016 , 67, 162-170	182
993	Venous Thromboembolism in Patients Diagnosed With Lung Cancer. 2016 , 67, 709-24	17
992	Treating patients with cancer and acute venous thromboembolism. 2016 , 17, 535-43	2
991	Hematologic Emergencies. 2016 , 221-251	
990	Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy. 2016 , 76, 331-41	5
989	New oral anticoagulants. 2016 , 6, 140-143	
988	Multidisciplinary Pulmonary Embolism Response Teams. 2016 , 133, 98-103	77
987	Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2016 , 149, 315-352	53 3090
986	Venous thromboembolism in hematopoietic stem cell transplant recipients. 2016 , 51, 473-8	14
985	Trousseau's syndrome: cancer-associated thrombosis. 2016 , 46, 204-8	83

984	Catheter-directed thrombolysis for extensive iliofemoral deep vein thrombosis: review of literature and ongoing trials. 2016 , 14, 189-200	16
983	Four key questions surrounding thrombolytic therapy for submassive pulmonary embolism. 2016 , 21, 47-52	18
982	How to effectively manage the event of bleeding complications when using anticoagulants. 2016 , 9, 37-50	11
981	Portal vein thrombosis: When to treat and how?. 2016 , 21, 61-9	36
980	Evaluation of nonpermanent inferior vena cava filter placement in patients with deep venous thrombosis after lower extremity fracture: A single-center retrospective study. 2016 , 31, 564-72	3
979	Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. 2016 , 54, 275-83	22
978	ST-segment elevation in V1-V4 in acute pulmonary embolism: a case presentation and review of literature. 2016 , 5, 579-586	11
977	[Management of pulmonary embolism: A 2015 update]. 2016 , 41, 51-62	1
976	[Management of deep-vein thrombosis: A 2015 update]. 2016 , 41, 42-50	8
975	Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Sufficient Sensitivity to Identify Patients at Very Low Risk of Death?. 2016 , 67, 260-2	
974	Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed With Venous Thromboembolism: Evidence-Based Clinical Practice Guideline. 2016 , 96, 143-66	26
973	EASL Clinical Practice Guidelines: Vascular diseases of the liver. 2016 , 64, 179-202	381
972	Should Low-Molecular-Weight Heparin be Preferred Over Unfractionated Heparin After Thrombolysis for Severity Pulmonary Embolism?. 2016 , 22, 395-9	3
971	Heparin: 100 years of pleiotropic effects. 2016 , 41, 636-43	8
970	Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban. 2016 , 22, 765-771	10
969	Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism. 2016 , 22, 209-21	4
968	Management of catheter-associated upper extremity deep venous thrombosis. 2016 , 4, 375-9	4
967	An Age-Adjusted D-dimer Threshold for Emergency Department Patients With Suspected Pulmonary Embolus: Accuracy and Clinical Implications. 2016 , 67, 249-57	22

966	Critical Care Management of Bariatric Surgery Complications. 2016 , 31, 511-28	5
965	Performance of five different bleeding-prediction scores in patients with acute pulmonary embolism. 2016 , 41, 312-20	42
964	Las trombosis venosas profundas distales de los miembros inferiores: un problema controvertido. 2016 , 68, 235-241	
963	Controversies in venous thromboembolism--2015. 2016 , 30, 27-33	7
962	Pulmonary Thromboembolism. 2016 , 1001-1030.e10	3
961	Automated Extraction of VTE Events From Narrative Radiology Reports in Electronic Health Records: A Validation Study. 2017 , 55, e73-e80	25
960	Catheter-directed thrombolysis versus full anticoagulation alone in treating proximal iliofemoral deep venous thrombosis. 2017 , 25, 111-112	1
959	An Algorithmic Approach to Management of Venous Thromboembolism. 2017 , 23, 511-517	1
958	Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations. 2017 , 43, 253-260	33
957	Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux. 2017 , 43, 261-269	23
956	Managing Extended Oral Anticoagulation After Unprovoked Venous Thromboembolism. 2017 , 22, 28-39	2
955	In-Hospital Management and Follow-Up Treatment of Venous Thromboembolism: Focus on New and Emerging Treatments. 2017 , 32, 299-311	6
954	Prevalence of Acute Deep Vein Thrombosis in Patients with Ankle and Foot Fractures Treated with Nonoperative Management-A Pilot Study. 2017 , 26, 53-59	3
953	Safety and efficacy of primary thromboprophylaxis in cancer patients. 2017 , 19, 1-11	14
952	Upper extremity deep vein thrombosis - The venous thromboembolism Cinderella?. 2017 , 32, 76-77	0
951	Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban. 2017 , 30, 381-384	0
950	External Validation of the Hestia Criteria for Identifying Acute Pulmonary Embolism Patients at Low Risk of Early Mortality. 2017 , 23, 769-774	14
949	Patterns in the management of superficial vein thrombosis. 2017 , 32, 207-213	7

948	Technique and Clinical Outcomes of Combined Stent Placement for Postthrombotic Chronic Total Occlusions of the Iliofemoral Veins. 2017 , 28, 373-379	10
947	Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a "real-world" study. 2017 , 43, 540-549	13
946	Systemic thrombolysis increases hemorrhagic stroke risk without survival benefit compared with catheter-directed intervention for the treatment of acute pulmonary embolism. 2017 , 5, 171-176.e1	17
945	Catheter-directed thrombolysis and pharmacomechanical thrombectomy improve midterm outcome in acute iliofemoral deep vein thrombosis. 2017 , 80, 72-79	22
944	Surgical Embolectomy for Acute Pulmonary Embolism: Systematic Review and Comprehensive Meta-Analyses. 2017 , 103, 982-990	28
943	The risk of gastrointestinal bleeding in patients receiving dabigatran etexilate: a systematic review and meta-analysis of the literature. 2017 , 49, 329-342	5
942	Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. 2017 , 15, 429-438	8
941	A first-in-human study of DS-1040, an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor, in healthy subjects. 2017 , 15, 961-971	21
940	Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. 2017 , 15, 848-857	17
939	Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. 2017 , 17, 74	11
938	Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. 2017 , 34, 620-637	6
937	Thrombolysis with intravenous recombinant tissue plasminogen activator during early postpartum period: a review of the literature. 2017 , 96, 529-535	12
936	Risk of Pulmonary Embolism After Cerebral Venous Thrombosis. 2017 , 48, 563-567	13
935	Early initiation of argatroban therapy in the management of acute superior mesenteric venous thrombosis. 2017 , 13, 1526-1534	8
934	Direct oral anticoagulants for superficial-vein thrombosis. 2017 , 4, e95-e96	2
933	Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial. 2017 , 4, e105-e113	67
932	Pulmonary Embolism in the Postanesthesia Care Unit: A Case Study. 2017 , 32, 6-14	3
931	Antibiotic use as a marker of acute infection and risk of first and recurrent venous thrombosis. 2017 , 176, 961-970	6

930	Medical Treatment for Postthrombotic Syndrome. 2017 , 34, 61-67	4
929	Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study. 2017 , 15, 907-916	36
928	Indications, complications and outcomes of inferior vena cava filters: A retrospective study. 2017 , 153, 123-128	18
927	Omega-3 fatty acids predict recurrent venous thromboembolism or total mortality in elderly patients with acute venous thromboembolism. 2017 , 15, 47-56	16
926	Trouble on Both Sides: Pulmonary Embolism with Pneumothorax. 2017 , 130, 530-533	
925	Testing for thrombophilia in mesenteric venous thrombosis - Retrospective original study and systematic review. 2017 , 31, 39-48	16
924	Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for the initial treatment of venous thromboembolism. 2017 , 2, CD001100	32
923	Net clinical benefit of hospitalization versus outpatient management of patients with acute pulmonary embolism. 2017 , 15, 685-694	29
922	Bleeding risk in patients with unprovoked venous thromboembolism: A critical appraisal of clinical prediction scores. 2017 , 152, 52-60	19
921	Impact of Anticoagulation in Elderly Patients With Pulmonary Embolism That Undergo IVC Filter Placement: A Retrospective Cohort Study. 2017 , 26, 1317-1322	3
920	Advances in oral anticoagulation therapy - What's in the pipeline?. 2017 , 31, 205-211	18
919	Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism. 2017 , 2, CD006771	4
918	Prognostic Value of Serum D-Dimer in Noncardioembolic Ischemic Stroke. 2017 , 44, 404-409	5
917	Surgery of the Inferior Vena Cava. 2017 ,	1
916	Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort. 2017 , 58, 2573-2581	23
915	Cardio-Oncology. 2017 ,	1
914	A decision model to estimate a risk threshold for venous thromboembolism prophylaxis in hospitalized medical patients. 2017 , 15, 1132-1141	5
913	Pulmonary embolism response teams. 2017 , 44, 19-29	14

912	Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study. 2017 , 4, e237-e244	29
911	Coagulopathic Complications of Cancer Patients. 2017 , 1-11	
910	The prevention and treatment of venous thromboembolism in pregnancy. 2017 , 15, 397-402	17
909	Thoracic Epidural Anesthesia and Prophylactic Three Times Daily Unfractionated Heparin Within an Enhanced Recovery After Surgery Pathway for Colorectal Surgery. 2017 , 42, 197-203	7
908	BET 2: Striking the right balance: anticoagulation and isolated distal deep vein thrombosis. 2017 , 34, 334-336	1
907	Acute Pulmonary Embolism (PE). 165-172	
906	Anticoagulants. 173-179	
905	Clinically relevant bleeding and thrombotic events in non-cirrhotic splanchnic vein thrombosis. Long-term follow up. 2017 , 154, 55-58	1
904	Preoperative and Pre-transplant Cardiac Evaluation in the Cancer Patient. 2017 , 125-159	
903	The creation and implementation of an outpatient pulmonary embolism treatment protocol. 2017 , 45, 123-129	8
902	Robotic-Assisted Inferior Vena Cava Filter Retrieval. 2017 , 13, 34-36	3
901	Antithrombotic Therapy for Venous Thromboembolic Disease. 2017 , 317, 2008-2009	7
900	How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy. 2017 , 129, 3285-3293	27
899	Venous Thromboembolism Requiring Extended Anticoagulation Among HIV-Infected Patients in a Rural, Resource-Constrained Setting in Western Kenya. 2017 , 51, 380-387	6
898	The danger of relying on the APTT and PT in patients on DOAC therapy, a potential patient safety issue. 2017 , 39 Suppl 1, 37-40	18
897	Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis. 2017 , 15, 1386-1391	16
896	Management of venous thromboembolism in myeloproliferative neoplasms. 2017 , 24, 108-114	7
895	Pharmacological management of pulmonary embolism. 2017 , 18, 79-93	3

894	The Use of Thrombolysis for Acute Pulmonary Embolism in the United States: National Trends and Patient Characteristics from 2006 to 2011. 2017 , 52, 615-621	5
893	Prognosis and Monitoring of VTE. 2017 , 40, 288-300	2
892	Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. 2017 , 2, e000188	23
891	Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. 2017 , 32, 157-164	31
890	Contemporary outcomes after venography-guided treatment of patients with May-Thurner syndrome. 2017 , 5, 667-676.e1	12
889	Derivation and Validation of a Clinical Prediction Scale for Isolated Distal Deep Venous Thrombosis in Patients after Acute Ischemic Stroke. 2017 , 26, 2087-2092	8
888	Intravascular forward-looking ultrasound transducers for microbubble-mediated sonothrombolysis. 2017 , 7, 3454	36
887	Midterm Outcomes of Pharmacomechanical Thrombectomy in the Treatment of Lower Extremity Deep Vein Thrombosis With a Rotational Thrombectomy Device. 2017 , 51, 301-306	6
886	Trombosis venosa profunda en un paciente con hipertiroidismo de novo. Presentaci3n de caso. 2017 , 26, 44-49	1
885	Novel Oral Anticoagulants in the Peri-Endoscopic Period. 2017 , 25, 223-229	
884	Venous Thromboembolism and Pulmonary Embolism Response Teams: An Overview. 2017 , 40, 237-250	2
883	[Diagnostic workup and therapy of acute venous diseases]. 2017 , 68, 595-602	
882	Thromboprophylaxis in Cancer Patients Undergoing Surgery. 2017 , 43, 672-681	3
881	Venous Thromboembolism: An Unrecognized Crisis in Gynecologic Oncology. 2017 , 129, 971-973	1
880	Upper extremity deep venous thrombosis after port insertion: What are the risk factors?. 2017 , 162, 437-444	6
879	Deep Venous Thrombosis of the Upper and Lower Extremity. 2017 , 40, 230-236	10
878	Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials. 2017 , 15, 1547-1558	10
877	The utility of on-site ultrasound screening in population at high risk for deep venous thrombosis in temporary housing after the great East Japan Earthquake. 2017 , 45, 566-574	9

876	Oral Anticoagulation Therapy. 2017 ,	1
875	[Choosing wisely recommendations in angiology]. 2017 , 58, 532-538	0
874	Update on the risk stratification of acute symptomatic pulmonary thromboembolism. 2017 , 217, 342-350	
873	Advanced Therapies in Venous Thromboembolism. 2017 , 40, 251-259	2
872	Consequences of Venous Thromboembolism, Including Chronic Thromboembolic Pulmonary Hypertension. 2017 , 40, 260-275	3
871	Controversies in Venous Thromboembolism. 2017 , 40, 301-305	1
870	Discharge or admit? Emergency department management of incidental pulmonary embolism in patients with cancer: a retrospective study. 2017 , 10, 19	12
869	Management of superficial venous thrombosis of the leg. 2017 , 55, 66-69	0
868	Anticoagulant Reversal and Anesthetic Considerations. 2017 , 35, 191-205	4
867	Intervention radiology for venous thrombosis: early thrombus removal using invasive methods. 2017 , 177, 173-184	6
866	Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism. 2017 , 3, e00229	10
865	May-Thurner syndrome: old acquaintance, new perspective : Case report. 2017 , 129, 362-365	3
864	Single-center retrospective review of ultrasound-accelerated versus traditional catheter-directed thrombolysis for acute lower extremity deep venous thrombosis. 2017 , 25, 525-532	5
863	Impact of Inferior Vena Cava Filter Placement on Short-Term Outcomes in Patients with Acute Pulmonary Embolism. 2017 , 42, 71-77	4
862	Editor's Choice - Management of the Diseases of Mesenteric Arteries and Veins: Clinical Practice Guidelines of the European Society of Vascular Surgery (ESVS). 2017 , 53, 460-510	236
861	Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding. 2017 , 43, 514-524	9
860	Why Temporary Filters Are Not Removed: Clinical Predictors in 1,000 Consecutive Cases. 2017 , 42, 64-70	8
859	A multidisciplinary quality improvement program increases the inferior vena cava filter retrieval rate. 2017 , 22, 51-56	15

858	Characterization of Guideline Evidence for Off-label Medication Use in the Intensive Care Unit. 2017 , 51, 529-542		2
857	Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. 2017 , 15, 1142-1154		33
856	Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?. 2017 , 23, 532-541		7
855	Hemodialysis Access Catheters. 2017 , 107-117		
854	Circulatory collapse, right ventricular dilatation, and alveolar dead space: A triad for the rapid diagnosis of massive pulmonary embolism. 2017 , 35, 936.e1-936.e4		3
853	Management of the Incidental Pulmonary Embolism. 2017 , 208, 485-488		15
852	Safety of warfarin in "high-risk" populations: A meta-analysis of randomized and controlled trials. 2017 , 150, 1-7		9
851	Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism. 2017 , 152, 87-92		1
850	Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α -Antiplasmin Inactivation. 2017 , 135, 1011-1020		32
849	Functional and Exercise Limitations After a First Episode of Pulmonary Embolism: Results of the ELOPE Prospective Cohort Study. <i>Chest</i> , 2017 , 151, 1058-1068	5-3	111
848	Vascular Diseases for the Non-Specialist. 2017 ,		3
847	A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism. 2017 , 70, 163-168		3
846	Surveillance, anticoagulation, or filter in calf vein thrombosis. 2017 , 5, 25-32		7
845	Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation. 2017 , 130, 482.e1-482.e9		5
844	Invited Commentary. 2017 , 5, 676-677		1
843	Absolute Neurocritical Care Review. 2017 ,		
842	Prevention and treatment of cancer-associated thrombosis in France: A national survey among vascular disease and supportive care specialists. 2017 , 42, 255-262		1
841	Portal vein thrombosis - a primer for the general physician. 2017 , 17, 479		

840	Compression therapy for prevention of post-thrombotic syndrome. 2017 , 9, CD004174	19
839	Frequency of use and acceptability of clinical prediction rules for pulmonary embolism among Swiss general internal medicine residents. 2017 , 160, 9-13	1
838	Contemporary outcomes of elective ilio caval and infrainguinal venous intervention for post-thrombotic chronic venous occlusive disease. 2017 , 5, 789-799	19
837	Are Prothrombotic Mutations a Time-to-Event Risk Factor?. 2017 , 48, 326-331	
836	Deep Venous Thrombosis. 2017 , 35, 743-770	43
835	Optimal long-term pharmacological treatment of patients with venous thromboembolism that was unprovoked or associated with weak risk factors. 2017 , 10, 921-931	
834	Vascular Access Complications: An Emergency Medicine Approach. 2017 , 35, 771-788	2
833	Diagnosis and Management of Pulmonary Embolism in the Hospitalized Patient. 2017 , 6, 517-531	
832	DVT Prevention in Stroke. 2017 , 17, 81	8
831	Thrombophilia Testing and Venous Thrombosis. 2017 , 377, 1177-1187	182
830	Practice patterns of retrievable inferior vena cava filters and predictors of filter retrieval in patients with pulmonary embolism. 2017 , 22, 512-517	2
829	A Systematic Review and Meta-analysis Comparing Anticoagulation versus No Anticoagulation and Shorter versus Longer duration of Anticoagulation for Treatment of Isolated Distal Deep Vein Thrombosis. 2017 , 43, 836-848	10
828	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. 2017 , 40, 538-580	2
827	Prescribing Errors With Low-Molecular-Weight Heparins. 2021 , 17, e587-e592	3
826	Safety of catheter-directed thrombolysis for the treatment of acute lower extremity deep vein thrombosis: A systematic review and meta-analysis. 2017 , 96, e7922	11
825	Stopping anticoagulation in a woman with unprovoked venous thromboembolism. 2017 , 189, E1112-E1114	2
824	Evaluating safety of thrombolysis in chronic kidney disease patients presenting with pulmonary embolism using propensity score matching. 2017 , 44, 324-329	5
823	Transesophageal Echocardiography-Guided Thrombus Extraction and Catheter-Directed Thrombolytic Therapy During Orthotopic Liver Transplantation. 2017 , 31, 2127-2130	6

- 822 Statins and venous thromboembolism: do they represent a viable therapeutic agent?. **2017**, 15, 629-637 6
- 821 Anticoagulation in Pulmonary Embolism: Update in the Age of Direct Oral Anticoagulants. **2017**, 20, 141-151 6
- 820 Medical Management of Pulmonary Embolism: Beyond Anticoagulation. **2017**, 20, 152-161 3
- 819 Does the presence of clinical symptoms of pulmonary embolism affect the outcome of patients with deep vein thrombosis?. **2017**, 157, 134-135
- 818 The natural history and outcomes of line-associated upper extremity deep venous thromboses in critically ill patients. **2017**, 5, 630-637 2
- 817 Update on the risk stratification of acute symptomatic pulmonary thromboembolism. **2017**, 217, 342-350 1
- 816 Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. **2017**, 40, 538-580 13
- 815 Spanish multicenter real - life registry of retrievable vena cava filters (REFiVeC). **2020**, 3, 26 5
- 814 Percutaneous Extraction of an Embolized IVC Filter Strut Embedded in the Right Ventricle. **2020**, 2, 2318-2322
- 813 Direct oral anticoagulants for therapeutic anticoagulation in postoperative pulmonary embolism after meningioma resection. **2020**, 81, 265-269 1
- 812 Compression stockings to prevent postthrombotic syndrome: Literature overview and presentation of the CELEST trial. **2020**, 4, 1239-1250 1
- 811 Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants. **2021**, 52, 315-323 0
- 810 Off-label Use for Direct Oral Anticoagulants: Valvular Atrial Fibrillation, Heart Failure, Left Ventricular Thrombus, Superficial Vein Thrombosis, Pulmonary Hypertension-a Systematic Review. **2021**, 55, 995-1009 1
- 809 Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology. **2020**, 20, 559-570 5
- 808 75-Year-Old Woman With Chest Pain and Shortness of Breath. **2020**, 95, e47-e52
- 807 Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?. **2020**, 55,
- 806 Response. *Chest*, **2020**, 157, 1397-1398 5:3
- 805 Consenso colombiano de fibrinólisis selectiva con catéter en enfermedad vascular tromboembólica. **2020**, 27, 55-65

804	Deep vein thrombosis and serum D-dimer after pelvic lymphadenectomy in gynecological cancer. 2020 , 30, 860-864	4
803	Confirm, Don't Conform Toward Thrombolysis in Acute Pulmonary Embolism in Out-of-Hospital Cardiac Arrest. <i>Chest</i> , 2020 , 157, 1396-1397	53
802	Prevention and Treatment of Thromboembolic Events in Patients with Cancer: Advances and Challenges. 2020 , 202, 124-127	
801	Effect on thromboprophylaxis among hospitalized patients using a system-wide multifaceted quality improvement intervention: Rationale and design for a multicenter cluster randomized clinical trial in China. 2020 , 225, 44-54	0
800	Concise Review of the Clinical Approach to the Exclusion and Diagnosis of Pulmonary Embolism in 2020. 2020 , 46, 527-538	1
799	Serious Complication of Anticoagulation in Vessel Thrombosis-associated Behçet Disease. 2020 , 59, 1615-1620	1
798	Midterm outcomes in patients with upper extremity deep vein thrombosis. 2020 , 8, 930-938.e2	4
797	Thromboprophylaxis in elective spinal surgery: A protocol for systematic review. 2020 , 99, e20127	1
796	Treatment of Acute Venous Thromboembolism. 2020 , 104, 631-646	
795	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. 2020 , 17, e1003101	8
794	Catheter-Based Therapies and Other Management Strategies for Deep Vein Thrombosis and Post-Thrombotic Syndrome. 2020 , 9,	7
793	Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism. 2020 , 13, e010651	5
792	Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. 2020 , 20, 301-309	13
791	Risk Stratification of Pulmonary Embolism. 2020 , 36, 437-448	1
790	Thrombolysis in Pulmonary Embolism: An Evidence-Based Approach to Treating Life-Threatening Pulmonary Emboli. 2020 , 36, 465-480	3
789	Special Considerations in Pulmonary Embolism: Clot-in-Transit and Incidental Pulmonary Embolism. 2020 , 36, 531-546	5
788	Validation of Bleeding Risk Prediction Scores for Patients With Major Bleeding on Direct Oral Anticoagulants. 2020 , 54, 1175-1184	4
787	Evaluation of the SAME-TT2R2 score to predict the quality of anticoagulation control in patients with venous thromboembolism treated with vitamin K antagonists: Findings from the RIETE registry. 2020 , 194, 178-182	1

786	Fatigue after initiating rivaroxaban for venous thromboembolism. 2020 , 4, 582-585	2
785	Real world data regarding the management of cancer-associated thrombosis. 2020 , 32, 289-294	2
784	Perioperative Management of Orthopaedic Patients with Hematologic Disorders: A Critical Analysis Review. 2020 , 8, e0001	1
783	Extended DOAC therapy in patients with VTE and potential risk of recurrence: A systematic review and meta-analysis. 2020 , 18, 2308-2317	2
782	Safety and feasibility of rivaroxaban in deferred workup of patients with suspected deep vein thrombosis. 2020 , 4, 2468-2476	2
781	Research Progress of Oxidative Stress and MicroRNAs in the Prevention of Catheter-Related Thrombus Under Resistance Exercise. 2020 , 26, 1076029620931931	1
780	Experience of a 40-day (6 week) LMWH treatment for isolated distal deep vein thrombosis. 2020 , 50, 837-843	0
779	Genomic susceptibility in practice: The regulatory trajectory of non-rare thrombophilia (NRT) genetic tests in the clinical management of venous thrombo-embolism (VTE). 2020 , 112903	2
778	Prevalence of Asymptomatic Venous Thromboembolism in Depressive Inpatients. 2020 , 16, 579-587	3
777	Review of Therapeutic Options for the Prevention of VTE in Total Joint Arthroplasty. 2020 , 5,	1
776	Heparin-Binding Copolymer as a Complete Antidote for Low-Molecular-Weight Heparins in Rats. 2020 , 373, 51-61	1
775	May-Thurner syndrome: an overlooked cause of venous thromboembolism. 2020 , 212, 402-403.e1	7
774	Prevalence and Outcomes of Thrombophilia in Patients with Acute Pulmonary Embolism. 2020 , 16, 75-85	0
773	Massive Fatal Pulmonary Embolism While on Therapeutic Heparin Drip. 2020 , 8, 2324709620914787	0
772	Cerebral and Splanchnic Vein Thrombosis: Advances, Challenges, and Unanswered Questions. 2020 , 9,	14
771	Prognosis in patients with cancer-associated venous thromboembolism: Comparison of the RIETE-VTE and modified Ottawa score. 2020 , 18, 1154-1161	3
770	Manual of Vascular Medicine. 2020 ,	
769	Asymptomatic Trauma Patients Screened for Venous Thromboembolism Have a Higher Risk Profile with Lower Rate of Pulmonary Embolism: A Five-Year Single-Institution Experience. 2020 , 86, 104-109	2

768	The Association of ICU Acuity With Adherence to ICU Evidence-Based Processes of Care. <i>Chest</i> , 2020 , 158, 579-587	53	1
767	Use of Statewide Administrative Data to Assess Clinical Outcomes: A Retrospective Cohort Study of Therapeutic Anticoagulation for Isolated Calf Vein Thrombosis. 2020 , 58, 658-662		
766	Fixing Misallocation with Guidelines: Awareness vs. Adherence. 2020 ,		2
765	Paget-Schroetter syndrome: A contemporary review of the controversies in management. 2020 , 35, 461-471		7
764	Anticoagulant treatment for subsegmental pulmonary embolism. 2020 , 2, CD010222		6
763	Anticoagulation management strategies in heart transplantation. 2020 , 63, 210-218		4
762	How I Manage Cancer-Associated Thrombosis. 2020 , 40, 38-46		4
761	Thrombotic disorders (part 1). 2020 , 110, 83		1
760	Inflammatory biomarkers in deep venous thrombosis organization, resolution, and post-thrombotic syndrome. 2020 , 8, 299-305		8
759	Analysis of patent, unstented lower extremity vein segment diameters in 266 patients with venous disease. 2020 , 8, 841-850		3
758	Superficial venous thrombosis: is it as benign as we think?. 2020 , 50, 416-420		
757	d-dimer is a predictor of clot resolution in patients with pulmonary thromboembolism: A retrospective cohort study. 2020 , 14, 549-556		1
756	Incidental venous thromboembolism, detected by chance, but still venous thromboembolism. 2020 , 55,		4
755	Changes in serum D-dimer level and effect of enoxaparin sodium after a cesarean section: a retrospective study. 2020 , 1-6		1
754	Timing of Thoracic Outlet Decompression after Thrombolysis for Primary Upper Extremity Deep Venous Thrombosis: A Systematic Review. 2020 , 66, 654-661		8
753	Central venous catheter-related thrombosis in children and adults. 2020 , 187, 103-112		24
752	A comprehensive evaluation of apixaban in the treatment of venous thromboembolism. 2020 , 13, 155-173		3
751	Incremental Value of ePLAR-The Echocardiographic Pulmonary to Left Atrial Ratio in the Assessment of Sub-Massive Pulmonary Emboli. 2020 , 9,		0

750	Treatment of thrombosis. 2020 , 105-144	
749	Deep vein thrombosis in the lower extremities after femoral neck fracture: A retrospective observational study. 2020 , 28, 2309499019901172	11
748	Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department. 2020 , 48, 41-48	0
747	Perioperative management of antithrombotic treatment. 2020 , 34, 35-50	3
746	WITHDRAWN: Anticoagulation management strategies in heart transplantation. 2020 ,	
745	Comments on the 2019 ESC guidelines on acute pulmonary embolism. 2020 , 73, 452-456	
744	Treatment of distal deep vein thrombosis. 2020 , 4, CD013422	8
743	Treatment of upper extremity deep vein thrombosis with apixaban and rivaroxaban. 2020 , 95, 817-823	10
742	Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status. 2020 , 22, 2026-2031	4
741	Congenital protein C deficiency and thrombosis in a dog. 2020 , 34, 1300-1303	2
740	Thrombolysis in massive and submassive pulmonary embolism during pregnancy and the puerperium: a systematic review. 2020 , 50, 929-941	7
739	D-dimer as a stand-alone test to rule out deep vein thrombosis. 2020 , 191, 134-139	8
738	Use of Direct Oral Anticoagulants Versus Traditional Therapies for Acute Venous Thromboembolism After Direct Discharge From the Emergency Department or After Hospitalization: An Audit of 16 Canadian Hospitals. 2020 , 42, 873-881	
737	The safety of anticoagulant therapy in the treatment of splanchnic vein thrombosis associated with acute pancreatitis. 2020 , 15, 929-931	
736	Modern Treatment Trends and Outcomes of Pulmonary Embolism With and Without Hemodynamic Significance. 2020 , 110, 1534-1540	5
735	Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic. 2020 , 8, 526-534	58
734	European guidelines on chronic mesenteric ischaemia - joint United European Gastroenterology, European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Gastrointestinal and Abdominal Radiology, Netherlands Association of Hepatogastroenterologists, Hellenic Society of Gastroenterology, Cardiovascular and Interventional Radiological Society of Europe, and Dutch Mesenteric Ischemia Study group clinical guidelines on the diagnosis and	45
733	The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. 2020 , 4, 655-666 treatment of patients with chronic mesenteric i. 2020 , 8, 371-395	33

732	Treatment of unusual thrombotic manifestations. 2020 , 135, 326-334	14
731	Acute treatment of venous thromboembolism. 2020 , 135, 305-316	12
730	Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis. 2020 , 4, 500-513	5
729	Safety of using direct oral anticoagulants in the diagnostic workup of outpatients with suspicion of acute venous thromboembolism. 2020 , 105, e307-e309	2
728	Prevention and Management of the Post-Thrombotic Syndrome. 2020 , 9,	19
727	Pharmacogenetic-guided and clinical warfarin dosing algorithm assessments with bleeding outcomes risk-stratified by genetic and covariate subgroups. 2020 , 317, 159-166	0
726	Less frequent post-thrombotic syndrome after successful catheter-directed thrombolysis for acute iliofemoral deep vein thrombosis. 2021 , 36, 237-245	1
725	The Natural History, Treatments, and Outcomes of Portal Vein Thrombosis in Patients With Inflammatory Bowel Disease. 2021 , 27, 215-223	9
724	Impact of a Blood Conservation Bundle Checklist on Perioperative Transfusion Rates during Myomectomy. 2021 , 28, 269-274	0
723	Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. 2021 , 51, 388-396	22
722	The effectiveness of exercise training in treating venous thromboembolism: a systematic review. 2021 , 49, 1-11	2
721	Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology). 2021 , 23, 799-811	0
720	Outpatient Treatment of Low-risk Pulmonary Embolism in the Era of Direct Oral Anticoagulants: A Systematic Review. 2021 , 28, 226-239	7
719	The perplexity of catheter-directed thrombolysis for deep venous thrombosis: the approaches play an important role. 2021 , 51, 757-766	2
718	Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents. 2021 , 209, 112893	3
717	Post-filter thromboembolic prophylaxis in vena cava filter carriers. 2021 , 36, 79-80	
716	Prescribing patterns and outcomes of venous thromboembolism prophylaxis in hospitalized medical and cancer patients: Observations from the Ottawa Hospital. 2021 , 197, 144-152	0
715	Weight-adjusted tinzaparin for venous thromboembolism prophylaxis in bariatric surgery patients weighing 160 kg or more. 2021 , 198, 1-6	1

714	Incidence and predictors of splanchnic vein thrombosis and mortality following hepatobiliary and pancreatic surgery. 2021 , 19, 797-804	1
713	Editor's Choice - European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. 2021 , 61, 9-82	69
712	Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. 2021 , 73, 366-413	89
711	Deep vein thrombosis in patients with neuromuscular disease who undergo tracheotomy with positive pressure ventilation. 2021 , 9, 63-67	0
710	Comparative Analysis of Procedural Outcomes and Complications Between De Novo and Upgraded Cardiac Resynchronization Therapy. 2021 , 7, 62-72	2
709	Direct Oral Anticoagulants Are a Potential Alternative to Low-Molecular-Weight Heparin for Thromboprophylaxis in Trauma Patients Sustaining Lower Extremity Fractures. 2021 , 258, 324-331	2
708	Chinese orthopaedic nurses' knowledge, attitude and venous thromboembolic prophylactic practices: A multicentric cross-sectional survey. 2021 , 30, 773-782	1
707	Risk of venous thromboembolism in rheumatoid arthritis. 2021 , 88, 105122	7
706	Thoracic Surgery for the Acute Care Surgeon. 2021 ,	
705	Massive pulmonary embolism in patients with extreme bleeding risk: a case series on the successful use of ultrasound-assisted, catheter directed thrombolysis in a district general hospital. 2021 , 51, 1120-1126	1
704	Low-molecular weight vs. unfractionated heparin for prevention of venous thromboembolism in general surgery: a meta-analysis. 2021 , 73, 75-83	
703	Acute pulmonary embolism multimodality imaging prior to endovascular therapy. 2021 , 37, 343-358	2
702	Anticoagulant therapy for splanchnic vein thrombosis: a systematic review and meta-analysis. 2021 , 137, 1233-1240	10
701	Evaluation of Time to Therapeutic Anticoagulation and Associated Outcomes in Critically Ill, Obese Patients With Pulmonary Embolism Receiving Unfractionated Heparin. 2021 , 34, 438-444	
700	Treatment Failures of Direct Oral Anticoagulants. 2021 , 28, e87-e95	9
699	[How to make the diagnosis of pulmonary embolism?]. 2021 , 38 Suppl 1, e7-e23	
698	Outcomes and Prognosis Factors in Patients With Vena Cava Filters in a Quaternary Medical Center: A 5-Year Retrospective Analysis. 2021 , 36, 277-283	0
697	Deep Vein Thrombosis and Pulmonary Embolus Thrombolysis and Endovascular Treatment. 2021 , 531-542	

- 696 Comparison of two escalated enoxaparin dosing regimens for venous thromboembolism prophylaxis in obese hospitalized patients. **2021**, 52, 577-583 0
- 695 Anticoagulation and Antiplatelet Guidelines. **2021**, 201-223
- 694 Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design. **2021**, 52, 567-576 2
- 693 Safety, Efficacy of an Accelerated Regimen of Low-Dose Recombinant Tissue-Type Plasminogen Activator for Reperfusion Therapy of Acute Pulmonary Embolism. **2021**, 27, 10760296211037920
- 692 The vascular side of COVID-19 disease. Position paper of the International Union of Angiology. **2020**, 39, 445-451 4
- 691 Clinical Effectiveness of Rivaroxaban in Patients With Idiopathic Pulmonary Fibrosis and Thrombosis of the Right Ventricle. **2021**, 7, 132-157 0
- 690 Oral Anticoagulant Therapy in the Arab World. **2021**, 1-27
- 689 Intracranial hemorrhage and out of hospital cardiac arrest. **2021**, 48, 351
- 688 Feasibility of anticoagulation using low molecular-weight heparin during catheter-directed thrombolysis for lower extremity deep venous thrombosis. **2021**, 19, 6 1
- 687 Soleal vein dilatation in the early phase of hospitalization is associated with subsequent development of deep vein thrombosis in patients with acute stroke. **2021**, 48, 97-104
- 686 Extracorporeal membrane oxygenation treatment for high-risk pulmonary embolism with cardiac arrest in a young adult male. **2021**, 12, 324-326 0
- 685 Unprovoked internal jugular vein thrombosis: a case report and literature review. **2021**, 19, 2 1
- 684 Review of Medical Therapies for the Management of Pulmonary Embolism. **2021**, 57, 4
- 683 Oral Anticoagulant Therapy in the Arab World. **2021**, 2871-2896
- 682 Direct oral anticoagulants for unusual-site venous thromboembolism. **2021**, 5, 265-277 4
- 681 Transdermal delivery of heparin using low-frequency sonophoresis in combination with sponge spicules for venous thrombosis treatment. **2021**, 9, 5612-5625 1
- 680 Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism. 1
- 679 Thromboembolism in Older Adults. **2020**, 7, 470016 1

678	Stroke in pregnancy. 2021 , 177, 283-293	0
677	Management of superficial venous thrombosis in unevaluated situations: Cancer, severe renal impairment, pregnancy and post-partum. 2021 , 36, 464-472	1
676	Retrieval of Bard Simon Nitinol inferior vena cava filters: Approaches, technical successes, complications, and clinical outcomes. 2021 , 36, 555-561	0
675	Systematic Review of Thrombolysis Therapy in the Management of Non-Cirrhosis-Related Portal Vein Thrombosis. 2021 , 25, 1579-1590	6
674	Endovascular Treatment for Lower Extremity Deep Vein Thrombosis: An Overview. 2021 , 22, 931-943	1
673	Perioperative Management of Polycythemia. 2021 , 405-409	
672	Bleeding and Thrombosis. 2021 , 491-499	
671	Extensive pulmonary embolism as complication of oligosymptomatic COVID-19: case report.. 2021 , 20, e20200239	0
670	Venous Thromboembolism. 2021 , 317-326	
669	Right Heart Thrombus and Pulmonary Embolism in Patients with Life-Threatening Bleeding: Management of a Complex Condition. 2021 , 3, 793-795	
668	A Pericardial Pin: Embolization of an Inferior Vena Cava Filter Strut Presenting as Acute Pericarditis. 2021 , 3, 304-308	0
667	Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms. 2021 , 41, 48-57	6
666	The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgery. 2021 , 51, 1480-1487	2
665	High-Risk Pulmonary Embolism: Embolectomy and Extracorporeal Membrane Oxygenation. 2021 , 42, 263-270	1
664	Bleeding Risk Assessment in Patients with Venous Thromboembolism. 2021 , 41, 267-274	0
663	A Purpuric Rash. 2021 , 325, 782-783	
662	Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE. 2021 , 5, 326-341	3
661	Is chemoprophylaxis required after total knee and total hip arthroplasty in the Asian population? A systematic review and network meta-analysis. 2021 , 198, 86-92	1

660	Effect of unfractionated heparin and low molecular weight heparin on the clotting of platelet-reduced whole blood: an in-vitro study utilizing thromboelastography. 2021 , 32, 305-311	0
659	Usefulness of D-dimer and Ultrasonography Screening for Detecting Deep Vein Thrombosis in Patients with Spinal Cord Injury Undergoing Rehabilitation. 2021 , 10,	1
658	A cross-sectional, multicenter, observational study to assess the prophylaxis of venous thromboembolism in Lebanese and Jordanian hospitals. 2021 , 19, 9	1
657	Migrated Inferior Vena Cava (IVC) Filter Strut: A Rare Cause of Chronic Distal Pancreatitis with Likely Malignant Transformation. 2021 , 22, e929599	
656	A Case Series of Catheter-Directed Thrombolysis With Mechanical Thrombectomy for Treating Severe Deep Vein Thrombosis. 2021 , 38, 56-61	
655	Phlegmasia Alba Dolens Complicating Rhabdomyolysis. 2021 , 13, e14080	
654	Prognostic Significance of Concomitant Superficial Vein Thrombosis in Patients with Deep Vein Thrombosis of the Lower Limbs. 2021 , 121, 1650-1659	1
653	Updated recommendations for the treatment of venous thromboembolism. 2021 , 56, 6-16	0
652	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies. 2021 , 5, 426-438	3
651	The utility of routine head CT for hemorrhage surveillance in post-craniotomy patients undergoing anticoagulation for venous thromboembolism. 2021 , 85, 78-83	1
650	Drugs in phase I and II clinical development for the prevention of stroke in patients with atrial fibrillation. 2021 , 30, 1057-1069	1
649	Atrial Fibrillation and Stroke. 2021 , 13, 243-255	0
648	Defining the human and health care costs of chronic venous insufficiency. 2021 , 34, 59-64	2
647	Cost-effectiveness of managing low-risk pulmonary embolism patients without hospitalization. The low-risk pulmonary embolism prospective management study. 2021 , 41, 80-83	1
646	Incidence and risk factors of venous thromboembolism after percutaneous nephrolithotomy: a single-center experience. 2021 , 39, 3571-3577	2
645	A review of upper extremity deep vein thrombosis. 2021 , 133, 3-10	1
644	Inflammatory Biomarkers in the Short-Term Prognosis of Venous Thromboembolism: A Narrative Review. 2021 , 22,	2
643	Guidelines for Perioperative Care for Emergency Laparotomy Enhanced Recovery After Surgery (ERAS) Society Recommendations: Part 1-Preoperative: Diagnosis, Rapid Assessment and Optimization. 2021 , 45, 1272-1290	15

- 642 Performance of the Wells score in predicting deep vein thrombosis in medical and surgical hospitalized patients with or without thromboprophylaxis: The R-WITT study. **2021**, 26, 288-296
- 641 Updates in Anticoagulation Therapy Monitoring. **2021**, 9, 7
- 640 Prediction models for recurrence and bleeding in patients with venous thromboembolism: A systematic review and critical appraisal. **2021**, 199, 85-96 2
- 639 Venous Thromboembolism: Genetics and Thrombophilias. **2021**, 42, 271-283 0
- 638 Comparison of Bleeding Risk Scores in Elderly Patients Receiving Extended Anticoagulation with Vitamin K Antagonists for Venous Thromboembolism. **2021**, 121, 1512-1522 1
- 637 Incidental Pulmonary Embolism - How Should We Treat It?. **2021**, 2
- 636 [Which aetiological investigations to undertake during the progress of PE/DVT?]. **2021**, 38 Suppl 1, e90-e98
- 635 Chinese expert consensus on diagnosis and treatment of trauma-induced hypercoagulopathy. **2021**, 8, 25 0
- 634 High prevalence of pulmonary embolism prior to cancer therapies in patients with ovarian and endometrial cancers detected by contrast-enhanced CT using D-dimer as an index. **2021**, 124, 106-114 0
- 633 Hospitalization for venous thromboembolic disease management: a 10 years Registry in Buenos Aires, Argentina. **2021**, 52, 1187-1194 0
- 632 Derivation and validation of a nomogram model for pulmonary thromboembolism in patients undergoing lung cancer surgery. **2021**, 10, 1829-1840 0
- 631 Internal Jugular Vein Thrombosis: Unusual Diagnosis of a Cervical Mass. **2021**, 13, e14516 0
- 630 Zur chirurgischen Behandlung der Varikophlebitis. **2021**, 26, 383-391
- 629 Society for Obstetric Anesthesia and Perinatology: Consensus Statement and Recommendations for Enhanced Recovery After Cesarean. **2021**, 132, 1362-1377 43
- 628 Ultrasound Imaging of Superficial Venous Thrombosis in the Upper and Lower Extremities: Closing the Gap Between Clinical Management Guidelines and Ultrasound Practice Parameters. **2021**, 1
- 627 Navigating inferior vena cava filters in invasive cardiology procedures: A systematic review. **2021**, 32, 1440-1448 0
- 626 The question of whether vena cava filters have a role in trauma patients remains unanswered. **2021**, 64, E244-E245 0
- 625 Delayed anticoagulation in venous thromboembolism: Reasons and associated outcomes. **2021**, 5, e12500 0

624	Outpatient treatment of emergency department patients diagnosed with venous thromboembolism. 2021 , 133, 11-19	0
623	Anticoagulation in COVID-19: current concepts and controversies. 2021 ,	19
622	Long-term risk of recurrent venous thromboembolism after a first contraceptive-related event: Data from REVERSE cohort study. 2021 , 19, 1526-1532	3
621	Upper Extremity Deep Vein Thrombosis: Current Knowledge and Future Directions. 2021 , 47, 677-691	2
620	A systematic review and meta-analysis for the management of Paget-Schroetter syndrome. 2021 , 9, 801-810.e5	
619	IVC filters - Indications for placement and retrieval trends- experience from a tertiary referral centre in India type of submission- full paper. 2021 , 73, 331-335	
618	Incidence and risk factors for venous thromboembolism in a cohort of Taiwanese patients with lung, gastric, pancreatic cancers or lymphoma. 2021 , 121, 360-360	0
617	Drug-drug interactions with warfarin: A systematic review and meta-analysis. 2021 , 87, 4051-4100	10
616	The characteristics and outcomes of critically ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study. 2021 , 52, 1061-1067	8
615	The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population. 2021 , 16, e0250502	1
614	Evaluation of anticoagulant therapy management in a teaching hospital in Tunisia: information and education for vitamin k antagonist newly treated patients need to be improved. 2021 , 29, 389-393	
613	Efficacy Estimation of Microbubble-Assisted Local Sonothrombolysis Using a Catheter with a Series of Miniature Transducers. 2021 , 12,	1
612	Cardiopulmonary Emergencies in Older Adults. 2021 , 39, 323-338	0
611	Robotic-assisted hiatal hernia repair and pulmonary embolism: an institution-based retrospective cohort study. 2021 , 1	
610	Evolution of CT findings after anticoagulant treatment for acute pulmonary embolism in patients with and without an ultimate diagnosis of CTEPH. 2021 ,	3
609	Prevalence and clinical outcomes of hospitalized patients with upper extremity deep vein thrombosis. 2021 ,	1
608	A nomogram based on easily obtainable parameters for distal deep venous thrombosis in patients after acute stroke. 2021 , 205, 106638	1
607	Mediastinal effusion due to pericardiocentesis with cardiac tamponade: a case report. 2021 , 21, 172	0

606	Cancer-Associated Splanchnic Vein Thrombosis. 2021 , 47, 931-941	2
605	Reducing emergency department visits in patients with deep vein thrombosis: introducing a standardised outpatient treatment pathway. 2021 , 10,	
604	Spleen infarct secondary to thrombus in COVID-19-related splenic vein: A case report. 2021 , 22, 180-183	1
603	An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug. 2021 ,	
602	Asia-Pacific venous thromboembolism consensus in knee and hip arthroplasty and hip fracture surgery: Part 1. Diagnosis and risk factors. 2021 , 33, 18	3
601	Splanchnic vein thrombosis: Clinical manifestations, risk factors, management, and outcomes. 2021 , 202, 90-95	2
600	Multidisciplinary Practice Variations of Anti-Thrombotic Strategies for Free Tissue Transfers. 229255032110247	
599	Systemic Thrombolysis for Treatment of Postpartum Saddle Embolism Complicated by Postpartum Hemorrhage: A Case Report and Brief Literature Review. 2021 , 2021, 5553296	
598	Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. 2021 , 202, 155-161	1
597	Endovascular Therapy for the Management of Acute Ilio-femoral Deep Vein Thrombosis. 2021 , 50, 270-278	
596	Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study. 2021 , 19, 2751-2759	4
595	Triaging deep vein thrombosis using ultrasonography after lower-extremity orthopedic surgery: analysis of a single-center experience. 2021 , 40, 442-448	
594	Clinical Practice for Venous Thromboembolism Prophylaxis in Patients Undergoing Oncological Surgeries. 2021 , 13, e16627	0
593	Prvention des complications thromboemboliques en chirurgie urologique. 2021 , 31, F99-F99	
592	Investigation and management of pulmonary embolism 1: a probability-based approach. 2021 , 82, 1-16	
591	Pharmacotherapy and Compression Therapy of DVT. 2021 , 58, 760-764	
590	Monotherapy Anticoagulation to Expedite Home Treatment of Patients Diagnosed With Venous Thromboembolism in the Emergency Department: A Pragmatic Effectiveness Trial. 2021 , 14, e007600	3
589	Patient education program at the forefront of cancer-associated thrombosis care. 2021 , 46, 215-223	0

588	Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College Hospital. 2021 ,			0
587	Treatment of May-Thurner's Syndrome and Associated Complications: A Multicenter Experience. 2021 , 14, 4705-4710			0
586	Wound complications and bleeding with new oral anticoagulants in patients undergoing total joint arthroplasty: A systematic review and meta-analysis of randomized controlled trials. 2021 ,			0
585	Evaluation of an Initiation Regimen of Warfarin for International Normalized Ratio Target 2.0 to 3.0. 2021 , 37, 286-292			
584	Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis. 2021 , 1			0
583	Effect of different initial anticoagulant strategies on short-term outcome of patients with symptomatic DVT in China. 2021 , 75, e14619			
582	Venous Thromboembolism Prophylaxis in Critically Ill Adults: A Systematic Review and Network Meta-analysis. <i>Chest</i> , 2021 ,	5-3		4
581	Female Gender is a Predictor of Lower Iliac Vein Stenting Patency Rates. 2021 ,			2
580	Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2021 , 160, e545-e608	5-3		48
579	Comparison of Anticoagulation Regimens Following Stent Placement for Nonthrombotic Lower Extremity Venous Disease. 2021 , 32, 1584-1590			6
578	New Internet-Based Warfarin Anticoagulation Management Approach After Mechanical Heart Valve Replacement: Prospective, Multicenter, Randomized Controlled Trial. 2021 , 23, e29529			1
577	Venoactive Drugs, Summary of the Clinical Trials and Guidelines. 2021 , 19, 21-26			
576	Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , 2021 , 160, 2247-2259	5-3		35
575	Invited Review: Optimal Management of Upper Extremity DVT: Is Venous Thoracic Outlet Syndrome Underrecognized?. 2021 ,			0
574	Contemporary rates of inferior vena cava filter thrombosis and risk factors. 2021 ,			3
573	Changes in anticoagulant prescription in a general hospital in 2008-2018. 2021 , 17, 544-551			
572	Efficacy and safety of hydro-mechanical defragmentation in intermediate- and high-risk pulmonary embolism. 2021 , 73, 84			
571	Venous Thromboembolism Requiring Anticoagulation Following Knee Arthroscopy in a Young Woman With an Intrauterine Contraceptive Device. 2021 , 44, e687-e690			0

570	Upper extremities deep vein thrombosis treated with oral direct anticoagulants: A prospective cohort study. 2021 , 339, 158-163	3
569	Optimal timing of venous thromboembolic chemoprophylaxis initiation following blunt solid organ injury: meta-analysis and systematic review. 2021 , 1	2
568	Synthesis of 3-aryl-4-(N-aryl)aminocoumarins via photoredox arylation and the evaluation of their biological activity. 2021 , 114, 105141	1
567	Current status survey of the extramural hospital management of venous thromboembolism after total hip and knee arthroplasty in China. 2021 , 22, 787	
566	Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary "Real Life" Experience. 2021 , 17, 619-629	
565	Retrievable Inferior Vena Cava Filters - Use, Removal, and Removal Techniques. 2021 ,	0
564	Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection. 2021 , 608, 121122	1
563	Long-Term Survival After Venous Thromboembolism: A Prospective Cohort Study. 2021 , 8, 749342	2
562	Risque de maladie thromboembolique veineuse dans la polyarthrite rhumatoïde. 2021 , 88, 338-345	
561	Prevention and Treatment of Postoperative Pulmonary Complications. 2022 , 277-288	
560	Prevention and Management of Deep Vein Thrombosis and Pulmonary Embolism. 2022 , 428-434	
559	Pulmonary Embolism Causing Severe Organ Failure. 2022 , 288-297	
558	Cardiovascular Drugs and Hemostasis. 2022 , 701-729	
557	Trends and In-Hospital Outcomes of Splanchnic Vein Thrombosis Associated with Gastrointestinal Malignancies: A Nationwide Analysis. 2021 , 8, 71-80	1
556	Our approach and review of current concepts of catheter directed procedures in acute limb ischemia. 2021 , 8, 18	
555	First-in-Human Study to Assess the Safety and Feasibility of the Bashir Endovascular Catheter for the Treatment of Acute Intermediate-Risk Pulmonary Embolism. 2021 , 14, e009611	5
554	Acute pulmonary embolism and systemic thrombolysis in the era of COVID-19 global pandemic 2020: a case series of seven patients admitted to a regional hospital in the French epidemic cluster. 2021 , 5, ytaa522	2
553	Thrombolytic strategies versus standard anticoagulation for acute deep vein thrombosis of the lower limb. 2021 , 1, CD002783	3

552	Extracorporeal Membrane Oxygenation in Pregnancy. 2021 , 197-210	
551	Isolated Pectoralis Minor Tendon Rupture with Subclavian Vein Thrombosis. 2021 , 2021, 8865592	0
550	The Perioperative Deep Vein Thrombosis in Lower Extremities in Patients With Pelvic Fracture: A Case-Control Study. 2021 , 27, 10760296211033024	0
549	Pulmonary Embolism. 2021 , 205-266	
548	Inferior Vena Cava Filters in the Management of Venous Thromboembolism. 114-127	1
547	Coagulation Disorders. 2016 , 203-223	2
546	Current Guidelines and Recommendations for Thrombolysis Use in Pulmonary Embolism. 2015 , 151-174	1
545	Postthrombotic Syndrome. 2015 , 4495-4522	1
544	Antithrombotika und Antihorrhagika. 2016 , 351-368	1
543	Antithrombotika und Antihorrhagika. 2017 , 353-372	1
542	Antithrombotika und Antihorrhagika. 2018 , 401-421	2
541	Antithrombotika und Antihorrhagika. 2019 , 531-555	3
540	Upper extremity deep vein thrombosis treated with direct oral anticoagulants: a multi-center real world experience. 2020 , 50, 355-360	8
539	Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. 2020 , 50, 72-81	266
538	Effects of Different Applications of Tranexamic Acid on Perioperative Blood Transfusion Rate and Postoperative Pain in Unilateral Total Knee Arthroplasty. 2021 , 38, 1143-1154	1
537	Antiphospholipid syndrome. 2015 , 1144-1152	5
536	Use of Vena Cava Filters and Venous Access Devices. 2013 , 563-594	1
535	Risk Of Recurrence After Withdrawal Of Anticoagulation In Patients With Unprovoked Venous Thromboembolism: External Validation Of The Vienna Nomogram And The Dash Prediction Score. 2019 , 55, 619-626	3

534	Venous thrombosis of the liver: current and emerging concepts in management. 2020 , 225, 54-69	4
533	Management of cancer-associated venous thromboembolism - a case-based practical approach. 2018 , 47, 77-89	12
532	Cessation of anticoagulation therapy following endovascular thrombus removal and stent placement for acute iliofemoral deep vein thrombosis. 2019 , 48, 331-339	6
531	[Susceptibility genetics of common conditions in clinical practice]. 2020 , 36, 515-520	1
530	Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial. 2020 , 46, 977-985	3
529	Clinical Outcomes of Incidental Venous Thromboembolism in Cancer and Noncancer Patients: The SWISS Venous Thromboembolism Registry (SWIVTER). 2021 , 121, 641-649	6
528	Jugular Vein Thrombosis and Anticoagulation Therapy in Lemierre's Syndrome A Post Hoc Observational and Population-Based Study of 82 Patients. 2021 , 8, ofaa585	9
527	Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism. 2020 , 31, 536-542	6
526	Life-threatening haemorrhage in patients without pulmonary embolism who received anticoagulants. 2015 , 2015,	1
525	Retroperitoneal haematoma associated with enoxaparin use in an elderly woman with chronic kidney disease. 2015 , 2015,	3
524	Thrombin Generation Profile in Various Lymphoma Sub-Groups and Its Augmentation by Andexanet Alfa. 2020 , 26, 1076029620983466	1
523	Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis. 2017 , 2017, 223-230	11
522	Catheter-related thrombosis: lifeline or a pain in the neck?. 2012 , 2012, 638-644	31
521	Role of Phosphodiesterase-5 Inhibitors in Acute Right Ventricular Failure Due to Pulmonary Embolism. 2019 , 20, 1144-1147	2
520	Analysis of risk factors for recurrence of deep venous thrombosis in lower extremities. 2014 , 20, 199-204	8
519	Recurrent Deep Vein Thrombosis After the First Venous Thromboembolism Event: A Single-Institution Experience. 2017 , 23, 2391-2399	3
518	Compression I from thrombosis to post-thrombotic syndrome. 2014 , 43, 227-231	1
517	Heparins I DOACS I VKA. 2015 , 44, 307-315	1

516	Expanding use of new oral anticoagulants. 2014 , 6, 93	15
515	Patterns and Appropriateness of Thrombophilia Testing in an Academic Medical Center. 2017 , 12, 705-709	14
514	Conception of a Personalized Medication Adherence Discharge Kit for Rivaroxaban. 2016 , 51, 60-67	1
513	Prevention of Venous Thromboembolism in Individuals with Spinal Cord Injury: Clinical Practice Guidelines for Health Care Providers, 3rd ed.: Consortium for Spinal Cord Medicine. 2016 , 22, 209-240	31
512	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. 2015 , 10, e0122520	52
511	Dual Processing Model for Medical Decision-Making: An Extension to Diagnostic Testing. 2015 , 10, e0134800	6
510	Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. 2015 , 10, e0143252	31
509	Analysis of Thrombophilia Test Ordering Practices at an Academic Center: A Proposal for Appropriate Testing to Reduce Harm and Cost. 2016 , 11, e0155326	21
508	Benefit of early discharge among patients with low-risk pulmonary embolism. 2017 , 12, e0185022	9
507	Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism. 2018 , 13, e0194673	9
506	Update on Management of Portal Vein Thrombosis and the Role of Novel Anticoagulants. 2019 , 7, 154-164	21
505	Thrombolysis in Massive Pulmonary Embolism. 2017 , 3, 8-11	1
504	Effect of Percutaneous Suction Thromboembolectomy on Improved Right Ventricular Function. 2019 , 46, 115-119	2
503	Retrospective Cohort Study of Venous Thromboembolism Rates in Ambulatory Cancer Patients: Association With Khorana Score and Other Risk Factors. 2019 , 8, 17-25	2
502	Role of perioperative monitoring in diagnosis of massive intraoperative cardiopulmonary embolism. 2014 , 6, 141-5	9
501	Admission rates for emergency department patients with venous thromboembolism and estimation of the proportion of low risk pulmonary embolism patients: a US perspective. 2016 , 3, 126-131	27
500	Pulmonary embolism in patients with COVID-19 and its treatment based on low-molecular-weight heparin. 2020 , 138, 349-351	1
499	Guidelines for superficial venous thrombosis. 2019 , 18, e20180105	5

498	Venous thromboembolism prophylaxis protocols at Brazilian hospitals - PROTEV Brazil. 2020 , 19, e20190119	2
497	[Features of lower extremities deep veins recanalization in patients with thrombosis by using of sulodexide]. 2015 , 58-64	3
496	Venous thromboembolism: current management. 2019 , 42, 123-126	4
495	Preoperative thromboprophylactic administration of low-molecular-weight-heparin significantly decreased the risk of intraoperative bleeding compared with heparin in patients undergoing video-assisted lobectomy for lung cancer. 2019 , 7, 90	5
494	Deep vein thrombosis and pregnancy. 2014 , 68-88	1
493	Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study. 2020 , 39, 112-117	2
492	Comparison of bipolar plasmakinetic transurethral enucleation and resection of prostate gland in patients receiving anticoagulants and/or platelet aggregation inhibitors. 2019 , 71, 286-293	10
491	Complications of central venous catheters insertion and exploitation. 2019 , 18, 127-139	0
490	The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations. 2015 , 13, 178-80	8
489	The evolution of anticoagulant therapy. 2016 , 14, 175-84	30
488	Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal. 2017 , 15, 369-377	9
487	MODERN TRENDS IN THE SURGICAL TREATMENT OF MASSIVE PULMONARY EMBOLISM (review of literature). 2020 , 178, 66-70	1
486	Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation. 2016 , 20, i-xxxiii, 1-190	19
485	Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants. 2019 , 34, e52	8
484	Pulmonary Embolism Masquerading as Severe Pneumonia: A Case Report. 2019 , 7, 396-399	3
483	Role of emerging vitamin K-dependent proteins: Growth arrest-specific protein 6, Gla-rich protein and periostin (Review). 2021 , 47,	5
482	Current Management of Pulmonary Thromboembolism. 2013 , 84, 659	3
481	Management of Venous Thrombosis in Atypical Location. 2014 , 86, 20	1

480	Superior vena cava syndrome as a clinical manifestation of recurrent cervical cancer. 2016 , 33, 246-7	1
479	Arrive: A retrospective registry of Indian patients with venous thromboembolism. 2016 , 20, 150-8	17
478	Venous thromboembolism in cancer patients - magnitude of problem, approach, and management. 2017 , 54, 308-312	9
477	Use of reteplase for thrombolysis in patients with massive pulmonary embolism diagnosed by bedside transthoracic echocardiography: A retrospective study of safety and efficacy. 2019 , 8, 3155-3159	1
476	Successful pulmonary thromboendarterectomy in a patient with sickle cell disease and associated resolution of a leg ulcer. 2018 , 35, 73-77	1
475	Anticoagulants for cancer-associated ischemic stroke. 2019 , 31, 144-148	1
474	Effectiveness of venous thromboembolism prophylaxis in patients with liver disease. 2019 , 11, 379-390	7
473	Case Report: Two Cases of Strongyloidiasis Presenting with Thrombotic Events. 2019 , 101, 418-421	2
472	Characterization of Venous Involvement in Vasculo-Behçet Disease. 2020 , 53, 381-386	2
471	Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline. 2015 , 35, 95-106	11
470	Effect of a dedicated inferior vena cava filter retrieval program on retrieval rates and number of patients lost to follow-up. 2020 , 26, 40-44	5
469	External Jugular Vein Thrombosis as a Sign of Metastatic Breast Cancer. 2017 , 13, 43-45	1
468	Thrombosis in children: Which test to whom, when and how much necessary?. 2018 , 53, 1-9	6
467	C20209T prothrombin gene mutation associated deep venous thrombosis in a hemodialysis patient. 2014 , 2, 1-4	2
466	Pulmonary embolism hotline 2012. Recent and expected trials. 2013 , 33, 43-50	3
465	Risk of recurrence of unusual site venous thromboembolism. 2013 , 33, 225-31	4
464	Anticoagulation after venous thromboembolism. Deciding on the optimal duration. 2013 , 33, 211-7	1
463	. 2017 , 109, 1-76	119

462	Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care. 2016 , 71, 36-46	9
461	Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. 2016 , 32, 1-22	22
460	[Operation and management guidelines for peripherally inserted central catheter in neonates (2021)]. 2021 , 23, 201-212	2
459	Venous Thromboembolism in Spinal Cord Injuries. 2021 , 329-340	
458	Pharmacotherapy in Spinal Cord Injuries. 2021 , 77-118	
457	Bleeding in elderly and senile patients with deep vein thrombosis on anticoagulant therapy. 2021 , 15, 170	1
456	Superficial phlebitis and thrombophlebitis. 2021 , 15, 211	3
455	Enfoque del tromboembolismo pulmonar agudo desde el momento inicial en el servicio de urgencias. 2021 , 40, 50-59	
454	The Incidence of Cancer Associated Thrombosis is Increasing Over Time. 2021 ,	1
453	Ovarian Hyperstimulation: Diagnosis, Prevention, and Management. 2021 , 39, 170-179	0
452	Deep Vein Thrombosis in Intravenous Drug Users: An Invisible Global Health Burden. 2021 , 13, e18457	0
451	Incidence of and risk factors for pre-operative deep venous thrombosis in geriatric intertrochanteric fracture patients. 2021 , 1	3
450	Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World. 2021 ,	0
449	Accelerated fibrin clot degradation is associated with arterial thromboembolism in patients following venous thrombosis: a cohort study. 2021 , 11, 21003	0
448	Direct Oral Anticoagulant Therapy for Isolated Distal Deep Vein Thrombosis Associated with Cancer in Routine Clinical Practice. 2021 , 10,	
447	New Oral Anticoagulants in Surgery. 2012 , 331-338	
446	Thrombotic and Hemostatic Aspects of Assisted Conception. 2012 , 237-245	
445	New treatments for venous thromboembolism. 2012 , 23, 358-361	

- 444 Ischemic Venous Thrombosis: Phlegmasia Cerulea Dolens and Venous Gangrene. 1213-1220
- 443 New antithrombotic agents in cancer patients. **2012**, 68-96
- 442 Diagnostic imaging of deep vein thrombosis. **2013**, 24, 364-369
- 441 Diagnosis and Treatment of Venous Thromboembolism in Cancer Patients. **2013**, 85, 481 1
- 440 Short-Term Mortality in Patients with Massive and Submassive Pulmonary Embolism Receiving Thrombolytic Therapy. **2013**, 84, 62 1
- 439 Venous Thromboembolism: Deep Vein Thrombosis and Pulmonary Embolism. **2014**, 147-159
- 438 Thrombotic Risk Factors. **2014**, 185-202
- 437 The Excessively Clotting Cancer Patient. **2014**, 161-183
- 436 Pulmonary Embolism. **2014**, 415-425
- 435 Patient Safety in Fast-Track Total Hip and Knee Replacement. **2014**, 147-151
- 434 Pulmonary Embolism. **2014**, 1-17
- 433 Open and Endovenous Treatments of Peripheral Venous Disease. **2014**, 1-28
- 432 Pulmonary embolism. **2014**, 392-400.e2
- 431 Biological thrombophilia. **2014**, 90-107
- 430 Index. **2014**, 178-179
- 429 Oral Anticoagulation. **2014**, 380-392
- 428 Critical Importance of Standardized Nomenclature and Classification in Venous Surgery and Interventional Treatments. **2014**, 1-21
- 427 Pulmonary Embolism. **2014**, 151-200

426 Diagnosis, Treatment, and Prevention of Cancer-Associated Venous Thromboembolism. **2014**, 542-561.e7

425 Diagnosis of recurrent deep vein thrombosis. **2014**, 40-51

424 Postthrombotic Syndrome. **2014**, 1-35

423 Contraceptive Options for Women with Thrombophilia and Thromboembolic Disease. **2014**, 205-235

422 Alteration of Factors Associated with Coagulation in Provoked Pulmonary Embolism. **2014**, 1, 5-9

421 Venous Thromboembolic Disease. **2015**, 185-197

420 Thrombophilia Testing in Splanchnic Vein Thrombosis. **2015**, 309-323

419 Treatment of Thrombosis in Antiphospholipid Syndrome. **2015**, 185-192

418 Thrombosen. **2015**, 739-748

417 Current Trends in the Management of Acute Deep Vein Thrombosis among Korean Vascular Surgeons. **2014**, 30, 139-43

416 Combined catheter thrombus fragmentation and percutaneous thrombectomy in a patient with massive pulmonary emboli and acute cerebral infarct. **2015**, 15, 72-4 2

415 Ambulatory Warfarin Management. **2015**, 27-51

414 Treatment of Venous Thromboembolism. **2015**, 151-177

413 Blutungs- und thromboembolische Komplikationen. **2015**, 313-327

412 Mechanical Thrombectomy by the Rolling Technique Using a Coronary Wire in a Patient with Recurrent Inferior Vena Cava Filter Thrombosis. **2015**, 88, 303

411 Superficial Thrombophlebitis. **2015**, 4483-4487

410 Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. **2015**, 6, 267-277 0

409 Anticoagulation as Adjunctive Treatment and One-Hour Alteplase Infusion. **2015**, 131-149

408 Venous Thromboembolism. **2015**, 1-11

407 Interventional Treatment of Deep Vein Thrombosis. **2015**, 4489-4493

406 Deep Vein Thrombosis. **2015**, 4455-4481

405 Surgery: Surgical Quality. **2015**, 211-218

404 Inferior Vena Cava Filters: Recognizing Indications for Placement and Retrieval. **2015**, 67-76

403 Critical Importance of Standardized Nomenclature and Classification in Venous Surgery and Interventional Treatments. **2015**, 4565-4583

402 Anticoagulation Management in the Emergency Department. **2015**, 229-248

401 Intensivtherapie bei Thrombose. **2015**, 1-17

400 Chapter 41. Thromboembolic Disease. **2015**,

399 Intensive Care Unit Ultrasound for Venous Thromboembolism. **2015**, 273-293

398 Open and Endoluminal Treatments for Peripheral Venous Disease. **2015**, 4399-4423

397 Anticoagulation Stewardship. **2015**, 249-274

1

396 Long-Term Management of Venous Thromboembolism: Strategies for Reducing the Risk of Recurrence. **2015**, 93-100

395 Advanced Therapy for Venous Thromboembolism: Understanding the Role of Systemic Fibrinolysis, Catheter-Based Therapy, and Surgery. **2015**, 51-65

394 Thromboembolieprophylaxe. **2015**, 267-276

393 Syndrome post-thrombotique. **2015**, 171-181

392 Pulmonary Embolism. **2015**, 4523-4538

391 Herz-Kreislauf-System. **2015**, 127-175

- 390 Anticoagulation for Venous Thromboembolism: Selecting the Optimal Parenteral and Oral Anticoagulant Regimen. **2015**, 77-91
- 389 Two Cases of Treatment with Thrombolysis and an Extracorporeal Membrane Oxygenator in Patients with Pulmonary Embolism and Cardiac Arrest. **2015**, 89, 210-214
- 388 Successful fibrinolytic and therapeutic hypothermic management of cardiac arrest following massive pulmonary embolism. **2015**, 2, 193-196 1
- 387 Management of Venous Thromboembolism. 830-837 2
- 386 Thromboembolism. **2016**, 145-154
- 385 Assessing the age of deep vein thrombus: A need for future perioperative medicine and anesthesia. **2016**, 10, 1-2 1
- 384 Venous Thromboembolism. **2016**, 203-210
- 383 Can Patients with Known Intracranial and Intraspinal Vascular Lesions Be Anticoagulated?. **2016**, 343-361
- 382 Frequency of deep vein thrombosis among hospitalized non-surgical Japanese patients with chronic obstructive pulmonary disease, infectious diseases, or inflammatory diseases. **2016**, 27, 54-63 1
- 381 Use of a dual lumen cannula for venovenous extra corporeal membrane oxygenation in a patient with acute respiratory distress syndrome and a previously inserted inferior vena cava filter: a case report. **2016**, 28, 78-82 2
- 380 Thromboembolic Disease in the Bariatric Patient: Prevention, Diagnosis, and Management. **2016**, 51-71
- 379 Management of antiplatelet and anticoagulant therapy for endoscopic procedures: Introduction to novel oral anticoagulants. **2016**, 108, 89-96 1
- 378 Diagnostic, Prognostic, and Therapeutic Challenges in Venous Thromboembolism. **2016**, 445-461
- 377 Anticoagulation in Cardiovascular Diseases. **2016**, 195-214
- 376 The Anticoagulation Treatment of Venous Thromboembolism: from Randomized Clinical Studies to the Data from the Real Clinical Practice. **2016**, 10, 106
- 375 High-Acuity Postoperative and Inpatient Issues. **2016**, 371-418
- 374 Anticoagulation Drugs: Indications, Therapeutic Monitoring, and Antidotes. **2016**, 503-517
- 373 Bleeding and Thrombosis in Cancer Patients. **2016**, 235-242

372 Bleeding and Thrombosis in a Cancer Patient. **2016**, 395-402

371 Unmet Clinical Needs of Antithrombotic Treatment in BCR/ABL-Negative Myeloproliferative Neoplasms. **2016**, 379-393

370 Complications of Venous Thromboembolic Disease. **2016**, 463-474

369 Cardiovascular Emergencies. **2016**, 91-104

368 Clinical factors associated with death from acute pulmonary embolism in Thailand. **2017**, 10, 129-132

367 Pulmonary Embolism Associated with Scrub Typhus. **2016**, 91, 224-228

366 Venous Etiologies of Acute Limb Ischemia. **2017**, 305-321

365 Angiologie. **2017**, 315-370

364 Oral Anticoagulant Therapy Post-Percutaneous Coronary Intervention. **2017**, 173-179

363 The Management of the Patients with Deep Vein Thrombosis in Need of Emergency Surgical Intervention. **2017**, 11, 164

362 Venöse Thrombembolien. **2017**, 85-103

361 Platelets in Deep Venous Thrombosis and Pulmonary Embolism. **2017**, 1043-1051

360 Exam 2 Questions. **2017**, 49-93

359 Impact of edoxaban approval for venous thromboembolism on length of hospitalization. **2017**, 28, 50-54 1

358 Venous Thromboembolism in Active Malignancy. **2017**, 269-276

357 Vena Cava Filters: State of the Art. **2017**, 217-232

356 Venous Thromboembolism: Diagnosis and Treatment. **2017**, 135-149

355 Venothrombotic Embolus (VTE). **2017**, 49-62

- 354 Venous Thromboembolism Associated with Foot and Ankle Surgery. **2017**, 9-27
- 353 Current Tendencies in the Prevention of Recurrent Venous Thromboembolism. **2017**, 11, 83
- 352 Angio I. **2017**, 335-340
- 351 After deep vein thrombosis, which patients refer to vascular specialist for anticoagulant withdrawal? A Delphi study results between general practitioners and vascular specialists. **2017**, 46, e77-e83
- 350 Heart and Lung Complications: Assessment and Prevention of Venous Thromboembolism and Cardiovascular Disease in Patients With Multiple Myeloma?. **2017**, 21, 37-46 2
- 349 High-Risk Pregnancy: Management Options. **2018**, 1
- 348 Upper Extremity Thrombosis. 192-204
- 347 Management of Intra-abdominal Thrombosis. 205-215
- 346 Laboratory Aspects in Diagnosis and Management of Venous Thromboembolism. 35-48
- 345 Management of Venous Thrombosis in the Lower Limbs. 13-20
- 344 Blut und blutbildende Organe. **2018**, 71-119
- 343 Resolution of the anel of Expert on Diagnostics, Prevention, and Treatment of Venous Thromboembolism (VTE) in Patients with Malignant Neoplasms. **2018**, 12, 57 1
- 342 Recent Advances in the Treatment of Venous Thromboembolism. **2018**, 27, 370-374
- 341 Evaluation of the Safety and Clinical Effectiveness of Endovascular Mechanical Fragmentation with Local Thrombolysis in the Patients Presenting with Pulmonary Embolism at Intermediate and High Risk of Early Death. **2018**, 12, 74
- 340 Indications, retrieval rate, and complications of inferior vena cava filters: Single-center experience in Saudi Arabia. **2018**, 13, 108-113 1
- 339 Migration of a fractured inferior vena cava filter strut to the right ventricle of the heart. **2018**, 2018, 2
- 338 The Optimal Duration and Selection of Anti-coagulants after First Episode of Unprovoked Venous Thromboembolism. **2018**, 4, 1-6
- 337 Trattamento delle sindromi compressive venose addominopelviche. **2018**, 23, 1-21

- 336 Prevention of venous thromboembolic complications in obstetrics and gynecology. **2018**, 165-168
- 335 Anticoagulants and Treatment of Venous Thromboembolism. **2019**, 163-193
- 334 Bleeding and Thrombotic Complications. **2019**, 301-306
- 333 The influence of prolonged antithrombotic therapy on the development of post-thrombotic syndrome in patients with proximal deep vein thrombosis of the lower limbs. **2018**, 83-88 2
- 332 Superficial venous thrombosis: Single-center experience and current recommendations. **2019**, 6, 235
- 331¹ Incidence and Risk Factors of Recurrent Venous Thromboembolism after Pulmonary Embolism. **2019**, 82, 341-347 2
- 330 Postoperative. **2019**, 65-73
- 329 Direct oral anticoagulants in oncology in clinical praxis. **2019**, 65, 45-50 1
- 328 Association between renal dysfunction and the development of bleeding during prophylactic doses of low molecular weight heparins, a nested case-control study. **2019**, 178,
- 327 Efficacy and Safety of Inferior Vena Cava Filters Implantation in Patients with Venous Thromboembolism. **2019**, 13, 236
- 326 Pharmacogenomics and Phytochemicals. **2019**, 165-186
- 325 Pulmonary Embolism after Bilateral Upper Limb Surgeries: A Case Report and Review of Literature. **2019**, 10, 362-367
- 324 Application of the probit method for elastographic evaluation of venous obliterating material after sclerotherapy procedure. **2019**, 84, e9-e15 1
- 323 Pearls in clinical obstetrics: challenges in anticoagulation in pregnancy. **2019**, 71, 125-132 0
- 322 Cerebral vein thrombosis associated with MTHFR A1289C mutation gene in a young postpartum woman. **2019**, 6, 26-30
- 321 Efficacy and tolerance of selective and non-selective factor Xa inhibitors in the prevention of thrombosis in kidney disease in patients with systemic lupus erythematosus and antiphospholipid syndrome. **2019**, 13, 26-34
- 320 Oberflächliche Thrombophlebitis. **2019**, 40,
- 319 Prescription Support by Pharmacists to Outpatients in Warfarin Control. **2019**, 45, 357-363 1

318	The Results of Thrombolytic Treatment in Patients With High-risk Pulmonary Embolism. 2019 , 5, 92-98	
317	Coagulation Management in Neurosurgical Critical Care. 2020 , 593-599	
316	Catheter-Related Deep Vein Thrombosis in Critically Ill Cancer Patients. 2020 , 1265-1272	
315	Acute and Chronic Respiratory Failure in Cancer Patients. 2020 , 445-475	0
314	CHANGES IN THE HEMOSTATIC SYSTEM AGAINST THE BACKGROUND OF VARIOUS TREATMENT REGIMENS IN PATIENTS WITH ATHEROSCLEROSIS OF LOWER EXTREMITIES. 2019 , 6, 49-59	
313	Venous Thromboembolic Disease. 2020 , 197-212	
312	Antiphospholipid Syndrome. 2020 , 181-201	
311	Cancer-Associated Thrombosis (CAT). 2020 , 127-145	
310	Thrombosis and Anticoagulation in Children. 2020 , 103-126	
309	Treatment for Pulmonary Embolism: Anticoagulation Selection and Duration. 2020 , 57-83	
308	Antithrombotika und Antihämorrhagika. 2020 , 395-420	
307	Treating Venous Thromboembolism Post Intracranial Hemorrhage: A Case Report. 2020 , 12, e6746	1
306	ACR Appropriateness Criteria [®] Radiologic Management of Iliofemoral Venous Thrombosis. 2020 , 17, S255-S264	0
305	[Treatment and secondary prevention of venous thromboembolism in cancer patients]. 2020 , 60, 71-79	2
304	Management of Superficial Vein Thrombosis in Patients with Varicose Veins: A Survey among Members of National Surgical Society from Republic of Moldova. 2020 , 36, 105-111	3
303	Comentarios a la guía ESC 2019 sobre embolia pulmonar aguda. 2020 , 73, 452-456	1
302	Mechanical Circulatory Support to Treat Pulmonary Embolism: Venoarterial Extracorporeal Membrane Oxygenation and Right Ventricular Assist Devices. 2020 , 47, 202-206	0
301	Recanalization of an Occluded Vena Cava Filter and Iliac Veins with Kissing Stents to Treat Postthrombotic Syndrome with a Venous Stasis Ulcer. 2020 , 36, 116-121	1

- 300 Post-operative oral chemoprophylaxis in patients undergoing hip arthroscopy mitigates VTE risk with a low side-effect profile. **2020**, 7, 524-532 0
- 299 A Fractured Inferior Vena Cava Strut Migrating to the Right Ventricle Without Any Cardiovascular Complaint: A Case Report and Review of Literature. **2020**, 12, e9779
- 298 Quantitative Volumetric Comparison of Direct Oral Anticoagulant and Vitamin K Antagonist Treatment for Pulmonary Thrombus Reduction During the Acute Phase in Symptomatic Patients. **2020**, 360, 153-160
- 297 Progress in Diagnosis and Treatment of Sudden Death Caused by Respiratory Diseases. **2021**, 299-321
- 296 Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD-VTE. **2021**, 0
- 295 Laboratory thrombophilia screening: essentials for hematologists. 1 0
- 294 The high-risk bleeding category of different scores in patients with venous thromboembolism: Systematic review and meta-analysis. **2021**, 94, 45-55 0
- 293 A case of phlegmasia cerulea dolens as a result of May-Thurner syndrome. **2020**, 113, 419-420 2
- 292 Deep venous thrombosis and pulmonary embolism. **2020**, 3711-3729 1
- 291 Case report of a 'snake thrombus' in the right heart: a rare finding on echocardiography. **2020**, 4, 1-6 0
- 290 Follow-up of guidelines and impact on the management of suspected deep vein thrombosis in emergency departments. **2020**, 45, 326-333
- 289 Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care. **2019**, 6, 160-173 0
- 288 Venous Disease. **2020**, 79-90
- 287 Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?. **2020**, 55, 1
- 286 Inferior Vena Cava Filters in Venous Thromboembolism. **2020**, 127-137
- 285 Interobserver agreement for the direct and indirect signs of pulmonary embolism evaluated using contrast enhanced magnetic angiography. **2020**, 7, 100256
- 284 Caval Filtration. **2020**, 611-618.e2
- 283 Development and validation of an informative manual on venous thromboembolism for the lay population. **2020**, 18, eAO5425 2

- 282 Pulmonary Embolism and Massive DVT for Emergency Critical Care. **2020**, 113-129
- 281 Comparison of Long-Term Outcomes of Regional Catheter Thrombolysis and Standard Conservative Treatment for Proximal Deep Vein Thrombosis of Lower Extremities. **2020**, 14, 10
- 280 Incidence and outcome of isolated distal deep vein thrombosis in kidney transplant recipients. **2020**, 98, 324-331 2
- 279 Facial Swelling and Shortness of Breath Are Not Always an Allergic Reaction: It Could Be Acute Superior Vena Cava Syndrome. **2020**, 11, 106-109
- 278 PROPHYLAXIS OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ACTIVE ONCOLOGICAL DISEASE, RECEIVING MEDICAL ANTI-CANCER CHEMOTHERAPY IN OUTPATIENT CONDITIONS. ROLE OF APIXABAN. **2020**, 46-54 0
- 277 Risk stratification for venous thrombosis in post-partum women in a tertiary care setup in south India. **2020**, 152, 523-526
- 276 Management of Filter-Related Chronic Iliocaval Occlusion. **2020**, 189-202
- 275 [Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?]. **2020**, 107, 224-233
- 274  **2020**, 5, 56-60
- 273 Upper gastrointestinal bleeding in superior mesenteric vein thrombosis. **2020**, 20, e3
- 272 Bilateral subretinal abscess in community-acquired meticillin-susceptible Staphylococcus aureus infection. **2020**, 50, 42-45
- 271 Efficacy and safety of direct oral anticoagulants in pediatrics and inherited thrombophilia: yes, we can. **2020**, 39, 89-90
- 270 Current Trends in the Duration of Anticoagulant Therapy for Venous Thromboembolism: A Systematic Review. **2021**, 13, e18992 0
- 269 Abrelcimab for Prevention of Venous Thromboembolism. **2021**, 385, 1821 0
- 268 Role of Transesophageal Echocardiography in the Diagnosis of Multi-chamber Intracardiac Thrombosis During Liver Transplantation: A Case Series. **2020**, 6, 194-199 2
- 267 Thrombolytic Therapy by Tissue Plasminogen Activator for Pulmonary Embolism. **2015**,
- 266 The Treatment of Venous Thromboembolism in Patients with Cancer. **2016**,
- 265 The Optimal Duration of Anticoagulation in Patients with Unprovoked Venous Thromboembolism. **2016**,

- 264 The Role of New Oral Anticoagulants (NOACs) in Cancer Patients. **2016**,
- 263 Pulmonary embolism. 60-79
- 262 Contraceptive Options for Women with Thrombophilia and Thromboembolic Disease. **2014**, 205-235 0
- 261 Venous Thromboembolism After Trauma. **2021**, 515-533
- 260 Pulmonary Embolism. **2021**, 53
- 259 Is guideline-driven prophylaxis for venous thromboembolism common practice in the South African private hospital setting?. **2020**, 62, e1-e9
- 258 The Difficult Clinical Decision of Thrombolytic Therapy for Submassive Pulmonary Embolism in a Community Hospital. **2020**, 12, e11148
- 257 Venous Thromboembolism. **2021**, 241-254
- 256 Venöse Interventionen. **2021**, 275-327
- 255 Management of upper extremity deep vein thrombosis in Occitanie: practice assessment. **2020**, 45, 288-293 1
- 254 Vertebral instrumentation and Phlegmasia cerulea dolens. **2020**, 31, 249-252
- 253 Thrombolysis in Acute Pulmonary Embolism: are we overdoing it?.
- 252 PURLs: An alternative to warfarin for patients with PE. **2012**, 61, 751-2
- 251 PURLs: a safer way to prevent VTE recurrence. **2012**, 61, 673-4
- 250 Use of ASA after warfarin for unprovoked VTE. **2013**, 59, 1075
- 249 Benefit vs. Risk of a Permanent Inferior Vena Cava Filter in Pulmonary Embolism with Anticoagulation Contraindication. **2013**, 8, 355-9 2
- 248 Intra-arterial Thrombolysis for Postoperative Digital Ischemia: A Case Report. **2014**, 14, e26 1
- 247 Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. **2014**, 60, 997-1001 10

- 246 Utilization of parenteral anticoagulants and warfarin: impact on the risk of venous thromboembolism recurrence in the outpatient setting. **2014**, 7, 444-51 7
- 245 Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority. **2015**, 13, 181-3 5
- 244 Early interventional therapy for acute massive pulmonary embolism guided by minimally invasive hemodynamic monitoring. **2015**, 8, 14011-7 1
- 243 Management of Deep Vein Thrombosis in Emergency Departments; Time to Change the Viewpoint. **2016**, 4, 47
- 242 Expanding a First-Order Logic Mitigation Framework to Handle Multimorbid Patient Preferences. **2015**, 2015, 895-904
- 241 Deficiencies of the Natural Anticoagulants - Novel Clinical Laboratory Aspects of Thrombophilia Testing. **2016**, 27, 130-46 5
- 240 Systemic Thrombolysis for Pulmonary Embolism: A Review. **2016**, 41, 770-775 18
- 239 Transcatheter Therapy for a Large Mobile Right Atrial Thrombus and Massive Pulmonary Embolism. **2016**, 28, E49-51 3
- 238 [Current Status of Prevention and Nursing on Venous Thromboembolism among Perioperative Patients with Lung Cancer]. **2017**, 20, 661-666
- 237 Systemic Fibrinolytic Therapy in the Presence of Absolute Contraindication; a Case Series. **2018**, 6, e25 3
- 236 Has the Time Come to Abandon Routine Use of Unfractionated Heparin in the Hospital Setting?. **2019**, 72, 160-162
- 235 Deep Vein Thrombosis in the Upper Extremities Associated with Protein C Deficiency: A Case Report. **2020**, 36, 520-522
- 234 Venous thromboembolism prophylaxis-prescribing patterns among elderly medical patients in a Saudi tertiary care center: success or failure?. **2020**, 17, 775-781 1
- 233 Assessment of a Pharmacist-Led Direct Oral Anticoagulant Monitoring Clinic. **2021**, 74, 7-14 0
- 232 Thrombolysis in Acute Pulmonary Embolism: Are we overdoing it?. **2021**, 22, 115-120
- 231 Validation of risk assessment models predicting venous thromboembolism in inpatients with AECOPD: a multicenter cohort study. **2021**, 0
- 230 SONO case series: 39-year-old man with leg swelling and pain. **2021**,
- 229 Perioperative Venous Thromboembolism. **2022**, 65-80 1

228	Anticoagulants in the Management of Pulmonary Embolism.	0
227	Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER. 2021 , 10, e021579	1
226	Inferior vena cava filter reduces pulmonary embolism but does not increase deep venous thrombosis: A systematic review and meta-analysis. 2021 ,	
225	Comparison of thrombotic events and mortality in patients with community-acquired pneumonia and COVID-19: a multicentre observational study. 2021 ,	7
224	Outcome of Elderly Patients with Venous Thromboembolism Treated with Direct Oral Anticoagulants-A Retrospective Cohort Study. 2021 , 10,	0
223	Enhanced Recovery after Surgery: Cesarean Delivery. 2021 , 39, 743-760	0
222	Varicose Vein. 2022 , 303-331	
221	Correlation Between the Fracture Line Plane and Perioperative Deep Vein Thrombosis in Patients with Tibial Fracture.. 2021 , 27, 10760296211067258	0
220	Effectiveness of flipped classroom among nursing students on venous thromboembolism (VTE). 2021 , 24, 1463-1470	1
219	Antithrombotika und Antihorrhagika. 2021 , 299-326	0
218	Risk Factors for Post-Thrombotic Syndrome in Patients With a First Proximal Deep Venous Thrombosis Treated With Direct Oral Anticoagulants.. 2022 , 33197211070889	0
217	Incidence of pulmonary embolism and impact on mortality in patients with malignant melanoma.. 2021 , 83, 72-76	
216	Venöse Thromboembolie (VTE): Epidemiologie, Pathophysiologie und natürlicher Verlauf. 2015 , 1-15	
215	Cerebral venous thrombosis. 2021 ,	1
214	Treatment of portal vein thrombosis: an updated narrative review. 2021 ,	1
213	National guidelines on the management of venous thromboembolism: Joint guideline of the Turkish Society of Cardiovascular Surgery, National Society of Vascular and Endovascular Surgery, and Phlebology Society.. 2021 , 29, 562-576	
212	Clots in unusual places: lots of stress, limited data, critical decisions. 2021 , 2021, 92-99	0
211	Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study.. 2022 , 17, e0261671	2

210	Blue Leg: Phlegmasia Cerulea Dolens Secondary to May Thurner Syndrome.. 2022 , 14, e21105	1
209	Successful Secondary Endovascular Intervention in Pediatric Patients with Venous Thromboembolic Events.. 2022 ,	
208	Superficial vein thrombosis: controversies on approach and therapy. 2022 , 28,	0
207	Acute Portal and Superior Mesenteric Vein Thrombosis with Topical Testosterone Therapy: An Adverse Drug Event Case Report.. 2022 , 8971900211073286	0
206	Validation of a modified Caprini risk assessment model in lung cancer patients undergoing surgery: Results of a multicenter cross-sectional observational study.. 2022 ,	0
205	Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation.. 2022 ,	0
204	Predicting pulmonary embolism among hospitalized patients with machine learning algorithms.. 2022 , 12, e12013	0
203	Emergency Department Management of Acute Venous Thromboembolism in Patients With Obesity With Intravenous Unfractionated Heparin and Anti-Xa Monitoring.. 2022 , 8971900221074935	
202	Gastroduodenal artery pseudoaneurysm and chronic superior mesenteric vein thrombosis treated with transcatheter embolization and stent dilatation, respectively: 7 year clinical and imaging follow-up.. 2022 , 17, 1013-1020	
201	Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment.. 2022 , 6, e12657	2
200	Rectus Sheath Hematoma in COVID-19 Patients as a Mortal Complication: A Retrospective Report. 2022 , 2022, 1-7	1
199	Warfarin Versus Direct Oral Anticoagulants For Patients Needing Treatment For Distal Deep Vein Thrombosis.. 2022 ,	0
198	Management of venous thromboembolism in pregnancy.. 2022 , 211, 106-113	1
197	Bleeding risk score: limits and practicability.. 2021 ,	0
196	Clinical effectiveness of a pneumatic compression device combined with low-molecular-weight heparin for the prevention of deep vein thrombosis in trauma patients: A single-center retrospective cohort study. 2022 , 13,	0
195	An Unwonted, Pedagogic Case Report on Effort Thrombosis of Right Brachial Vein. 2022 , 10, 8-18	
194	Duration of anticoagulation for upper extremity deep vein thrombosis associated with cancer and central venous catheter: Outcome of a cohort study.. 2022 , 47, 11-18	
193	Thrombose porte: Quand prescrire un traitement anticoagulant?. 2022 ,	

- 192 Treatment of Atypical Clots.. **2022**, 42, 10-18
- 191 Incidence, clinical characteristics and long-term prognosis of postoperative symptomatic venous thromboembolism: a retrospective cohort study.. **2022**, 12, e055090 ○
- 190 Clinical presentation of isolated calf deep vein thrombosis in inpatients and prevalence of associated pulmonary embolism.. **2022**, ○
- 189 The Efficacy of Low Dose Edoxaban for the Treatment of Venous Thromboembolism. **2022**, 33, 21-27
- 188 Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism.. **2022**, ○
- 187 A Comparative Analysis of Catheter Directed Thrombolysis with Anticoagulation Alone or Systemic tPA in Acute Pulmonary Embolism with Cor Pulmonale.. **2022**, 8850666221083241
- 186 Deep Vein Thrombosis is Common After Cardiac Ablation and Pre-Procedural D-Dimer Could Predict Risk.. **2022**,
- 185 Recommendations from the ICM-VTE: Hip & Knee.. **2022**, 104, 180-231 1
- 184 Incidence of upper extremity deep vein thrombosis in the retrosternal reconstruction after esophagectomy.. **2022**, 22, 91 1
- 183 Anticoagulants decrease the risk for catheter-related venous thrombosis in patients with chronic intestinal failure: A long-term cohort study.. **2021**, ○
- 182 Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!. **2022**, 74, 18 1
- 181 Recommendations from the ICM-VTE: General.. **2022**, 104, 4-162 ○
- 180 Postoperative venous thromboembolism after surgery for stage IA non-small-cell lung cancer: A single-center, prospective cohort study.. **2022**,
- 179 Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients.. **2022**, 1 ○
- 178 Case Report: Splanchnic Vein Thrombosis as a Complication of Necrotizing Acute Pancreatitis in a Pediatric Patient.. **2022**, 9, 747671 ○
- 177 Early Detection and Management of Venous Thrombosis in Skull Base Surgery: Role of Routine Doppler Ultrasound Monitoring.. **2022**, ○
- 176 Perioperative Anticoagulation Management.. **2022**, 45, 119-131 ○
- 175 A new pre-test probability score for diagnosis of deep vein thrombosis in patients before surgery.. **2021**, 1

- 174 Clinical use of tissue plasminogen activator for systemic thrombolysis in dogs and cats.. **2022**, 41, 154-164
- 173 Ultra-early therapeutic anticoagulation after craniotomy - A single institution experience.. **2022**, 100, 46-51 ○
- 172 Paget-Schroetter Syndrome. 56E-56H
- 171 Nonspecific ST-Segment and T-Wave (NS-STT) on Electrocardiogram is Associated with Increasing the Incidence of Perioperative Deep Vein Thrombosis in Patients with Lower Extremity Fracture Under 75 Years Old. **2021**, 14, 8631-8641
- 170 MPN and thrombosis was hard enough . . . now there's COVID-19 thrombosis too. **2021**, 2021, 710-717 ○
- 169 [Acute management of spontaneous intracerebral hemorrhage].. **2021**,
- 168 Pulmonary Embolism Readmission Trend Over the Years: A National Readmission Database Study.
- 167 Evidence-Based Minireview: Should warfarin or a direct oral anticoagulant be used in patients presenting with thrombosis in the splanchnic or cerebral veins?. **2021**, 2021, 100-105 1
- 166 Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis.. **2021**, 10, 1257
- 165 THE GLOBAL EVOLUTION OF DEEP VEIN THROMBOSIS PUBLICATIONS: A BIBLIOMETRIC ANALYSIS. 569-584
- 164 Effectiveness and safety of extended oral anticoagulant therapy in patients with venous thromboembolism: a retrospective cohort study.. **2022**, 1
- 163 Evaluation of the Padua Prediction Score ability to predict venous thromboembolism in Israeli non-surgical hospitalized patients using electronic medical records.. **2022**, 12, 6121
- 162 Evaluating the Appropriateness of Pulmonary Embolism Admissions in a Community Hospital Emergency Department. **2022**,
- 161 Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study.. **2022**, 1
- 160 Table_1.DOCX. **2018**,
- 159 Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation. **2021**, 19, 495-505
- 158 Catheter-related superior vena cava thrombosis-how do we face it?. **2021**, 24, 512-514
- 157 Role of Physical Therapists in the Management of Individuals at Risk for or Diagnosed with Venous Thromboembolism: Evidence-Based Clinical Practice Guideline 2022.. **2022**, ○

- 156 Evulation of Systemic Thrombolytic Treatment in the Emergency Service in Unstable and Resuscitated Patients Due To Massive Pulmonary Embolism. ○
- 155 Prevalence and risk factors of preoperative venous thromboembolism in patients with malignant musculoskeletal tumors: an analysis based on D-dimer screening and imaging.. **2022**, 20, 22 ○
- 154 Catheter-Directed Thrombolysis for Postpartum Deep Venous Thrombosis.. **2022**, 9, 814057
- 153 Catheter directed thrombolysis for deep vein thrombosis in 2022: Rationale, evidence base and future directions.. **2022**,
- 152 Fixed-Dose Factor Eight Inhibitor Bypassing Activity (FEIBA) in the Management of Warfarin-Associated Coagulopathies. **2022**, 10, 50 ○
- 151 Brachial Plexopathy Due to Upper-Extremity Deep Vein Thrombosis: A Case Report. **2022**, 24, 15-18
- 150 Venous thromboembolism in chronic gastrointestinal disorders.. **2022**, 1-12
- 149 Risk stratification to optimize the management of acute pulmonary embolism.. **2022**,
- 148 Peripherally inserted central venous catheter-related thrombosis. **2022**, 29, 209-210
- 147 Outpatient versus inpatient treatment for acute pulmonary embolism.. **2022**, 5, CD010019
- 146 Deep Vein Thrombosis and Pulmonary Embolism in Spinal Cord Injuries. **2022**, 513-526
- 145 Pharmacokinetics and Pharmacotherapeutics in Spinal Cord Injuries. **2022**, 169-216
- 144 Cancer-Associated Deep Vein Thrombosis: Insights from Randomized Trials and Real-Life Practice. **2022**, 16, 156
- 143 Antithrombotic Therapy for Venous Thromboembolism.. **2022**, 1 ○
- 142 Nursing Care of Deep Vein Thrombosis. **2022**, 12, 4461-4465
- 141 Integrating Multidisciplinary Individualized Medication Recommendations Into the Traditional Pharmacists Consultation Method: A Retrospective Study Using Propensity Score Matching Analysis. **2022**, 59, 004695802210814
- 140 Guidelines for thrombophilia testing: A British Society for Haematology guideline. ○
- 139 Clinical experiences of high-risk pulmonary thromboembolism receiving extracorporeal membrane oxygenation in single institution.

138	Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis.	1
137	Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.	0
136	Massive external validation of a machine learning algorithm to predict pulmonary embolism in hospitalized patients. 2022,	
135	The effect of rivaroxaban on the diagnostic value of D-dimer in patients with suspected deep vein thrombosis. 2022,	1
134	Venous thromboembolism and Cancer. 2022, 439-466	
133	Timing of Venous Thromboembolism Chemoprophylaxis Using Objective Hemoglobin Criteria in Blunt Solid Organ Injury.	
132	Splanchnic venous thrombosis: aetiologies and a review of the literature.	1
131	Emergency management of incidental pulmonary embolism (IPE). 2022, 1,	1
130	A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. 2022, 69,	0
129	Blood Being Tricky: Anticoagulation-Resistant Venous Thromboembolism (VTE). 2022,	
128	Risks, diagnosis, and management of recurrent cancer-associated thrombosis (CAT): a narrative review.	0
127	Effectiveness and safety of extended treatment with direct oral anticoagulants for venous thromboembolism in Japan: A retrospective cohort study using claims data. 2022, 100113	
126	Home Parenteral and Enteral Nutrition. 2022, 14, 2558	2
125	Currently available drugs for the treatment of Coronavirus-2. 2022, 77-95	
124	Successful recanalization of completely obstructed portal vein thrombosis after right hepatectomy for perihilar cholangiocarcinoma by aspiration thrombectomy via the ileocolic mesenteric vein and subsequent systemic anticoagulation with edoxaban.	
123	Pathological changes of a spleen and prevention of infectious complications in asplenic patients. 2022, 19, 202-206	
122	Central venous catheters-related-thrombosis and risk factors in oncological patients: a retrospective evaluation of recent risk scores. 030089162211114	
121	Critical Quality Control Methods for a Novel Anticoagulant Candidate LFG-Na by HPSEC-MALLS-RID and Bioactivity Assays. 2022, 27, 4522	2

120 Portal vein thrombosis in a noncirrhotic patient after hemihepatectomy: A case report and review of literature. **2022**, 10, 7130-7137

119 Detection of Incidental Pulmonary Embolism on Conventional Contrast-Enhanced Chest CT: Comparison of an Artificial Intelligence Algorithm and Clinical Reports. 2

118 Optimal quality of vitamin K antagonist therapy in Japanese patients with venous thromboembolism. **2022**,

117 Adherence to Antithrombotic Therapy for Patients Attending a Multidisciplinary Thrombosis Service in Canada [A Cross-Sectional Survey. Volume 16, 1771-1780

116 Pharmacotherapy for pulmonary embolism: new anticoagulants. **2022**, 65, 442-448

115 Racial differences in venous thromboembolism: A surveillance program in Durham County, North Carolina. **2022**, 6,

114 Cellular, Molecular, and Enzymatic Signatures of Thrombi are Vascular Bed-Dependent.

113 Les thromboses veineuses sous traitement anticoagulant: mise au point diagnostique, biologique et thérapeutique. **2022**,

112 Pathological Analysis and Clinical Evolution After Radiological Removal of Retrievable Vena Cava Filters. 153857442211207

111 Evaluating the immunogenicity of heparin and heparin derivatives by measuring their binding to platelet factor 4 using biolayer interferometry. 9,

110 Stenting across Inferior Vena Cava (IVC) filters can be a safe and effective alternative to a complex retrieval. **2022**,

109 Characteristics and predictors of venous thrombosis recurrence in patients with cancer and catheter-related thrombosis. **2022**, 6,

108 Eine Armschwellung mit camouflierter Ursache. **2022**, 111, 568-575

107 The Resolution Rate of Pulmonary Embolism on CT Pulmonary Angiography: a Prospective Study. **2022**, 155, 110466

106 Long-term clinical outcomes in older patients with acute venous thromboembolism who have renal impairment. **2022**, 218, 64-71

105 Optimization of thrombolytic dose for treatment of pulmonary emboli using endobronchial ultrasound-guided transbronchial needle injection. **2022**, 0

104 Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review. 0

103 Validation of high concentrated thrombin time assay for unfractionated heparin monitoring. 0

102	Causes of long-term mortality in patients with venous thromboembolism in the real world: From the COMMAND VTE registry. 2022 , 219, 30-39	0
101	Adherence to Thrombophilia Testing Guidelines and its Influence on Anticoagulation Therapy: A Single-Center Cross-Sectional Study.	0
100	The use of fondaparinux and rituximab for recurrent thrombotic events in antiphospholipid syndrome. 096120332211221	0
99	Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review.	0
98	Pulmonary Embolism and Chronic Obstructive Pulmonary Disease.	0
97	Machine learning-based prediction of the post-thrombotic syndrome: Model development and validation study. 9,	0
96	Advances in Percutaneous Management of Pulmonary Embolism. 2022 , 31, 203-212	0
95	Comparison of Effectiveness and Safety Among 3 Direct Oral Anticoagulants in Patients With Venous Thromboembolism [A Single-Center Retrospective Study] 2022 ,	0
94	Prevention, Diagnosis and Treatment of Thromboembolic Complications in Traumatology and Orthopedics: Methodological Guidelines. 2022 , 28, 136-166	1
93	Deep Venous Thrombosis. 2022 , 175, ITC129-ITC144	0
92	Comparative Effectiveness and Safety of Extended Anticoagulant Therapy among Medicare Beneficiaries with Venous Thromboembolism.	0
91	Venous Thromboembolism Prophylaxis Use by Pediatric Orthopedic Surgeons in Canada for the Pediatric Orthopedic Surgical Population. 2022 ,	0
90	Quality-of-Life (QOL) and Patient-Reported Outcome Measures (PROMs) Following Intervention for Chronic Venous Disease. 2022 , 415-428	0
89	Effectiveness of Fondaparinux in the Japanese Population with Acute Venous Thromboembolism -A Study Comparing Patients with and without Cancer-. 2022 ,	0
88	Staging of Portal Vein Thrombosis: Recurrent Thrombosis and Prognostic Factors for Recurrence in Non-Cirrhotic Non-Tumoral Portal Vein Thrombosis (PVT). 2022 , 599-611	0
87	Anticoagulation in Splanchnic Vein Thrombosis With and Without Underlying Liver Disease. 2022 , 649-667	0
86	Effect of low molecular weight heparin on bleeding after radical gastrectomy: A retrospective study from a high-volume center in China. 2022 , 1, 100003	0
85	Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review.	1

- 84 Impact of Paxlovid on International Normalized Ratio among Patients on Chronic Warfarin Therapy. ○
- 83 Strutting Through: Migration of Fractured Inferior Vena Cava Filter Through the Right Ventricle. **2022**, ○
- 82 Implementation of a pharmacological prophylaxis bundle to prevent obstetric-associated venous thromboembolism. ○
- 81 Gunther Tulip Filter Strut Penetration: Benign long-term follow-up. **2022**, ○
- 80 Indian Society of Critical Care Medicine Consensus Statement for Prevention of Venous Thromboembolism in the Critical Care Unit. **2022**, 26, S51-S65 ○
- 79 Length of Anticoagulation in Provoked Venous Thromboembolism: A Multicenter Study of How Real-World Practice Mirrors Guideline Recommendations. **2022**, 11, ○
- 78 Epidemiology and Treatment Patterns of Venous Thromboembolism: an Observational Study of Nationwide Time-Series Trends in Japan. ○
- 77 Cannula provoked upper extremity superficial vein thrombophlebitis: are we overtreating?. ○
- 76 Differences in duration of anticoagulation after pulmonary embolism and deep vein thrombosis: Findings from the SWiss Venous ThromboEmbolism Registry (SWIVTER). **2022**, 220, 65-71 ○
- 75 Clinical Vascular. **2017**, 158-179 ○
- 74 Cost-effective treatment for deep-vein thrombosis in rural tertiary care hospital. **2022**, 9, 287 ○
- 73 BLASKI I CIENIE WSPÓZESNEJ FARMAKOTERAPII ANTYKOAGULACYJNEJ. **2016**, 14, 64-72 ○
- 72 Society of Interventional Radiology Position Statement on the Endovascular Management of Acute Iliofemoral Deep Vein Thrombosis. **2022**, ○
- 71 Acute Upper Extremity Vein Thrombosis in Recurrent Shoulder Dislocation. **2022**, ○
- 70 Self-reported adherence to direct oral anticoagulants versus warfarin therapy in a specialized thrombosis service: a cross-sectional study of patients in a Canadian Health Region. ○
- 69 Cerebral venous sinus thrombosis as the initial presentation of occult adult leukemia. **2022**, 16, 73 ○
- 68 COVID-19 IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: THE RISK OF THROMBOEMBOLIC EVENTS AND CURRENT OPTIONS FOR ANTITHROMBOTIC PROPHYLAXIS. **2022**, 4, 88-103 ○
- 67 Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis. **2022**, 1, 1

- 66 Effectiveness and safety of the direct oral anticoagulant in acute distal deep vein thrombosis: From the prospective multicenter observational study, J_uactly, in Japan. 026835552211413 ○
- 65 Clinical and Safety Outcomes Associated with Extended Treatment of Venous Thromboembolism: A Network Meta-Analysis. **2022**, 9, 414 1
- 64 Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis. **2022**, 101, e31948 1
- 63 Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery. **2022**, 2022, ○
- 62 Subclavian Effort and Upper Limb Thrombosis **1** Lesson Learned. **2022**, 51, 294-299 ○
- 61 Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. e072623 ○
- 60 Timing of Venous Thromboembolism Chemoprophylaxis Using Objective Hemoglobin Criteria in Blunt Solid Organ Injury. **2022**, ○
- 59 Right Lower Extremity Phlegmasia Cerulea Dolens Due to Iliotibial Vein Thrombosis With Compartment Syndrome and Circulatory Shock: Case Report and Review. **2022**, ○
- 58 Perioperative Challenges in a Septic Shock Patient With Extensive Splanchnic and Extra-Splanchnic Vein Thrombosis Up to the Right Atrium. **2022**, ○
- 57 Pharmaco-Mechanical Thrombectomy vs. Conventional Anticoagulant Management of Acute Lower Extremity Deep Vein Thrombosis - Long-Term Outcomes. **2022**, 64, 601-610 ○
- 56 Reduced-Dose Apixaban in the Treatment of Left Ventricular Thrombus: A Report of 2 Cases. 089719002211450 ○
- 55 Adherence to thrombophilia testing guidelines and its influence on anticoagulation therapy: A single-center cross-sectional study. **2022**, ○
- 54 Temporary inferior vena cava filters factors associated with non-removal. ○
- 53 Current treatment strategies for primary upper extremity deep venous thrombosis; a retrospective observational multicenter case series. 9, ○
- 52 Derivation and validation of a nomogram model for venous thromboembolism in patients undergoing borderline resectable pancreatic cancer surgery. ○
- 51 Antithrombotic Management in Spine Surgery in the Elderly. **2023**, 19-49 ○
- 50 Validation of the IMPROVE bleeding risk assessment model in surgical patients: Results from the Dissolve-2 Study. **2023**, ○
- 49 Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs. ○

- 48 Endovascular Venous Interventions - A State-of-the-Art Review. **2023**, 48, 101534 ○
- 47 One filter may be enough for duplicate inferior vena cava filter implantation in patients with deep venous thrombosis: Two cases report. **2022**, 101, e32480 ○
- 46 Thrombose in der Intensivmedizin. **2022**, 1-8 ○
- 45 Modern approaches to the prevention of venous thromboembolic complications in patients with active cancer. **2023**, 12, 44-62 ○
- 44 Endovenous techniques for superficial vein ablation for treatment of venous ulcers. **2023**, 381-403 ○
- 43 Deep vein thrombosis and prevention of postthrombotic syndrome. **2023**, 297-314 ○
- 42 Clinical outcomes of AngioJet pharmacomechanical thrombectomy versus catheter-directed thrombolysis for the treatment of filter-related caval thrombosis. 11, 598-609 ○
- 41 Impact of Time to Intervention on Catheter-Directed Therapy for Pulmonary Embolism. **2023**, 5, e0828 ○
- 40 Derivation and External Validation of a Risk Prediction Model for Pulmonary Embolism in Patients With Lung Cancer: A Large Retrospective Cohort Study. **2023**, 29, 107602962311516 ○
- 39 Comparison of VTE risk scores in guidelines for VTE diagnosis in nonsurgical hospitalized patients with suspected VTE. **2023**, 21, ○
- 38 Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis. **2023**, 24, 2262 ○
- 37 Predictors of long-term outcomes after catheter-directed thrombolysis combined with stent implantation in acute deep vein thrombosis secondary to iliac vein compression. **2023**, 102, e32646 ○
- 36 Predictive factors on postoperative venous thromboembolism after minimally invasive colorectal cancer surgery: a retrospective observational study. **2023**, 23, ○
- 35 How I do it. Thoracic outlet syndrome and the transaxillary approach. **2023**, 9, 101128 ○
- 34 Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of pulmonary embolism. **2023**, 2023, 1
- 33 Biological Properties of Heparins Modified with an Arylazopyrazole-Based Photoswitch. **2023**, 66, 1778-1789 ○
- 32 Thromboplastin calibration revisited to look for possible revision of the World Health Organization recommendations. **2023**, 21, 311-316 ○
- 31 High fibrinogen and mixed proximal and distal thrombosis are associated with the risk of residual venous thrombosis in patients with posttraumatic deep vein thrombosis. 10, ○

- 30 Antithrombotische Therapie. **2022**, 233-263
- 29 Development of Henoch-Schoenlein purpura in a child with idiopathic hypereosinophilia syndrome with multiple thrombotic onset: A case report. **11**, 952-961
- 28 Relationship between baseline D-dimer and prognosis in Japanese patients with venous thromboembolism: Insights from the J-VACT study. **10**,
- 27 Performance of a Prospective Anticoagulation Stratification Algorithm After Liver Transplantation. **2023**, 9, e1453
- 26 Prevención de la enfermedad tromboembólica venosa en el paciente médico. **2023**, 160, 397-399
- 25 Managing Pulmonary Embolism. **2023**,
- 24 Risk factors and new diagnostic index for deep venous thrombosis of lower extremities in elderly patients with traumatic femoral neck fracture. **9**,
- 23 Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences. **2023**, 40, 1705-1735
- 22 Safety and Effectiveness of Mechanical Thrombectomy From the Fully Enrolled Multicenter, Prospective CLOUT Registry. **2023**, 2, 100585
- 21 Prevalence of perioperative asymptomatic venous thromboses of the lower extremity in 30 consecutive patients undergoing transsphenoidal surgery for Cushing's disease. **2023**, 13,
- 20 Physical activity for children with deep vein thrombosis and pulmonary embolism on anticoagulation: a scoping review. **2023**, 7, 100094
- 19 Nursing Care and Barriers for Prevention of Venous Thromboembolism in Total Knee and Hip Arthroplasty Patients: A Qualitative Study. Volume 16, 547-556
- 18 Updated Trends in Inferior Vena Cava Filter Use by Indication in the United States After Food and Drug Administration Safety Warnings: A Decade Analysis From 2010 to 2019. 152660282311560
- 17 Venous Disease. **2023**, 321-338
- 16 Associations between Coronavirus and Immune Response, Cardiorespiratory Fitness Rehabilitation and Physical Activity: A Brief Report. **2023**, 20, 4651
- 15 Posttraumatic Lip Replantation in a Pregnant Woman. **2022**, 10, e4662
- 14 Evolving paradigm of thrombolysis in pulmonary embolism: Comprehensive review of clinical manifestations, indications, recent advances and guideline. **11**, 1702-1711
- 13 Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations.

- 12 Antithrombotics and Gastrointestinal Prophylaxis: A Systematic Review. Publish Ahead of Print, ○
- 11 Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study. **2023**, ○
- 10 A 10-year Australian experience of rare intraabdominal venous thrombosis with comparison to deep vein thrombosis and pulmonary embolism. **2023**, 34, 191-198 ○
- 9 Systemic Anticoagulation and Inpatient Outcomes of Pancreatic Cancer: Real-World Evidence from U.S. Nationwide Inpatient Sample. **2023**, 15, 1985 ○
- 8 Exam 1: Section 5. **2023**, 103-127 ○
- 7 Venoarterial extracorporeal membrane oxygenation for protected catheter-based embolectomy in high-risk/massive pulmonary embolism. 026765912311677 ○
- 6 Patients with BMI >25 kg/m² as a Target Population for Improvement of Rate of Follow-up Duplex Venous Ultrasound Examinations Following Initial Incomplete Examinations. **2023**, ○
- 5 Comparison of AngioJet Thrombectomy System Versus Suction Catheter with the Adjunct of Catheter-Directed Thrombolysis for Lower Extremity Deep Venous Thrombosis. 155335062311691 ○
- 4 Thrombolytic Therapy in Acute Pulmonary Embolism. **2023**, 119-128 ○
- 3 Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis. **2023**, 2023, 1
- 2 Aspirin for Thromboprophylaxis after a Fracture. **2023**, 388, e57 ○
- 1 Prevention of venous thromboembolic disease in medical patient. **2023**, ○